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CHAPTER ONE
1.1. The manifestation of schizophrenia
Schizophrenia is one of the most serious mental disorders of humankind. It affects 
about 1% of the population worldwide and has devastating consequences, including 
suicide in 10% of sufferers (e.g. Lewis & Lieberman, 2000). Schizophrenia also has 
serious social impact with sufferers accounting for more than one third of the 
homeless population in western society (Folsom & Jeste, 2002).
The clinical features of schizophrenia are highly disabling and fall into the 
three symptom clusters outlined below.
• Positive symptoms (additional to normal human experience)
Hallucinations (usually auditory), delusions (often of a paranoid nature),
irrational thoughts and communication (often perceived to be under someone else’s 
control), abnormal behaviour, including aggressive behaviour and stereotyped 
movement.
• Negative symptoms (lacking relative to normal human experience)
Blunting of emotions, social withdrawal, avolition (reduced motivation),
anhedonia (reduced capacity to experience pleasure).
• Cognitive symptoms
Deficits of attention and memory.
The name ‘schizophrenia’ means ‘divided mind’ and it was first used by Eugen 
Bleuler in 1911 following his observation that patients seemed to alternate between 
normal and abnormal mental states. By this, he referred to psychotic episodes that
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commonly characterise schizophrenia. It is during these episodes that the positive 
symptoms are at their most severe. These episodes are often separated by periods in 
which individuals are not obviously psychotic, but tend to experience more of the 
negative symptoms. The negative symptoms of schizophrenia are the most difficult to 
treat and are often considered to predict the long-term course of positive symptoms 
(e.g. Pogue-Geile & Harrow, 1985). Patients who experience predominantly negative 
symptoms are often the most severely ill and tend to have the poorest prognosis. For 
example, in a longitudinal study, Ho, Nopoulos, Flaum, Arndt, and Andreasen (2004) 
showed that negative symptom severity is moderately and significantly correlated 
with later unemployment, financial dependence on social service agencies, 
impairment in the ability to perform household duties, inability to maintain 
relationships and to participate in recreational activities. Pogue-Geile and Harrow 
(1985) also found that blunted affect and poverty of speech predicted poor outcome in 
terms of symptom severity, social functioning, independence of others and 
rehospitalisation. Similarly, Wieselgren, Lindstrom and Lindstrom (1996) found that 
negative symptoms measured using the Comprehensive Psychopathological Rating 
Scale (CPRS) predicted poor social functioning 5 years after hospitalisation during a 
patient’s first psychotic episode. The implications of such findings are even more 
severe when it is considered that feelings of hopelessness and poor functioning are 
significant risk factors for suicide in schizophrenia (Cohen, Test, & Brown, 1990; 
Kaplan & Harrow, 1999).
Schizophrenia manifests itself as three main subtypes, based on features 
present during psychotic episodes:
• Paranoid Schizophrenia
Delusions predominate.
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• Disorganised Schizophrenia
Disorganised behaviour and speech, lack of/inappropriate emotional 
expression, early age of onset and steadily worsening course without substantial 
remission periods.
• Catatonic Schizophrenia
Unusual movement, gesturing and catatonia.
Meaningless repetition of phrases.
1.2 The aetiology of schizophrenia
The causes of schizophrenia are far from fully established, although the work of 
Gottesman (1991) has clearly illustrated a genetic link. Gottesman ranked relatives of 
individuals with schizophrenia in terms of what percentage of genes they shared with 
the sufferer. The chances that a person will have the disorder declines as the 
proportion of genes shared with the sufferer decreases, so that first-degree relatives, 
such as offspring, who share 50% of the sufferer’s genes, have a higher incidence of 
schizophrenia than second-degree relatives, who share 25% of the sufferer’s DNA. 
Despite this genetic component, studies of monozygotic twins showing a 45% 
concordance rate despite sharing 100% of genes with a sufferer, demonstrate that 
genetic factors are not the only cause (e.g. Kallmann, 1946).
Schizophrenia is often associated with anatomical abnormalities in the brain, 
including enlarged ventricles reflecting loss of surrounding brain tissue, thinning of 
the cortex of the medial temporal lobe, reduction in the size of the anterior 
hippocampus and disturbance in blood flow to the temporal lobe (Ananth, et al.,
2002; Shenton, Dickey, Frumin, & McCarley, 2001; Vita & De Peri, 2007; Vita, De 
Peri, Silenzi, & Dieci, 2006). These abnormalities are seen most commonly in
12
patients who have predominantly negative symptoms (Ho, et al., 2003; Maj, Starace, 
& Kemali, 1987; Pearlson, Garbacz, Breakey, Ahn, & Depaulo, 1984; Williams, 
Reveley, Kolakowska, Ardem, & Mandelbrote, 1985). To highlight some examples, 
Mathalon, Sullivan, Lim, and Pfefferbaum (2001) showed that prefrontal grey matter 
decline and expansion of the frontal sulci was associated with greater negative 
symptom severity. Similarly, Ho et al. (2003) found that decreased frontal lobe 
volume white matter volume and enlargement of the frontal sulci and lateral 
ventricles was associated with higher levels of negative symptoms. Furthermore, 
patients with poor outcome showed the largest lateral ventricular enlargement. This 
may suggest that the increased brain structure abnormalities in individuals with 
greater negative symptom severity could account for the increased illness severity and 
poorer prognosis in these patients.
Interestingly, Suddath, Christison, Torrey, Casanova and Weinberger, (1990) 
discovered that when one person in a pair of monozygotic twins is affected by 
schizophrenia, only the affected individual displays evidence of the above-mentioned 
structural abnormalities using MRI scans. Since genes alone cannot account for these 
structural abnormalities, it has been suggested that genetic factors are necessary for 
schizophrenia to develop, but environmental challenges, such as maternal viral 
infection (e.g. Brown, 2006; Boksa, 2008), or childhood abuse (e.g. Janssen et al.,
2004) must also occur for the disorder to develop. However, the exact combination of 
aberrant genes and environmental insults most likely to produce the disease state 
remains unclear (Lewis & Lieberman, 2000).
In addition to the structural abnormalities evident in schizophrenia, 
abnormalities in synaptic transmission have also been implicated. In particular,
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changes in dopaminergic and glutamatergic transmission have formed the basis of the 
two main theories relating to schizophrenia.
1.3 The dopamine hypothesis of schizophrenia
There are four major dopaminergic pathways in the brain: the mesolimbic pathway, 
the mesocortical pathway, the nigrostriatal pathway and the tuberoinfundibular 
pathway. The mesolimbic pathway transmits dopamine from the ventral tegmental are 
to the nucleus accumbens. It is important in memory and motivating behaviours (e.g. 
Pezze & Feldon, 2004). The mesocortical pathway runs from the ventral tegmental 
area to the frontal cortex and surrounding structures. There is some evidence that 
malfunctions of this pathway may contribute to hallucinations and disordered 
thinking (Silbersweig, Stem, Frith, Cahill et al. 1995). The nigrostriatal pathway 
transmits dopamine from the substantia nigra to the striatum and is involved in motor 
control (Ungerstedt & Arbuthnott, 1970). The tuberoinfundibular pathway runs from 
the hypothalamus to the pituitary gland and influences the secretion of certain 
hormones, including prolactin (This may be implicated in the weight gain induced by 
antipsychotic medication (Gudelsky, Koenig, Simonovic, Koyama, et al. 1987).
Interestingly, it has been found that dopaminergic pathways can interact 
producing bi-directional effects on dopamine in different brain areas. Projections 
from the prefrontal cortex regulate extracellular dopamine via their connections with 
the ventral tegmental area. However, by labelling anterograde and retrograde 
projections between these areas, Carr and Seasack (2000) observed that afferents 
from the prefrontal cortex project to mesoprefrontal dopaminergic neurones, but not 
mesoaccumbal dopaminergic neurones. On the other hand, prefrontal afferents project 
to mesoaccumbel GABA-ergic neurones, but not mesoprefrontal GABA-ergic
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neurones. In this way, prefrontal cortex activity can result in an increase in prefrontal 
dopamine release alongside a simultaneous decrease in dopamine release from the 
nucleus accumbens. The effect has been observed practically by Jackson, Frost and 
Moghaddam (2001) who found that accumbal dopamine release was reduced when 
the prefrontal cortex was electrically stimulated at levels produced during 
performance of cognitive tasks.
The dopamine hypothesis proposed by Carlsson (1978) suggests that 
excessive dopamine synthesis and release underlies the symptoms of schizophrenia. 
Two main findings underlie this theory. Firstly, it has been found that amphetamine, a 
drug that enhances neurotransmission via the release of dopamine, can produce 
symptoms that can be difficult to distinguish from a psychotic episode when taken by 
humans (e.g. Hollister, 1986). Secondly, drugs that are effective in treating the 
positive symptoms of schizophrenia often block D2 receptors (e.g. chlorpromazine) or 
prevent neuronal dopamine storage (e.g. reserpine). In fact, Seeman, Lee, Chauwong 
and Wong (1976) examined a large number of antipsychotics and found a strong 
correlation between clinical potency and ability to bind to D2 receptors.
Imaging studies have provided further evidence for increased dopamine 
release in schizophrenia. For example, Laurelle (2001) measured binding of a 
dopamine antagonist, raclopride, to striatal D2 receptors. When injected, amphetamine 
caused release of dopamine, which in turn displaced raclopride, reducing the signal 
intensity. In participants with schizophrenia, this displacement was greater, indicating 
that amphetamine induced greater dopamine release in sufferers than controls. This 
effect was absent in sufferers during remission periods, further implicating dopamine 
in positive symptomatology.
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Despite these findings, the fact that newer drugs, such as clozapine, have little 
effect on D2 receptors indicates that increased dopamine release is not fully 
responsible for the symptoms of schizophrenia. This has led to a revision of the 
original model, suggesting that dopamine up-regulation in the mesolimbic system, 
which runs from the ventral tegmental area to many components of the limbic system, 
gives rise to the positive symptoms of schizophrenia. It further suggests that negative 
symptoms are produced by dopamine down-regulation in the mesocortical system, 
which runs from the ventral tegmental area to the prefrontal cortex, an area involved 
in motivation, attention and social behaviour (Weinberger, 1987).
Weiner (2003) also cites evidence that bi-directional effects on dopamine 
release are responsible for different facets of schizophrenia. Latent inhibition is 
disrupted in rats by admisnistration of amphetamine, an agent which causes dopamine 
release (Angrist, Sathananthan, Wilk & Gershon, 1974). However, latent inhibition is 
potentiated by antipsychotic drugs which reduce dopamine release (Weiner & Feldon, 
1987). Weiner suggests that since latent inhibition is imapired during the acute phases 
of schizophrenia, and intact during the chronic phases, bi-directional effects on 
dopamine may be involved.
1.4 The glutamate hypothesis of schizophrenia
The revised version of the dopamine hypothesis may provide a useful explanation of 
the neurotransmitter abnormalities underlying the symptoms of schizophrenia. 
However, it is difficult to test this theory directly via administration of dopamine 
receptor antagonists in humans or animals because such drugs cannot produce the bi­
directional effects on dopaminergic transmission that the model suggests are required 
to produce both positive and negative symptoms. Developing treatment strategies
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based on this theory would pose an even greater problem since it is difficult to 
envisage how dopamine-altering pharmacological agents could produce opposing 
effects on dopamine activity in different brain areas.
Glutamate is another neurotransmitter implicated in schizophrenia (e.g. 
Moghaddam, 2003), as it has been suggested that N-methyl-D-aspartate (NMDA) 
(glutamate) receptor hypofunction may underlie the symptoms of the disorder. This 
idea has arisen from findings that NMDA receptor antagonists such as phencyclidine 
(PCP) and s-(+)-ketamine produce a psychotic state that is more reminiscent of 
schizophrenia than dopaminergic psychostimulants, such as amphetamine, since both 
negative and cognitive symptoms are induced (e.g. Javitt & Zukin, 1991; Lahti, 
Weiler, Michaelidis, Parwani, & Tamminga, 2001). Treatment with NMDA 
antagonists can also exacerbate psychosis in schizophrenic patients (Lahti, Koffel, 
Laporte, & Tamminga, 1995). In addition, post-mortem studies have found reduced 
densities of glutamate receptor mRNAs in the frontal cortex of schizophrenics who 
did not receive neuroleptic treatment for over six months prior to their death 
(Sokolov, 1998).
NMDA receptor antagonists, such as PCP, bind both to NMDA receptors and 
dopaminergic neurone terminals in the nucleus accumbens. When PCP binds to 
NMDA receptors it inhibits the release of dopamine. However, at the dopaminergic 
neurone terminals of the nucleus accumbens, PCP acts in a similar way to 
amphetamine by increasing dopamine release and reducing reuptake (Javitt, 2010). 
The ability of NMDA receptor antagonists to produce contrasting effects on 
dopamine release suggests that the glutamate hypothesis is superior to the hypothesis 
that relies on dopamine alone. It is possible that NMDA receptor hypofunction
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produces the effects outlined in the revised dopamine hypothesis. However, the 
glutamate hypothesis also attempts to identify the cause of dopamine dysregulation.
The glutamate hypothesis has broadened the number of neurotransmitter 
systems considered in drug hunting efforts. For example, NMDA receptor antagonists 
such as PCP also bring about a reduction in parvalbumin-containing neurones in the 
prefrontal cortex (Cochran, Fujimara, Morris & Pratt, 2002). This is also evident in 
the post-mortem brains of schizophrenia patients (e.g. Beasley & Reynolds, 1997; 
Reynolds, 2000). Parvalbumin is known to be a calcium binding protein found in 
selective subpopulations of GABA-ergic neurones (Reynolds et al, 2000). Support for 
the role of GABA in schizophrenia has also come from evidence that mRNA 
encoding the enzyme responsible for synthesising GABA from glutamate, glutamate 
decarboxylase (GAD), is reduced in the prefrontal cortex in schizophrenia (Volk, 
Austin, Pierri & Sampson, 2000). Additionally, post-mortem investigations have also 
revealed a deficit in a subset of GABA-ergic neuronal terminals determined by GAT- 
1, a GABA uptake transporter (Woo, Whitehead, Melchitzty & Lewis, 1998).
1.5 The treatment of schizophrenia
Antipsychotic drugs are usually considered to fall into two categories. The drugs 
originally developed tend to have their effects via blockade of dopamine receptors 
and are known as typical antipsychotics. This drug group includes the phenothiazines 
(e.g. chlorpromazine), butyrophenones (haloperidol), and the thioxanthenes. The 
newer drugs are commonly referred to as atypical antipsychotics. Although there is 
some debate as to what defines an atypical drug (e.g. Remington, 2003), most atypical 
compounds have different pharmacological action compared with typical drugs. 
Additionally, typical antipsychotics often produce disabling motor problems due to
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D2 receptor blockade in the basal ganglia (e.g. Parkinsonism and tardive dyskinesia - 
involuntary tongue and trunk movements). However, by avoiding potent D2 blockade, 
some of the atypical treatments produce fewer motor side effects (Leucht, Pitschel- 
Walz, Abraham, & Kissling, 1999).
Crow (1980) first drew the conclusion that the positive symptoms of 
schizophrenia are often ameliorated by available antipsychotics, whereas the negative 
symptoms are usually treatment resistant. This followed evidence from Johnstone, 
Frith, Gold, & Stevens (1979) who found that ds-flupenthixol had no greater efficacy 
against negative symptoms than its inactive isomer. More recently evidence has 
arisen suggesting that atypical antipsychotics are superior to typical antipsychotics in 
the treatment of negative symptoms (see King, 1998, for a review). For example, 
Chouinard et al. (1993) and Marder and Meibach (1994) found that risperidone (an 
atypical drug) produced a greater decrease in negative symptoms than haloperidol, 
when assessed using the Positive and Negative Syndrome Scale for Schizophrenia 
(PANSS) negative subscale and the Brief Psychiatric Rating subscales. Similarly, the 
atypical drugs olanzapine and amisulpiride have also been shown to be more effective 
thaN haloperidol in reducing negative symptoms (Beasley, et al., 1996; Freeman, 
1997). However, the assessment of the efficacy of pharmacological treatments against 
negative symptoms is difficult because it is difficult to determine whether 
improvements are the result of treatment of the pathophysiology specifically related 
to negative symptoms or whether the improvement is secondary to the treatment of 
positive symptoms. For example, a reduction in social avoidance could be secondary 
to a decrease in paranoia. Miller, Perry, Cadoret and Andreasen (1994) sought to 
disentangle these negative symptom treatment effects by measuring correlations 
between improvements in negative symptoms and improvements in positive and
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disorganised symptoms. They found that negative symptoms (assessed using SANS) 
improved with clozapine treatment, but this improvement was not correlated with 
improvement in positive symptoms, depression or drug-induced extra-pyramidal side- 
effects. Although there was a correlation between negative symptoms and 
disorganised symptoms, Miller et al. suggested that these symptoms change in 
parallel but are independent of each other. Using this evidence, they proposed that 
clozapine’s therapeutic effect on core negative symptoms is at least partially mediated 
via a direct effect on the pathology associated with negative symptoms, and therefore 
was independent of its effects on positive symptoms.
Despite the above evidence, there has been some debate over the advantages 
of atypical drugs, with a large-scale study suggesting that atypical drugs do not 
provide greater relief of symptoms, even though they reduce the risk of extra- 
pyramidal side-effects (Geddes, et al., 2000). Geddes suggested that the reason for the 
apparent superiority of atypical drugs may be because prescribed doses of typical 
drugs are often too high and therefore cause disabling side-effects. However, using 
another large-scale meta-analysis Davis, Chen and Glick (2003) found that the 
efficacy of atypical drugs over typical drugs was not biased by the dose used. Davis et 
al argued that the claim made by Geddes et al. (2000) asserting that differences in the 
efficacy and tolerability of typical and atypical drugs is not apparent after controlling 
for the higher than recommended doses of typical drugs is unfounded because 
tolerability problems were measured in terms of adherence to medication, which 
would be lower with less effective drugs.
Whether or not atypical drugs are more effective than typical drugs in the 
treatment of schizophrenia, the need for better medications is undisputed. Lack of 
patient adherence to prescribed medications indicates that no currently available drug
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is sufficiently effective. Adherence to antipsychotic treatment is in fact a major 
problem, causing poorer functional outcomes in patients and great economic costs 
due to increased relapse rates and hospitalisations (e.g. Ascher-Svanum, et al., 2006; 
Fenton, Blyler, & Heinssen, 1997). In a study by Ascher-Svanum et al. (2008) only 
35% of patients treated with haloperidol were found to be adherent to their 
medication, compared to 61% adherence with atypical antipsychotics. This suggests 
that adherence is better with atypicals than typicals, but nevertheless, adherence to all 
available oral antipsychotics is far from optimal.
A number of studies have shown that one of the most crucial factors 
determining adherence is the effectiveness of the treatment (e.g. Freudenreich, 
Cather, Evins, Henderson, & Goff, 2004; Rettenbacher, et al., 2004). Kikkert et al. 
(2006) found that contrary to the assumption widely held by healthcare professionals, 
patients consider efficacy of treatment to be more important than severity of side- 
effects in terms of their decision to continue taking their medication. In light of this, 
since most antipsychotics are effective against positive symptoms but are largely 
ineffective against negative symptoms, it is plausible that problems with patient 
compliance may be due primarily to the lack of treatment efficacy against negative 
symptoms. In support of this view, it has been found that objective quality of life 
measures such as participation in activities and maintenance of personal relationships 
are predicted most strongly by the presence and severity of negative, rather than 
positive, symptoms (Narvaez, Twamley, McKibbin, Heaton, & Patterson, 2008). 
Quality of life is now increasingly acknowledged to be as important as treatment 
outcomes in schizophrenia patients (e.g. Ruggeri, et al., 2005). The fact that currently 
available treatments are only effective in targeting positive symptoms is therefore a 
major problem. Indeed, even in studies that have found atypical antipsychotics to be
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superior to typical drugs, the efficacy of atypical treatments is still far from adequate. 
For example, although the study by Miller et al. (1994) (cited above) showed that 
clozapine was more effective than haloperidol in the treatment of negative symptoms, 
the improvement in these symptoms only reached 31%. This further supports the fact 
that treatments for negative symptoms are urgently needed in order for patient 
adherence and personal suffering to be improved.
1.6 The importance of animal models in treatment development
Schizophrenia has proved to be a challenging disorder to model in animals since its 
origin is unknown and its diagnosis relies on behavioural abnormalities that may only 
be expressed in humans. It is also difficult to discern the fidelity of animal models 
since no obvious biological marker exists (Lipska & Weinberger, 2000).
Nevertheless, animal models of schizophrenia have been used to investigate the 
pathology of the disease and to the aid the development of new treatments (e.g. Lewis 
& Lieberman, 2000; Lipska & Weinberger, 2000; Morris, Cochran, & Pratt, 2005). 
Most of the available models reflect the pathology and behavioural manifestations of 
the positive symptoms of schizophrenia. This is reflected by the fact that the majority 
of treatments developed for schizophrenia have been most effective against the 
positive symptoms. However, in order to screen new treatments to assess their 
potential efficacy against negative symptoms in a pre-clinical setting, it is of great 
benefit to have animal models that reliably reflect those aspects of the disease. This is 
particularly difficult in animals since negative symptoms are often described as 
emotional in nature.
One main objective of this body of work is to attempt to identify an analogue 
of the negative symptom, anhedonia, in an animal model of schizophrenia. An
22
important feature of a model is that it should not be impractical to use in large scale 
studies such as those generally used in pharmaceutical research. If a reliable indicator 
of anhedonia could be generated in animals, this could provide an invaluable screen 
for the development of therapeutic compounds.
1.7 Anhedonia in schizophrenia
Anhedonia is commonly understood as a diminished capacity to experience pleasure. 
Classic descriptions of schizophrenia, provided by Kraeplin (1919) and Bleuler 
(1911) emphasised the presence of anhedonia. At a later date major theorists such as 
Rado (1956) and Meehl (1962) proposed that anhedonia may be one of the four 
cardinal symptoms of schizophrenia. Meehl further suggested that anhedonia is an 
indicator of genetic vulnerability necessary for the onset of schizophrenia and also 
predicts the severity of the social impairments that will be experienced by a sufferer. 
However, more recently, Pelizza and Ferrari (2009) found that out of a sample of 80 
schizophrenia sufferers, anhedonia scores were only significantly higher than controls 
in 45% of patients. Positive correlations of anhedonia with negative and disorganised 
symptoms were found, indicating that Meehl’s hypothesis of anhedonia being a 
necessary factor in the aetiology of schizophrenia is limited, at most, to subgroups 
characterised by high levels of negative and disorganised symptoms. However, since 
this subgroup is the most problematic to treat and has the poorest prognosis in terms 
of functional outcome, the study of anhedonia is of great importance.
Anhedonia is often classified into different forms. Chapman, Chapman and 
Raulin (1976) drew a distinction between two types of anhedonia, physical and social, 
and devised scales of assessment for each. The physical assessment scale included a 
variety of pleasures such as viewing a sunset, eating and drinking, whereas the social
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anhedonia scale contained pleasures associated with spending time with others and 
having friendships. Chapman et al. confirmed that people with schizophrenia 
generally have significantly higher levels of physical and social anhedonia than 
controls. Andreasen (1982) subsequently included these two forms of anhedonia in 
the anhedonia-asociality subscale of the Scale for the Assessment of Negative 
Symptoms (SANS), the most frequently used measure of anhedonia in modem 
clinical research.
Another distinction that has been made between different forms of anhedonia 
relies on the distinction between pleasure that occurs at the time of a particular 
experience (consummatory pleasure) and pleasure that occurs in advance of an 
experience (anticipatory pleasure) (Gard, Gard, Kring, & John, 2006). Gard et al. 
(2006) reported that people with schizophrenia experience lower levels of 
anticipatory pleasure than controls, but display intact consummatory pleasure.
A major factor that hampers the diagnosis and development of treatments for 
anhedonia stems from the fact that diagnostic scales of assessment most commonly 
do not differentiate between the different forms of the symptom outlined above. 
Additionally, diagnostic tools tend to obscure the boundaries between purely hedonic 
factors and other capacities that are also often impaired in schizophrenia, such as 
motivational and cognitive factors (Horan, Kring, & Blanchard, 2006). For example, 
the SANS questionnaire contains items that enquire about the frequency of 
engagement in physically or socially enjoyable activities. However, the ratings 
provided by such questions may reflect cognitive deficits, motivational issues, 
financial constraints or paranoia, for example, rather than an inability to experience 
pleasure per se.
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The occurrence of cognitive impairment in schizophrenia has been well- 
documented: In particular, memory impairment and deficits in executive function 
have been frequently highlighted. Impairments in both immediate and delayed recall 
have been found during acute psychotic episodes and during remission (e.g.
Mohamed, Paulsen, O’Leary, Arndt, et al., 1999; Hoff, Riorden, O’Donnell, Morris, 
et al., 1992). Verbal and spatial memory deficits also appear to be essential 
components of schizophrenic pathology (e.g. Saykin, Shtasel, Gur, Kester, et al.,
1994; Joyce, Hutton, Mutsata, Webb, et al., 2002).
People with schizophrenia have difficulties with problem-solving and 
planning (Hutton, Puri, Duncan, Robbins, et al., 1998). Aspects of executive 
functioning such as sequencing, organisation and flexibility show high levels of 
impairment in patients with first episode schizophrenia compared with controls 
(Mohamed et al, 1999).
There is much evidence that although anhedonia is correlated to other 
symptoms (Blanchard, Mueser, & Bellack, 1998; Pelizza & Ferrari, 2009), it is in fact 
a distinct aspect of schizophrenia (Horan et al, 2006). For example, anhedonia and 
depression often show some overlap and can be difficult to differentiate clinically, but 
numerous factor analysis studies show that anhedonia and depression constitute 
separate factors in schizophrenia patients (Hafner, Loffler, Maurer, Hambrecht, & van 
der Heiden, 1999; Kitamura & Suga, 1991; Kulhara & Avasthi, 2003). In addition, 
anhedonia in schizophrenia also differs from anhedonia present in major depression, 
since in schizophrenia, anhedonia is stable over time and tends to remain during 
remission from psychotic symptoms, whereas anhedonia in depression tends to co­
occur with depressive episodes (Pelizza & Ferrari, 2009). Anhedonia is also 
frequently confused with apathy. Although people with anhedonia show a reduction
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in positive emotions, the majority show equal or greater levels of negative emotions 
(e.g. Suslow, Roestel, Ohrmann, & Arolt, 2003), indicating that most do not 
experience global apathy. The fact that amelioration of psychotic symptoms in 
schizophrenia is not correlated with improvement in negative symptoms also 
demonstrates conclusively that anhedonia is not associated with positive symptoms 
(Miller et al, 1994). For this reason, animal models that reflect the positive symptoms 
of schizophrenia, or any of the other negative symptoms, are not adequate to serve as 
a pre-clinical screening tool for drugs with potential to treat anhedonia.
1.8 Treatment of anhedonia
Most of the available treatments for schizophrenia, and particularly typical 
antipsychotics, are D2 receptor antagonists. The revised dopamine hypothesis suggests 
that positive symptoms may result from an increase in dopaminergic activity in the 
mesolimbic system, whereas negative symptoms may result from a decrease in 
dopaminergic activity in the mesocortical system. However, neuroimaging has shown 
that reduced dopaminergic activity in the mesolimbic system is associated with severe 
negative symptoms. This bi-directional relationship between mesolimbic dopamine 
activity and schizophrenia symptoms may account for the worsening of negative 
symptoms caused by drugs that alleviate the positive symptoms (Juckel, et al., 2006). 
Indeed, it has been reported that just a single dose of haloperidol or respiridone can 
induce negative symptoms in healthy individuals (Artaloytia, Arango, Lahti, Sanz, 
Pascual, Cubero, et al., 2006). On the basis of such findings, it has been suggested 
that drugs targeting neurotransmitter systems other than the dopaminergic system 
may be more effective in the treatment of anhedonia (Erhart, Marder, & Carpenter, 
2006; Wolf, 2006). As mentioned previously, the development of appropriate
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treatments for anhedonia will be greatly enhanced by the generation of pre-clinical 
models of the symptom.
1.9 Choosing a modelling method
Traditionally, animal models of schizophrenia have involved manipulation of the 
dopaminergic neurotransmitter system (Lipska & Weinberger, 2000). This has meant 
that most antipsychotic drugs produced to date have their effects via the dopaminergic 
system. The side effects of these drugs, along with their inability to treat the non- 
psychotic symptoms of schizophrenia have led to the development of new models in 
recent years.
Neurodevelopmental Models
Neurodevelopmental models attempt to reflect the hypothesised aetiology of 
schizophrenia. A number of studies have implicated developmental insults as 
contributory factors in the disease process. These factors include malnutrition (e.g. 
Susser & Lin, 1992), obstetrical complications during pregnancy or birth (e.g. 
Dalman, Allebeck, Cullberg, Grunewald, & Koster, 1999), and maternal influenza 
(Adams, Kendell, Hare, & Munkjorgensen, 1993). When these factors are imposed in 
animals, aspects of schizophrenia-like behaviour and pathology result. For example, 
gestational malnutrition has been shown to negatively affect learning and cognition 
(Tonkiss & Galler, 1990).Obstetrical complications have been reflected in animals by 
carrying out caesarean birth or inducing anoxia during birth, resulting in changes in 
dopamine activity in the mesolimbic system in adulthood (e.g. ElKhodor & Boksa, 
1997). Additionally, pre-natal exposure to influenza has been reported to cause 
disorganised hippocampal pyramidal cells, consistent with what is seen in
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schizophrenia, in some of the offspring of mice exposed to the virus (Cotter, et al., 
1995).
Other neurodevelopmental models do not seek to reflect the causes of the 
disease, but to produce disease-like pathology by disrupting neurogenesis. An 
example of this is the methylazoxymethanol acetate (MAM) model. This model relies 
upon disruption of neurodevelopment by administration of a DNA methylating agent 
to pregnant rats on gestational day 17 (GDI7). At this stage in development MAM 
exposure affects development of the frontal and temporal cortices, resulting in 
neuroanatomical and behavioural features resembling those in schizophrenia. 
Neuroanatomically, GDI7 MAM exposure produces reductions in cortical thickness 
in the medial pre-frontal cortex and the hippocampus (Flagstad, et al., 2004; Le Pen, 
et al., 2006). In the human condition, similar reductions in cortical thickness have 
been found in the pre-frontal cortex and the temporal lobe (Wright, et al., 2000).
Other developmental models of schizophrenia have relied upon neonatal 
lesioning of the hippocampus. It has been found that neonatal lesions of the ventral 
hippocampus produce increased mesolimbic dopamine transmission, enhanced 
sensitivity to NMDA receptor antagonists, and impairments in latent inhibition and 
social behaviours which, in similarity to the disease state, appear only in adulthood 
(see Lipska & Weinberger, 2000 for a review).
Genetic Models
Genetic epidemiological studies have suggested that genetic factors are largely 
responsible for individual variation in susceptibility to schizophrenia. The 
susceptibility genes for which the most supporting data is available are those encoding
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dysbindin (DTNBP1) and neuregulin 1 (NRG1) (Owen, Craddock, O’Donovan,
2005).
Dysbindin binds to both a- and p- dystobrevin, which are components of the 
dystrophin glycoprotein complex (Benson, Newey, Martin-Rendon, Hawkes, et al., 
2001). Dysbindin is reduced in the schizophrenic brain within glutamatergic neurones 
of the hippocampus (Straub, 2002), and a reduction in glutamate release has been 
found in cultured neurones with reduced DTNBP1 expression (Numakawa, Yagasaki, 
Ishimoto, Okada, et al., 2004). This suggests that DTNBP1 may contribute to 
schizophrenia risk by altering glutamate release.
Neuregulin 1 encodes around fifteen proteins with a wide range of functions in 
the brain, including, neurotransmission, axon guidance, glial differentiation, 
myelination and synaptogenesis (Corfas, Roy & Buxbaum, 2004). Impairment in any 
of these functions could increase an individual’s susceptibility to schizophrenia.
A more recent discovery concerns the involvement of the gene ZNF804A in 
schizophrenia. O’Donovan, Craddock, Norton et al. (2008) carried out a genome-wide 
association study reported evidence for association between rs 1344706 within 
ZNF804A (encoding zinc-finger protein 804A). Proteins with this zinc-finger domain 
were originally identified as DNA-binding molecules with a role in transcription. In 
addition, the mouse homologue of ZNF804A has recently been suggested to be 
involved in the regulation of early neurodevelopment (Chung, Lee, Deocaris, Min et 
al., 2010). Although much work is still to be done to understand the role of this gene, 
its genome-wide significance is attracting much research activity (Donohoe, Morris & 
Corvin, 2010)
Schizophrenia has also been associated with several chromosomal 
abnormalities (MacIntyre, Blackwood, Porteous, Pickward, et al., 2003). For example,
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adults with 22ql 1 deletion syndrome have an increased risk for schizophrenia 
(Williams & Owen, 2004). Candidate genes mapping to this region include catechol- 
O-methyltransferase (COMT) and proline dehydrogenase (PRODH) (Kirov, Williams, 
Preece, et al., 2004). Additionally, a chromosomal translocation has been implicated 
in schizophrenia, disrupting two genes on chromosome 1: DISCI and DISC2. DISCI 
appears to be related to neuronal migration and intracellular transport, compatible 
with a role in schizophrenia (Ozeki, Tomoda, Kleiderlein, Kamiya, et al., 2003).
Genetic models have been produced on the basis that genetic abnormalities are 
associated with predisposition to schizophrenia. Such models have been used to 
investigate the involvement of neurotransmitter receptors in schizophrenia and have 
been useful for the replication of social anhedonia. For example, Mohn, Gainetdinov, 
Caron and Koller (1999) created a mouse model of schizophrenia by producing a 
mutant strain with reduced numbers of NMD A receptors. Unlike control animals, 
these mice tended to avoid social contact with one another, an abnormality that was 
reversed by acute clozapine treatment. Genetic models have the added benefit that 
they can be used to study the interaction between developmental and genetic factors 
in the aetiology of schizophrenia.
NMDA receptor antagonism
Pharmacological models produced by acute and sub-chronic administration of NMDA 
antagonists such as PCP, s-(+)-ketamine and (+)MK-801 have become popular in 
recent years. These models have evolved from ideas surrounding the glutamate 
hypothesis of schizophrenia (see section 1.4). Morris et al. (2005) suggested that 
NMDA antagonists, and in particular PCP, are purported to be unrivalled in their 
ability to mimic both the positive and negative symptoms of schizophrenia and the
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underlying pathology of the disorder. In humans, acute treatment with NMDA 
antagonists (particularly PCP and s-(+)-ketamine) can induce positive symptoms (e.g. 
Krystal, et al., 1994; Malhotra, et al., 1996) and cognitive deficits (Malhotra et al, 
1996). The translational capacity of this treatment into a pre-clinical setting has also 
been revealed. For example, in rodents, acute doses of NMDA antagonists can induce 
effects which may relate to schizophrenic symptomatology, such as augmented 
stereotyped behaviours and hyperlocomotion (e.g. Castellani & Adams, 1981; Verma 
& Moghaddam, 1996)1. Additionally, Dunn and Killcross (2007) observed that 
conditional discrimination performance is disrupted by acute administration of PCP. 
In a conditional discrimination task, animals learn to make an appropriate response 
according to the particular stimulus that is presented to them. For example, in this 
study, animals were reinforced if they pressed a left lever in response to a click, or a 
right lever in response to a tone. Impairment in this task can be likened to a cognitive 
deficit in humans with schizophrenia whereby difficulty is experienced in using 
environmental cues to inform goal-directed behaviour (e.g. Stratta, Daneluzzo, 
Bustini, Casacchia, & Rossi, 1998; Stratta, Daneluzzo, Bustini, Prosperini, & Rossi,
2000). Dunn and Killcross proposed that PCP disrupts conditional discrimination 
performance by increasing extracellular levels of dopamine in the pre-frontal cortex. 
This is supported by their finding that drugs that are antagonists of Di receptors 
(abundant in the pre-frontal cortex) are able to attenuate this deficit, whereas 
antagonists of D2 receptors (almost absent from the pre-frontal cortex) are not.
Sub-chronic administration of PCP in rodents is thought to be even more 
relevant than acute treatment as a model of schizophrenia as it appears to have greater 
capacity to produce the non-psychotic symptoms of schizophrenia (Morris, et al.,
1 Hyperlocomotion is thought to reflect dysfunction within the striatal dopaminergic system, related to 
the positive symptoms o f schizophrenia.
2005). For example, in humans, repeated exposure to PCP produces long-term 
cognitive deficits (e.g. Cosgrove & Newell, 1991) and negative symptoms (Javitt & 
Zukin, 1991). This thought to be because, in contrast to acute PCP treatment, sub­
chronic treatment produces a reduction in glucose utilisation and blood flow in the 
prefrontal cortex (hypofrontality). This hypofrontality is exhibited in schizophrenia 
and it correlates with deficits in cognitive function (e.g. Buchsbaum, et al., 1990).
In addition to these pathological changes, rats that receive withdrawal from 
sub-chronic PCP treatment also show changes in social behaviour (Sams-Dodd, 1998) 
that are closely related to the abnormalities observed in schizophrenia (but see also 
Jenkins, Harte, McKibben, Elliott, & Reynolds, 2008). In addition, rats treated sub- 
chronically with PCP also exhibit cognitive deficits in terms of conditional 
discrimination performance (e.g. Dunn & Killcross, 2006). Dunn and Killcross (2006) 
also attribute this deficit to disturbance in pre-frontal dopaminergic activity since sub­
chronic PCP treatment reduces levels of prefrontal dopamine. In their investigation 
cognitive function was improved following clozapine treatment, which is known to 
restore pre-frontal dopamine, but not by haloperidol, which has an opposite effect on 
dopamine activity. Dunn and Killcross suggested that the sub-chronic PCP model 
therefore has significant predictive validity since the efficacy of clozapine but not 
haloperidol in the amelioration of cognitive deficits in rats may reflect the superiority 
of certain atypical antipsychotics in the treatment of cognitive symptoms in humans.
Attempts to model schizophrenic anhedonia using the NMDA antagonist PCP 
have already been made. It has been claimed that an analogue of anhedonia is present 
in rats twenty hours after a large (15mg/kg) dose of PCP (Baird, Turgeon, Wallman,
& Hulick, 2008; Turgeon & Hoge, 2003). This was inferred from a decrease in the 
amount of sucrose consumed voluntarily by PCP-treated animals. Decreased
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voluntary consumption of a sucrose solution is a commonly used indicator of 
anhedonia in stress-induced models of human affective disorders (e.g. Papp & Moryl, 
1994; Papp, Willner, & Muscat, 1991; Rygula, et al., 2005; Willner, Lappas, Cheeta, 
& Muscat, 1994; Zurita, Martijena, Cuadra, Brandao, & Molina, 2000; Zurita & 
Molina, 1999). However, the assumption that general consumption reflects a hedonic 
response is problematic since the amount an animal consumes may reflect a number 
of ingestive and motor factors that do not necessarily relate to the value or liking of a 
reward. Unfortunately, there are also problems with the face validity of a 
schizophrenia model produced by withdrawal from an acute high dose of PCP such as 
that produced by Turgeon and Hoge (2003) since the pathology produced by 
administration of large doses of PCP is inconsistent with that seen in schizophrenia 
(Olney, Labruyere, & Price, 1989).
Despite the limitations of the above studies, it is plausible that NMDA 
antagonists do in fact have the potential to produce anhedonia in animals. Indeed, the 
similarity between the pathology brought about by sub-chronic PCP treatment and 
that seen in schizophrenia, along with the numerous reports of the effectiveness of 
NMDA antagonists in producing negative and cognitive symptoms in both humans 
and animals (e.g. Javitt & Zukin, 1991; Lahti et al. 2001; Dunn & Killcross, 2006) 
suggest that models produced via NMDA antagonist administration hold great 
promise as a model of anhedonia. In addition, NMDA antagonist treatment is 
relatively practical to implement in large scale pharmacological screening studies, and 
could therefore be more useful in drug development than other, more labour-intensive 
models. For these reasons, pharmacological treatment with NMDA antagonists was 
selected as a primary modelling method throughout this thesis in order to explore the 
presence of anhedonia.
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1.10 NMDA antagonist mechanism of action
NMDA receptors act at selective ion channels and are therefore known as ionotropic 
glutamate receptors. They are tetramers comprised of at least one NR1 subunit in 
combination with different numbers of NR2 and NR3 subunits. Each subunit can exist 
as one of a number of isoforms, thereby allowing the formation of many different 
NMDA receptors with distinct pharmacological properties (Lynch & Guttmann,
2001). Unusually for the ionotropic glutamate receptors, glutamate is not the only 
agonist of the NMDA receptor. Glycine is a co-agonist and both transmitters must 
bind in order for the receptor to function (Johnson & Ascher, 1987). At resting 
membrane potentials NMDA receptors are inactive due to a voltage-dependent block 
of the channel pore by magnesium ions, preventing ion flow through it. Sustained 
activation of AMPA receptors depolarises the post-synaptic cell, releasing the channel 
inhibition and thus allowing NMDA receptor activation and cation influx, thereby 
enabling a variety of signalling cascades (Lynch and Guttmann, 2001).
The NMDA receptor antagonist PCP is a non-competitive antagonist and is frequently 
referred to as an ‘open channel blocker’. Open channel blockers enter the NMDA 
receptor-associated ion channel only when it is already open, and become trapped 
inside the channel when the agonist unbinds. Javitt and Zukin (1991) suggested that, 
despite PCP’s other action on potassium and sodium channels, it is the blockade of 
NMDA receptor-associated calcium channels that underlie its psychotomimetic 
properties. S-(+)-ketamine is a weaker blocker, and (+)MK-801 a more potent 
blocker, of these same channels (Ellison, 1994).
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1.11 Measurement of hedonic responses in animals
Traditionally, assessment of the hedonic value of rewards has relied upon 
measurements of general consumption, preference, or willingness to make 
instrumental responses. The assumption behind such tests is that the palatability of a 
reinforcer is inextricably linked to the amount an animal consumes. Berridge (1996) 
has suggested that consumption actually reflects how much an animal wants a 
reinforcer, whereas palatability reflects how much an animal likes it. Via a review of 
taste reactivity studies he has suggested that ‘wanting’ and ‘liking’ are two separate 
components of reward value.
Taste reactivity was developed by Grill and Norgen (1978b) to provide a more 
informative measure of hedonic responses in rats than general consumption. This 
method involves infusing a small quantity of a taste solution directly into a rat’s oral 
cavity and video-recording the response for frame by frame analysis. Grill and 
Norgen examined sucrose, NaCl, HCL and quinine, and found that the responses to 
these taste stimuli were consistent within and between rats. Responses to quinine, a 
substance known to be bitter and unpalatable, involved gaping and increased body 
movement, whereas responses to sucrose, known to be sweet and palatable, were 
characterised by patterns of mouth movements and tongue protrusions. Since 
reactions to palatable (e.g. sweet) and unpalatable (e.g. bitter) solutions are well 
characterised, the taste reactivity test allows the palatability of novel tastants to be 
assessed by examining whether their taste reactivity profiles are a better match to 
those produced by sucrose or quinine.
There are also examples of taste reactivity changing because of learning. For 
example, when a palatable tastant is paired with lithium chloride administration in 
rats, consumption of that solution is subsequently reduced. Taste reactivity testing
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shows that the tastant also becomes aversive under such circumstances (Berridge, 
Grill, & Norgren, 1981; Grill & Norgren, 1978a; Parker, Hutchison, & Riley, 1982). 
However, Parker (2003) cites evidence that although a number of stimuli can cause a 
reduction in the consumption of a solution it is paired with, stimuli that do not 
produce nausea do not produce an aversion to the taste of the solution. This is true in 
the case of foot-shock, for example (Pelchat, Grill, Rozin, & Jacobs, 1983). Parker 
(2003) suggests that the reduction in consumption brought about by nausea is related 
to a conditioned disgust response in which an animal learns to dislike the tastant, 
whereas reduced consumption brought about by pairing with other aversive stimuli is 
related to a conditioned fear response in which the palatability of the tastant is 
unchanged. Findings indicating that reduced consumption is not always accompanied 
by palatability changes support the idea that taste reactivity responses reflect 
palatability (or liking) rather than characteristic responses to the sensory properties of 
a tastant. That is, a learned association between an aversive stimulus and a taste 
should not change the sensory properties of the tastant, but it can change the hedonic 
reaction to it. Such observations are consistent with the ideas of Berridge (1996), who 
suggested that palatability is not reflexive, but instead reflects both the sensory 
properties of a tastant and its prior associations.
There are also instances where conditioned associations produce an increase 
in palatability using taste reactivity testing. For example, Myers and Sclafani (2001b) 
showed that pairing flavoured saccharin with intragastric glucose infusion resulted in 
an increase in the palatability, indicated by an increased number of positive 
responses.
Taste reactivity studies, examining brain and pharmacological manipulations 
have also indicated that wanting (linked to the motivation to consume) and liking
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(linked to palatability) do not always co-vary and can frequently be manipulated 
separately (Berridge, 1996). For example, Berridge, Venier and Robinson (1989) 
brought about ablation of the dopaminergic neurones of the substantia nigra by 
treating rats with 6-hydroxydopamine. The subsequent depletion of dopamine caused 
rats to become aphagic. However, their hedonic reactions to sweet and bitter solutions 
remained intact, indicating that wanting had changed independently of liking.
Berridge (1996) cites another dramatic example of this dissociation in rats who 
received electrical stimulation of the lateral hypothalamus, a treatment which 
potentiates feeding. Taste reactivity tests showed that hedonic reactions were not 
potentiated and unexpectedly, aversive reactions were enhanced (1991).
Data from such taste reactivity studies led Berridge (1996) to conclude that 
consumption (linked to wanting) is controlled mainly by mesotelencephalic dopamine 
neurotransmitter systems, whereas palatability (linked to liking) appears to be linked 
to opioid and GABA neurotransmitter systems. The idea that dopamine is not closely 
linked to liking, is not inconsistent with the fact that typical antipsychotics are not 
effective in the treatment of anhedonia.
Taste reactivity studies conclusively demonstrate that consumption and 
palatability do not always co-vary. In relation to the study of anhedonia, palatability 
(linked to liking) would have greater relevance than consumption (linked to wanting). 
Therefore, for the investigation of anhedonia in animal models, measures of general 
consumption are not sufficient. However, despite its advantages over general 
consumption measures, the taste reactivity method has limitations that prevent it from 
being effective for examining the presence of anhedonia. The most crucial of these is 
that taste reactivity tests can only provide categorical information as to whether 
something is palatable or aversive to an animal, but it cannot give information on how
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palatable a substance is. Since anhedonia is characterised by a reduction in the 
capacity to experience pleasure, but may not make normally pleasurable experiences 
aversive, it is unlikely that taste reactivity will enable the detection of anhedonia.
Another way in which the value of a reward can be measured, with more 
direct relevance to anhedonia, is to examine its palatability via microstructural 
analysis of licking during ingestion. Rats rarely show continuous consumption of a 
liquid. Instead they perform repeated clusters of licks separated by pauses. The 
number of licks in each cluster (cluster size) has a positive, monotonic relationship 
with the concentration of a palatable solution such as sucrose (Davis & Smith, 1992; 
Hsiao & Fan, 1993; Spector, Klumpp, & Kaplan, 1998). Cluster size has a negative 
monotonic relationship with the concentration of an unpalatable solution such as 
quinine (Spector & St John, 1998). These findings have led to the idea that cluster 
size may be a useful measure of reinforcer palatability and hence, reward value. 
Importantly, cluster size is not simply a reflection of the amount consumed. For 
example, although cluster size increases with increased sucrose concentration, the 
amount consumed varies in an inverted U-shaped function (e.g. Emits & Corbit, 
1973). This relationship means that it is possible to select many pairs of different 
concentrations in which each solution, when offered to a rat, gives rise to different 
cluster size measurements, whilst overall consumption may be the same. In addition, 
studies of conditioned taste aversion have also shown that palatability and 
consumption can dissociate. For example, Dwyer, Boakes, and Hayward (2008) 
showed that consumption of a palatable saccharin solution is reduced by pairing with 
amphetamine administration, lithium administration or forced wheel running. 
However, only lithium administration and wheel running produced a reduction in 
cluster size indicative of reduced palatability. This is consistent with Parker’s
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suggestion that palatability is only reduced by stimuli that induce nausea (Parker 
2003). In contrast, Myers and Sclafani (2001a) demonstrated that flavour preference 
learning can increase the palatability of the CS+ flavour using lick cluster size 
measures in addition to their concurrent analysis of taste reactivity. Moreover, a 
flavour conditioning study by Dwyer (2008) showed that palatability responses can be 
modified in situations even when consumption is not. In this study, conditioned 
stimulus (CS) flavours were paired with 2% and 16% maltodextrin as the 
unconditioned stimuli (US). CS1 was paired with 2% maltodextrin and CS2 was 
paired with 16% maltodextrin. Both flavours were then tested in combination with 
both maltodextrin concentrations and it was found that animals consumed more CS1 
than CS2 when paired with 2% maltodextrin, but not when paired with 16% 
maltodextrin. On the other hand cluster size was always greater with CS1 than with 
CS2. In summary, there is a double dissociation between cluster size measures of 
palatability and measures of consumption whereby some treatments affect cluster size 
but not consumption, while others affect consumption but not cluster size.
In addition to the parallels between palatability measurements made using 
microstructural analysis and those made using taste reactivity testing, the lick analysis 
method also benefits from its sensitivity to drug treatments. For example, Higgs and 
Cooper (2005) investigated the effects of the benzodiazepine receptor agonist, 
midazolam maleate, on the licking microstructure of water-deprived rats during 
ingestion of sodium chloride solutions. Midazolam increased the amount of solution 
consumed by increasing the size of lick clusters rather than by increasing the number 
of lick clusters. Therefore the analysis of licking suggests that the benzodiazepine 
receptor agonist increased intake by increasing the perceived palatability of the 
solution. Other drugs that increase consumption may do so in different ways. For
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example, morphine causes an increase in the number of lick clusters produced but 
does not increase cluster size (Higgs & Cooper, 1998). Microstructural analysis of 
licking is therefore a very useful method for discerning the mode of action of 
different drugs.
The sensitivity of microstructural analysis to small changes in hedonic value, 
in addition to the fact that lick recordings can be automated make this method more 
accurate and less cumbersome than the taste reactivity method for examining hedonic 
responses. In the absence of changes in the test solution, any change in palatability 
indicates an effect on animal itself. Therefore, the lick analysis method provides a 
very useful tool for exploring the presence of anhedonia in pre-clinical animal 
models, and so is the primary measurement used for the experiments presented in this 
thesis.
1.12 Using the lick analysis method
The lick analysis method relies on the automated recording of each lick made by each 
rat. From this data the number and size of lick clusters and the average inter-lick 
interval (ILI) within clusters can be extracted. Throughout this thesis, licks separated 
by an interval of less than 0.5s are considered to fall within the same cluster. If this 
interval is exceeded, further licks mark the beginning of a new cluster. This cluster 
definition was utilised by Davis and Smith (1992). A Is criterion has been used by 
other researchers (e.g. Spector, et al., 1998). However, this makes little difference as 
most pauses greater than 0.5s are also greater than Is (e.g. Davis & Smith, 1992; 
Spector etal. 1998).
The ability to calculate the average interval between each lick is a major 
advantage of this method. ILI normally shows very little variability, except when
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motoric changes are induced: for example, by changes in posture (Weijnen, 1998), or 
disturbances in motor pattern generation in the hind brain (Aja, Sahandy, Ladenheim, 
Schwartz, & Moran, 2001). Since an increase in ILI is likely to impact upon cluster 
size measurements, it is very useful to be able to monitor this parameter when using 
drugs that may produce motor abnormality. For this reason, ILI was monitored for all 
experiments in this thesis. However, since it generally indicates motor problems, and 
does not reflect hedonic value, ILI will only be reported when drug-induced changes, 
indicative of motor abnormality, arise.
1.13 Summary
To conclude, the introduction to this thesis has discussed the importance of anhedonia 
as a negative symptom of schizophrenia and has highlighted the limitations of 
currently available treatments in ameliorating this symptom. The lack of animal 
models able to reliably reflect the negative symptoms of schizophrenia has hindered 
progress in the development of adequate treatment. The assessment of anhedonia in 
an animal model of schizophrenia will require a sensitive measure of hedonic 
reactions. I have suggested that microstructural analysis of licking during ingestion 
provides such a method by giving an index of palatability that is sensitive to small 
changes in hedonic value. The advantages of pharmacological models relying on 
NMDA receptor antagonist treatment in rodents has also been discussed since this 
method has translational validity and is efficient to produce, making it useful for 
large-scale screening of therapeutic compounds. Therefore, the main focus of this 
thesis will be to examine NMDA receptor antagonist models of schizophrenia using 
microstructural analysis of licking. The initial work presented will describe my 
attempts to use lick analysis in conjunction with operant schedules of reinforcement.
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Subsequent chapters will focus on the effects of NMDA receptor antagonists on lick 
analysis measures during voluntary consumption in the absence of operant 
responding.
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CHAPTER TWO
Effects of operant responding on drinking behaviour
2.1 Introduction
Assays incorporating various schedules of instrumental responding have been used to 
compare the in vivo effects of NMDA antagonists to examine their potential to model 
the motivational and cognitive deficits present in schizophrenia. For example, 
Gilmour et al. (2009) compared a selection of NMDA antagonists, including PCP, s- 
(+)-ketamine and (+)MK-801 using a series of variable interval (VI) schedules of 
reinforcement. In an operant VI schedule, animals are rewarded after a variable 
period of time if they press an ‘active’ lever following this interval. It was found that 
s-(+)-ketamine produced a dose-dependent decrease in instrumental output, whereas 
PCP and (+)MK-801 produced bi-directional effects in which lower doses increased 
responding and higher doses eventually decreased responding. It is possible that the 
performance disparity produced by these drugs may reflect differences in motivation 
to obtain reinforcers. It is also possible that decreased responding may be secondary 
to a drug-induced reduction in the perceived hedonic value of the reinforcer, which 
may be likened to anhedonia.
There are, however, several reasons why decreased instrumental responding 
cannot be unambiguously interpreted in terms of reduced hedonic value. Firstly, the 
physical effort involved in lever pressing may mean that this measure will be affected 
by any motoric changes induced by drugs. Secondly, it has been shown that with 
continued operant training, performance can become habitual rather than goal- 
directed. This means that a cue such as a lever may elicit a response regardless of the 
outcome value, once a stimulus-response habit has been formed (Dickinson &
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Balleine, 2002). A third reason why changes in instrumental responding cannot be 
confidently used for the purposes of studying anhedonia stems from the apparent 
dissociation between ‘wanting’ and ‘liking’ discussed earlier (Berridge et al, 1996). 
Lever pressing is an appetitive response that more closely reflects motivation to 
obtain a reinforcer than the reinforcer’s hedonic value per se, and therefore this 
measure alone is not adequate to infer changes in an animal’s capacity to experience 
pleasure. For these reasons, it was considered that a useful initial step in attempting to 
assess hedonic value would be to combine operant responding with the lick analysis 
technique described in the introduction by training rats to press a lever to gain access 
to a sucrose solution.
Preliminary training sessions were carried out to determine whether food- 
restricted rats would reliably press a lever to gain access to a sucrose solution. Fixed 
ratio (FR) schedules were used for this purpose. In a fixed ratio schedule a reinforcer 
is presented to an animal after they have made a specified number of lever presses. 
During the preliminary training sessions the fixed ratio response requirement was 
gradually increased from one lever press (FR1) to 50 lever presses (FR50). 
Interestingly, it was observed that the size of lick clusters during ingestion of the 
sucrose reinforcer increased as the response requirement was raised. This increase in 
cluster size may have been due to the extra experience of drinking in the experimental 
apparatus. However, it could also be reflective of an effect whereby the more effort 
rats expended to obtain the reinforcer, the greater its perceived palatability. Although 
the latter would be an important and interesting effect, it would also imply that the 
measurement of hedonic value using operant schedules has a major confound. 
Therefore, Experiment 1 sought to determine whether increased reinforcer experience
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or increased effort was responsible for the increased cluster size observed with 
increasing response requirement.
2.2 Experiment 1
Method
Subjects
Experiment 1 was conducted in the behavioural neuroscience laboratory at the School 
of Psychology, Cardiff University. 12 male hooded Lister rats supplied by OLAC, 
Bicester, UK were used. They were housed in pairs on a 12 hour /12 hour light / dark 
cycle and experimental procedures were performed 4 hours into the light portion of 
the cycle. The animals were maintained on a food restricted diet with ad libitum water 
access for the duration of the experiment. Their initial free-feeding weights ranged 
285-330 grams. Daily food rations were placed in the home cages 30 minutes after 
completion of the experimental session. Food rations were monitored and adjusted to 
maintain the animals at no less than 85% of their free-feeding weights.
Apparatus
Testing was carried out in a room containing 4 operant chambers measuring 
30><24x21cm. These chambers were housed in light and sound attenuation boxes. The 
chamber floor consisted of 19 steel rods measuring 4.8mm in diameter. Two of the 
chamber walls were clear perspex and two were aluminium. A lever was positioned 
on the right hand side of one of the aluminium walls and a hole was positioned 5 cm 
above the grid floor on the left hand side to allow rats to access solutions during 
experimental sessions. Solutions were given in 50ml bottles attached to stainless steel
45
drinking spouts. These were fastened to motorised holders that positioned the metal 
spout level with the wall of the chamber, and retracted it when required. A contact- 
sensitive lickometer registered the time of each lick to the nearest 0.01s. This was 
recorded by a computer using MED-PC software (Med Associates Inc., St Albans, 
VT, USA). Licks separated by an interval of less than 0.5s were considered to fall 
within the same cluster. The number and size of lick clusters, the average inter-lick 
interval (ILI) within clusters, and the number of licks produced during each reinforcer 
presentation were extracted from the data recorded.
The amount of solution consumed by each animal was measured by weighing 
the drinking bottles before and after each session. The reinforcer was a 10% 
weight/weight sucrose solution.
Procedure
Rats received daily (Monday-Friday) 30 minute sessions throughout training and 
testing. In the first eleven sessions rats were trained to press a lever to gain 60 
seconds of sucrose access on random ratio (RR) schedules. During RR schedules 
reinforcement is presented after an average number of responses. During training, the 
average number of responses required for each reinforcer was increased from 1 to 50. 
Once animals were responding reliably on the RR50 schedule they received 
alternating sessions with RR10 and RR50 response ratios for four days. This was 
counterbalanced so that half of the animals received RR10 schedules on days 1 and 3, 
and half received RR50 schedules. This was reversed on days 2 and 4. Because 
animals were able to earn more rewards on the RR10 than the RR50 schedule, data 
analysis was performed on the first five rewards of each day only.
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Results
Statistical significance was set at p <.05 throughout this thesis. Figure 1A shows the 
mean number of licks per cluster in both the high response requirement (RR50) and 
low response requirement (RR10) conditions. Figure IB shows the mean number of 
licks produced per 60 second reinforcer. The lick cluster size measure of palatability 
was significantly higher in the high response requirement condition than in the low 
response requirement condition (/(l 1)=4.60,/k.001). By contrast, there were more 
licks/reinforcer when the response requirement was low than when the response 
requirement was high (/(l l)=2.73,/>=.020).
Summary of Experiment 1
Experiment 1 demonstrated that rats can be trained to press a lever to obtain 
moderately extended access to a sucrose solution. Additionally, it has shown that rats 
required to press a lever 50 times (high effort) to receive a sucrose reinforcer perceive 
this reward to be more palatable than when they press a lever only 10 times (low 
effort). This effect suggests there is a confound in the combined use of operant 
schedules and lick analysis to investigate anhedonia in pre-clinical models of 
schizophrenia.
2.3 Experiment 2
Although the findings of Experiment 1 complicate the use of operant responding in 
the measurement of hedonic value, the behavioural effect of reinforcer palatability 
increasing with effort is both unexpected and particularly interesting and thus 
warrants exploration. In fact, the effect bears striking resemblance to the human
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Figure 1: Shows the mean number of licks/cluster (Panel A) and licks/reinforcer 
(Panel B) with standard error of the mean (SEM), in low effort (RR10) and high effort 
(RR50) conditions.
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phenomenon whereby greater value is placed on the things worked hardest for. For 
this reason, I will now explore theoretical accounts relating to this effect.
According to Festinger (1957), this tendency can be attributed to cognitive 
dissonance: a state of psychological discomfort that occurs when there is a 
discrepancy between a person’s attitude and their actions. In such circumstances, 
humans try to reduce this dissonance by modifying their attitudes to complement their 
behaviour.
Festinger and Carlsmith (1959) paid people either $1 or $20 to take part in an 
essentially boring task and then tell a potential participant that the task was 
interesting. Intriguingly, when completing a questionnaire immediately following the 
task, participants paid $1 judged the task as more interesting than those paid $20. 
Festinger and Carlsmith argued that since $1 was not sufficient payment to justify the 
participants’ actions, they instead altered their perception of the task to reduce the 
dissonance that was produced by behaving in a way that conflicted with their attitude.
More recently, evidence has been found that conscious reasoning is not 
required for cognitive dissonance-like effects. Lieberman, Ochsner, Gilbert, & 
Schacter (2001) showed amnesics a number of art prints and asked them to rate each 
picture. They were later shown sets of these prints. Each set comprised of two pairs of 
prints, previously rated equal by the participants. The participants were then asked to 
choose which pair they would prefer to put up in their house. This requisite forced 
participants to perform a counter-attitudinal behaviour as they were asked to choose 
between things that they had previously described as equal. When asked to re-rate the 
initial two groups of art prints, participants rated the chosen prints higher and the 
rejected prints lower than they had in their initial rating. Interestingly, amnesics
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showed as much behaviour-induced change in their ratings as controls, despite having 
no explicit memory of the prints they had previously been asked to choose between, 
or the choices they had made. Festinger (1957) proposed that dissonance is produced 
when there is a discrepancy between a person’s attitudes and their behaviour. This 
produces psychological discomfort which may be resolved by that person changing 
their attitudes. According to this theory, a person must attribute the psychological 
discomfort experienced to a particular behaviour. This suggestion seems to rely on the 
person remembering their previously held attitudes or their counter-attitudinal 
behaviour. However, since the amnesic participants in this study have no memory of 
their initial picture ratings or the choices they subsequently made, this suggests that 
behaviour-induced attitude change may be more automatic than cognitive dissonance 
theory posits. Interestingly, similar effects have been observed using an adaptation of 
this paradigm in monkeys and young children, again raising the possibility that 
complex cognitive reasoning may not be required (Egan, Santos, & Bloom, 2007). 
However, West, Beckman, Vonk and Jett (in press) suggest that this effect does not 
exist in non-primates. In experimental trials, a variety of primate and non-primate 
species were given choices between two equally preferred food items and then 
presented with the rejected item and another equally preferred item. In control trials, 
animals were presented with one accessible and one inaccessible food item.
Following this they were presented with the previously inaccessible item and a novel 
item. It was found that primates preferred the novel item in experimental but not 
control trials. West et al. suggested that the primates resolved cognitive dissonance by 
reducing the value of items they rejected. However this did not occur in non-primate 
species.
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Another interesting effect that has been explained in terms of cognitive 
dissonance reduction is ‘Effort Justification’, in which greater value is given to 
rewards that are harder to obtain. In a classic study by Aronson and Mills (1959), 
young women underwent ‘severe’ or ‘mild’ initiation to join a discussion group. 
Participants in the severe initiation condition were asked to read aloud a sexually 
explicit passage, whereas those in the mild initiation group were given much less 
embarrassing material to read. When asked to rate the discussion group, the severe 
initiation group's ratings were significantly higher than those of the mild initiation 
group. That is, manipulating the effort required to join the group changed the 
participants’ perceived value of the outcome of their behaviour. Aronson and Mills 
suggested that the group whose initiation process was more difficult increased their 
valuation of the discussion group to resolve the dissonant relationship produced by 
undergoing severe embarrassment in order to join a discussion group of little value. 
There is some ambiguity as to whether the original proponents of cognitive 
dissonance theory believed that reasoned thought is necessary for behaviour-induced 
attitude change. However, the language used implies that this may be the case.
One way to investigate whether complex cognitive processing is required for 
effort justification is to determine whether this effect occurs in non-human animals. A 
number of studies indicate that some avian species show preference for stimuli 
associated with high effort tasks. For example, Kacelnik and Marsh (2002) found that 
starlings trained to fly either a short or long distance to reach different coloured 
response keys, which could be pecked to obtain a food reward, tended to prefer the 
coloured key that followed the highest effort (longest flight) when given a choice 
between both response keys. Similarly, Clement, Feltus, Kaiser, and Zentall (2000) 
presented pigeons with two different simple simultaneous discriminations, one that
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followed 20 pecks to an initial stimulus, and one that followed a single peck. 
Following this, pigeons showed a preference for the discrimination stimuli that 
followed the highest effort (20 pecks). However, these studies assess preference for 
stimuli that precede food reinforcement and do not measure the value of the reinforcer 
itself. There is therefore a fundamental distinction between these animal-based studies 
and those demonstrating effort justification in humans.
The suggestion that such an effort justification effect can occur in rats was 
raised by Lawrence and Festinger (1962), who manipulated the effort required for a 
reward by altering the incline of a ramp leading to a goal box containing food. The 
behavioural measure of reward value used in this experiment was resistance to 
extinction. Lawrence and Festinger asserted that since the high effort response took 
longer to extinguish, the rats must have learned more about these trials than the low 
effort trials. However, they suggested that since the reinforcer was the same in both 
trials, learning could have only been improved if animals perceived the reinforcer that 
followed high effort as more valuable. However, their behavioural measure of reward 
value, resistance to extinction, has subsequently been shown to be an inadequate 
measure of response strength, as it is thought to indicate ‘what’ is learned during a 
task rather than ‘how much’ is learned (Mackintosh, 1974). This point is illustrated by 
the fact that, in an operant context, extinction of a response is faster when an animal 
previously received large reinforcers than when they had received small reinforcers. 
Mackintosh argues that this effect can be explained by the idea that discrimination 
between training (where the reinforcer is present) and extinction (where it is absent) is 
easier when the reinforcer is large than when it is small. Mackintosh further 
illustrates the point that resistance to extinction is an indicator of what is learned 
rather than how much by referring to the fact that partial reinforcement leads to
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slower extinction of a response than continuous reinforcement. Similarly, this can be 
explained by the fact that it is easier to discriminate continuous reinforcement (where 
the reinforcer is present on every trial) from extinction (when it is never present) than 
it is to discriminate partial reinforcement (where the reinforcer is present on some 
trials but not others) from extinction. The effect reported by Lawrence and Festinger 
therefore provides insufficient evidence that effort increases the value of cues 
associated with rewards by causing an animal to learn more about them. In addition, 
Mackintosh’s suggestion can directly explain the effect observed by Lawrence and 
Festinger. Since a low effort response holds little salience, if the reinforcer is removed 
from this training situation the difference between training and test situations is large 
and more obvious than if a reinforcer is removed from a training condition that 
requires high effort, which holds greater salience. That is, the reinforcer would form a 
greater part of the whole training situation when the effort requirement is low and so 
its removal would create a greater generalisation decrement.
Several studies have failed to find effort-induced changes in reward value in 
rats. Armus (2001) and Jellison (2003) manipulated the effort required to press a lever 
to obtain sucrose pellets. Rats were rewarded with either grape or bacon flavoured 
sucrose pellets according to the degree of effort required. The value of these 
flavoured pellets was then assessed in a Y maze (Armus, 2001) or a T maze (Jellison, 
2003) in which the flavoured pellets associated with different effort requirements 
served as rewards for choosing particular maze arms. Animals showed no preference 
for arms containing reinforcers associated with high effort. The failure to find a 
significant effect of effort on reward value may have been due to the vast differences 
between the operant training context and the maze context used for testing, which 
may have prevented any effort-induced changes in flavour preference from
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transferring to the test context. Indeed, as noted by Zentall and Singer (2007), by the 
time the rats had learned about the new test context, any effort-induced flavour 
preference obtained during operant training may have reached extinction. In addition, 
Jellison (2003) noted that rats showed poor discrimination between grape and bacon 
flavoured pellets in preliminary experiments. This fact, coupled with the knowledge 
that rats tend to alternate spontaneously when visiting maze arms, suggests that Y and 
T mazes may not provide sufficiently sensitive tests for detecting effort-induced 
changes in the value of rewards.
However, the combination of operant responding and lick analysis employed 
in Experiment 1 provides an appropriate method to assess whether rats are subject to 
the effort justification effect. If this is the case then rewards that follow large numbers 
of lever presses (equivalent to the severe initiation in Aronson and Mill’s 1959 study) 
should be perceived to be of greater value than rewards that follow few lever presses 
(equivalent to the mild initiation). Experiment 1 showed that this is indeed the case. 
However, the effort involved in the lever press response requirement has two obvious 
components: work and waiting time, because it takes more work and more time to 
press a lever 50 times than 10. Therefore Experiment 2 investigated the possibility 
that differences in the interval between reinforcers in low and high ratio schedules 
may account for the changes in reward palatability seen in Experiment 1, using a 
procedure in which rats either worked (lever pressed), or just waited to be rewarded.
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Method
Subjects and Apparatus
16 male Hooded Lister rats supplied by OLAC Bicester, UK were used. Husbandry 
procedures and experimental apparatus were the same as those detailed for 
Experiment 1.
Procedure
The rats received daily (Monday-Friday) 30 minute sessions throughout training and 
testing. Rats were pre-trained to press a lever to gain 60 seconds of sucrose access on 
fixed ratio (FR) schedules. During FR schedules reinforcement is presented after a 
specific number of responses. During training, the number of responses required for 
each reinforcer was increased from 1 to 50. Once animals were responding reliably on 
the FR50 schedule they were run in four conditions: a low effort master condition, a 
low effort yoked condition, a high effort master condition, and a high effort yoked 
condition. When run in the low and high effort master conditions, rats were required 
to make 10 or 50 lever presses respectively to receive a 60 second presentation of 
sucrose. Rats in the corresponding yoked conditions received reinforcement at the 
same time as the master animals but did not have access to the lever (See Table 1). By 
making some rats work to obtain the reinforcer, whilst corresponding animals simply 
waited the same length of time, the effects of time and work on reinforcer value could 
be isolated.
Each rat was tested twice in all four conditions and the order in which rats 
were assigned to each condition was counter-balanced. The animals were re-trained 
on FR10 and FR50 schedules after every two test days to ensure that they continued
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Table 1:
Design o f experiment 2.
Condition Description
Low effort master 
High effort master 
Low effort yoked 
High effort yoked
Fixed response requirement of 10 lever presses
Fixed response requirement of 50 lever presses
No lever pressing required.
Rats reinforced at the same time as the low effort master 
No lever pressing required.
Rats reinforced at the same time as the high effort master
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to lever press. The data presented here was averaged over the two tests in each 
condition.
Results
A two way ANOVA was carried out with effort level and master/yoked status as the 
within-subjects variables. Figure 2A shows the mean number of licks/cluster in the 
yoked and master conditions, for both the low and the high effort conditions (FRIO 
and FR50). Overall, when in the high effort (FR50) conditions rats produced 
significantly more licks/cluster than rats in the low effort (FRIO) conditions,
F(1,15)=27.92, p<.001. Palatability also differed significantly between master and 
yoked conditions, with licks/bout being higher in the master conditions. 
JF(l,15)=13.33,/?=.002. Crucially, an interaction occurred between the two 
independent variables, F(l,15)=8.7,/?=.01, whereby the palatability difference 
between the high and low effort conditions was greater in the master condition than in 
the yoked condition. The number of licks/reinforcer (Figure 2B) was unaffected by 
effort requirement, F(l,15)=1.17,p= 298, or yoking status, F(l,15)=1.88,/?=. 191, and 
there was no interaction, F< 1. The number of reinforcers obtained in a session 
differed according to effort condition, F(1,15)=60.5,/k.001, with a mean of 12.6 
obtained in the low effort condition and 8.8 in the high effort condition.
Summary of Experiment 2
As with Experiment 1, Experiment 2 showed that the sucrose reinforcer was 
perceived as more palatable in the high effort condition than in the low effort 
condition. Experiment 2 also showed that the palatability difference between the high
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Figure 2: Panel A shows the mean number of licks/cluster with SEM, as a factor of 
effort level (FR10 v FR50) and yoking status. Panel B shows the mean number of 
licks/reinforcer with SEM, as a factor of effort level and yoking status.
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and low effort conditions was increased when the animals had to work (lever press) 
for the reinforcer, rather than just wait for it.
2.4 Discussion
Experiments 1 and 2 indicate that rats perceived a sucrose reinforcer as more 
palatable in the high effort condition than in the low effort condition. The finding that 
the palatability difference between the high and low effort conditions was further 
enhanced when the animals had to work (lever press) for the reinforcer suggests that 
although the greater intervals between reinforcers in the high effort condition 
increased the palatability of the reinforcer, the effect of operant work was greater than 
that of time alone. This effect does not appear to be a physiological compensatory 
mechanism to alleviate thirst or energy expenditure since the amount consumed per 
reinforcer was not increased by raising the effort requirement. These results suggest 
that like humans, rats place more value on the things they work hardest for. Such an 
effort justification effect in humans would likely be attributed to mechanisms such as 
cognitive dissonance. Although appealing to such a theory to account for the rats’ 
behaviour is possible, one of the guiding principles of comparative psychology is to 
interpret an animal’s behaviour in the simplest possible terms (Morgan, 1894).
In an experiment by Clement et al. (2000), pigeons were required to peck a 
white light either once or twenty times to receive one of two different simultaneous 
colour discrimination problems. Pecks on the correct colour of each discrimination 
(S+) were rewarded with food. Following training, when pigeons were given a choice 
between the two positive (S+) colours, they showed a preference for the colour that 
followed the greatest effort during training. Clement et al. (2000) proposed that such a 
result could be attributed to ‘within-trial contrast’. This account suggests that the
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value of a positive stimulus is judged relative to the motivational state of the animal 
prior to its presentation. A twenty-peck response requirement is presumably more 
aversive than a single peck requirement. Therefore the appearance of the S+ that 
normally follows twenty pecks may be a relatively greater improvement in conditions 
(a greater contrast) than the appearance of the S+ that normally follows one peck. In 
this way a preference may develop for the outcome that follows higher effort. The 
experiment by Clement et al. is not a direct replication of the human effort 
justification effect, since the value of the reinforcer itself (the food reward) was not 
measured. However, the theoretical interpretation offered for their findings is 
interesting. If the results of this experiment were to be interpreted according to a 
contrast theory account, the palatability difference that emerged between master and 
yoked conditions indicates that an increase in the interval between reinforcers is 
aversive. However, an increase in the work required for reinforcement is even more 
aversive than an increase in the waiting time. Contrast provides one example of a 
parsimonious account of the behaviour I report here (and of other examples of effort 
justification) that does not require the involvement of any effortful cognitive 
mechanisms.
The findings of Clement et al. (2000) have been extended to demonstrate that 
other aversive events, besides effort, also enhance preference for discriminative 
stimuli. These include longer delay to reinforcement (DiGian, Friedrich, & Zentall, 
2004), and the absence of reinforcement (Friedrich, Clement, & Zentall, 2005). 
Increased effort and hunger have both been found to induce changes in preference for 
discriminative stimuli in starlings (Kacelnik & Marsh, 2002; Marsh, Schuck-Paim, & 
Kacelnik, 2004). However, up until now, research that has shown significant effects 
of effort on reward value has assessed preference for stimuli that precede
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reinforcement rather than measuring the value of primary reinforcers. In most cases 
this is necessary because ensuring that the objective values of different primary 
reinforcers are equal is difficult. However, in examples of real-life cognitive 
dissonance discussed by social psychologists (e.g. Aronson & Mills, 1959) these 
intermediate stimuli are not the point of interest. The novel method employing 
analysis of licking in combination with operant responding has enabled quantification 
of the effects of effort on the value of the primary reinforcer itself. This has provided 
the first direct analogue of the human effort justification phenomenon in animals. The 
discovery that behaviour-induced changes in perceived reward value are not unique to 
humans calls into question the use of complex cognitive theories to account for this 
intriguing phenomenon in general. It is a reminder that Lloyd Morgan’s (1894, p.53) 
cannon "In no case may we interpret an action as the outcome of the exercise of a 
higher psychical faculty, if it can be interpreted as the outcome of one which stands 
lower in the psychological scale," should be borne in mind when examining human as 
well as non-human behaviour.
The finding that effort enhances reward value in rats also highlights a problem 
that may confound operant studies that use an animal’s willingness to expend effort as 
a measure of reward value. If animals expend different levels of effort in a task, this 
may influence the hedonic value of a reinforcer. For instance, animals that are more 
inclined to respond for a reinforcer may experience a boost in the palatability of that 
reinforcer, which may in turn increase responding further. If animals are less inclined 
to respond, perhaps because of an anhedonic affect that lowers the palatability of 
reinforcers, these animals will not experience an effort-induced increase in 
palatability and therefore, any difference between control and drug-treated animals 
will be increased. This suggests that lever pressing should not be combined with
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analysis of licking in my attempts to assess anhedonia in pre-clinical models of 
schizophrenia. For this reason, the following three chapters have assessed hedonic 
responses in using the lick analysis method in the absence of operant responding.
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CHAPTER THREE
Acute NMDA receptor antagonists and drinking behaviour
3.1 Introduction
It is well documented that antagonism of NMDA receptors via a single administration 
of agents such as PCP, s-(+)-ketamine and (+)MK-801 can produce behavioural and 
cognitive deficits in healthy volunteers that closely mimic schizophrenia (Javitt & 
Zukin, 1991; Krystal, et al., 1994). Such treatments can also exacerbate psychosis in 
schizophrenic patients (e.g. Lahti, et al., 1995)
PCP was originally marketed as an anaesthetic agent that has its effects 
without causing respiratory or circulatory depression (Domino, Chodoff, & Corssen, 
1965). However, it was soon found that other symptoms of PCP treatment, including 
paranoia and auditory hallucinations, were difficult to distinguish from those of 
schizophrenia (Smith, 1980). In rodents, acute doses of PCP can induce effects which 
may relate to schizophrenic symptomatology, such as augmented stereotyped 
behaviours and hyperlocomotion (e.g. Castellani & Adams, 1981; Verma & 
Moghaddam, 1996). PCP acts on a range of receptors and ion channels. However, 
Javitt and Zukin (1991) considered all of these actions and proposed that it is the 
NMDA antagonist properties of PCP that are responsible for its psychotomimetic 
actions, via the blockade of calcium channels (see section 1.10). S-(+)-ketamine also 
acts on NMDA receptors, although it is a weaker open channel blocker than PCP. 
Acute s-(+)-ketamine treatment is reported to produce schizophrenia-like symptoms 
in healthy volunteers, including performance deficits in verbal fluency, word recall 
and the Wisconsin Card Sorting test (Krystal, et al., 1994)
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(+)MK-801 produces a more selective and potent blockade of NMDA 
receptors than either PCP or s-(+)-ketamine. Owing to its cardiovascular side-effects, 
(+)MK-801 is not used for human studies, but it has been found to produce similar 
effects to PCP when administered to pigeons, rats and monkeys (Koek, Woods, & 
Winger, 1988). However, whereas PCP is purported to provide a ‘full’ model of 
schizophrenia, unrivalled in its ability to mimic both the positive and negative 
symptoms of schizophrenia (Morris, et al., 2005), evidence that (+)MK-801 can 
produce effects that parallel the non-psychotic symptoms of schizophrenia is far more 
limited (e.g. Seillier & Giufffida, 2009). Despite this, (+)MK-801 is often used 
interchangeably with PCP in the production of pre-clinical animal models of 
schizophrenia whilst, due to its relative safety, s-(+)-ketamine is the drug of choice 
for modelling aspects of schizophrenia in human volunteers (e.g. Passie, Karst,
Wiese, Emrich, & Schneider, 2005).
Gilmour et al. (2009) argued that it is inaccurate to assume that these NMDA 
receptor antagonists are equivalent and that inferences made about the behavioural 
effects of one drug can be applied to drugs with similar pharmacological action. In 
their study, a selection of NMDA antagonists, including PCP, s-(+)-ketamine and 
(+)MK-801, were systematically compared using a series of variable interval (VI) 
schedules of reinforcement. In an operant VI schedule, animals are rewarded after a 
variable period of time if they press an ‘active’ lever following this interval. It was 
revealed that the way in which various NMDA antagonists affect operant responding 
can differ greatly. For example, in a simple VI schedule, s-(+)-ketamine produced a 
dose-dependent decrease in instrumental output, whereas PCP and (+)MK-801 
produced bi-directional effects in which lower doses increased responding and higher 
doses eventually decreased responding.
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It is possible that the performance disparity produced by these drugs may 
reflect differences in the hedonic value of reinforcers. For instance, decreased 
responding may reflect an amotivational state produced by the drug or may instead be 
secondary to a reduction in the perceived hedonic value of the reinforcer. Since the 
effects of PCP, s-(+)-ketamine and (+)MK-801 are not as generalisable as often 
presumed, it is possible that the potential of each of these drugs to produce a model of 
schizophrenic anhedonia may vary considerably. For this reason, Experiment 3 
examined the effects of single doses of these drugs on drinking behaviour, using the 
lick analysis technique described previously as an index of perceived reinforcer value. 
This experiment was conducted as an initial screen to examine whether there are any 
obvious effects of these drugs on hedonic value, which may either account for the 
effects observed on operant behaviour, or may indicate which of these drugs may 
hold the most potential for the pre-clinical modelling of anhedonia.
3.2 Experiment 3
Experiments 3a, 3b and 3c examined the effects of single doses of PCP, s-(+)- 
ketamine and (+)MK-801 on drinking behaviour.
Methods
Subjects
Experiment 3 was conducted in the behavioural neuroscience laboratory at the School 
of Psychology, Cardiff University. Forty eight male hooded Lister rats supplied by 
OLAC, Bicester, UK were used. Husbandry details were as reported in chapter 2. The 
initial free-feeding weights of the animals ranged 291-340 grams. Daily food rations 
were placed in the home cages 30 minutes after completion of the experimental
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session. Food rations were monitored and adjusted to maintain the animals at no less 
than 85% of their free-feeding weights.
Apparatus
Testing was carried out in a room containing 16 drinking chambers. These were white 
plastic boxes measuring 32><15xl2cm with metal grid floors and wire mesh lids. 
Fluids were given in 50ml cylinders attached to stainless steel drinking spouts. These 
spouts were positioned on the left hand side of the chamber at the beginning of each 
experimental session. A contact sensitive lickometer registered the time of each lick 
to the nearest 0.01s. This was recorded by a computer using MED-PC software (Med 
Associates Inc. St. Albans, USA). The amount of fluid consumed by each animal was 
measured by weighing the drinking bottle before and after each session. The solutions 
used for this experiment were 4% and 16% (weight / weight) sucrose, made using 
deionised water.
Drugs
The drugs used in this experiment were the non-competitive NMDA receptor 
antagonists, phencyclidine hydrochloride (Experiment 3a), S-(+)-ketamine 
hydrochloride (Experiment 3b), and (+)MK-801 hydrogen maleate (Experiment 3c), 
supplied by Sigma-Aldrich, UK. These drugs were made into solution using 5% 
(weight / volume) glucose. PCP was formulated at 1 mg/ml, S-(+)-ketamine was 
formulated at 5mg/ml and (+)MK-801 was formulated at 0.05 mg/ml. All drugs were 
injected at lml/kg. The sterile glucose solution was also used for vehicle injections. 
The drug doses reported refer to the base weight of compounds. These doses were 
chosen as their effects on operant responding is known (Gilmour et al. 2009).
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Training
All animals received access to 4% or 16% sucrose in the lickometer cages for 10 
minutes each day (Monday-Friday). The sucrose concentration given to each animal 
remained the same throughout the experiment. Animals received 16 days of pre­
training to ensure that a steady level of consumption was reached prior to the first 
drug test. Animals then received weekly acute drug tests (on Fridays), preceded by 
four days of pre-training sessions (Monday-Thursday). PCP was given on the first 
week, MK-801 on the second, and ketamine on the third. Drug testing was carried out 
between-subject and animals were assigned to drug or vehicle treatment groups on the 
basis of the pre-training data obtained the day before each drug test. There were four 
conditions for each drug test: 4% sucrose with drug, 4% sucrose with vehicle, 16% 
sucrose with drug and 16% sucrose with vehicle.
Data Analysis
The lick cluster criterion used was the same as that used in chapter 2. The data were 
analysed using a two-way analysis of variance (ANOVA) with drug/vehicle treatment 
and sucrose concentration as between-subject factors. The data for two animals were 
removed from the analysis of the (+)MK-801 drug test because an abnormally high 
volume per lick calculation indicated that there was either a leakage of the drinking 
bottles or a failure with the lick recording apparatus. The data removed for one of the 
animals came from the 16% sucrose, vehicle-treated group. The other came from the 
4% sucrose, (+)MK-801 treatment group.
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Results of Experiment 3
Figure 3 shows the results of Experiment 3a with PCP. Figure 4 shows the results of 
Experiment 3b with s-(+)-ketamine. Figure 5 shows the results of Experiment 3c with 
(+)MK-801. Each figure includes the mean amount of sucrose consumed (panel A), 
the mean number of licks/cluster (panel B) and the mean ILI (panel C), for 4% and 
16% sucrose, after acute drug treatment.
Experiment 3a
Overall consumption of sucrose was numerically but not significantly decreased 
following PCP treatment, F(l,44)=3.24,/?=.070. Consumption of the 16% solution 
was higher than consumption of the 4% solution, F(l,44)=17.65, p<.001. There was 
no interaction between sucrose concentration and drug treatment, F(l,44)=1.15, 
p= 290.
PCP treatment produced an overall decrease in licks/cluster, F(1,44)=14.89, 
p<.001. Licks/cluster during consumption of 16% sucrose was numerically, but not 
significantly, higher than licks/cluster for 4% sucrose, F(1,44)=3.50, p=.068. There 
was no interaction between drug treatment and sucrose concentration, F< 1.
ILI was significantly increased by PCP treatment, F(l,44)=9.38,/?=.004. ILI 
was also lower for 16% sucrose than for 4% sucrose, F(1,44)=4.13, p=.048. No 
interaction occurred between drug treatment and sucrose concentration, F<1.
Experiment 3 b
S-(+)-ketamine significantly decreased overall sucrose consumption, F(l,44)=4.87, 
p=.033. Consumption of 16% sucrose was higher than consumption of 4% sucrose,
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F(1,44)=10.45, /?=.002. There was no interaction between drug treatment and sucrose 
concentration, F< 1.
S-(+)-ketamine treatment produced an overall decrease in licks/cluster, 
F(l,44)=5.67,/?=.022. Licks/cluster was higher during consumption of 16% sucrose 
than during consumption of 4% sucrose, F(1,44)=17.25, p<.001. No interaction 
occurred between drug treatment and sucrose concentration, F<1.
S-(+)-ketamine significantly increased ILI, F(l,44)=93.84, p<.001. There was 
no significant effect of concentration on ILI, F(1,44)=3.73, p=.060, and no interaction 
between drug treatment and sucrose concentration, F< 1.
Experiment 3c
(+)MK-801 produced no effect on sucrose consumption, F< 1. Consumption of 16% 
sucrose was higher than 4% sucrose, F(l,42)=6.94,/?=.012. There was no interaction 
between drug treatment and sucrose concentration, F=1.82,/?=.184.
Licks/cluster was unaffected by (+)MK-801 treatment, F<\. Unexpectedly, 
there was no effect of sucrose concentration, F< 1. There was also no interaction 
between drug treatment and sucrose concentration, F< 1.
(+)MK-801 produced a marginal decrease in ILI, F(l,42)=3.86,/?=.056. ILI 
was also lower for 16% sucrose than for 4% sucrose, F(1,42)=7.91, p=.001. There 
was no interaction between drug treatment and sucrose concentration, F< 1.
Summary of Experiment 3
In Experiment 3a, the cluster size distinction between 4% and 16% sucrose was not as 
strong as would be expected. This is likely to be due to the between-subject design of 
the experiment as cluster size is very variable between animals. PCP and s-(+)-
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ketamine produced a similar decrease in cluster size at the doses selected. However, 
neither decrease can be interpreted as an anhedonic effect because of the concurrent 
increase in inter-lick interval (ILI). ILI normally shows very little variability, except 
when motoric changes are induced. It is therefore possible that the reduced cluster 
size brought about by these drugs is an artefact of motor abnormality. In order to 
assess whether hedonic deficits are present in the absence of motor abnormality, 
lower drug doses may need to be tested.
(+)MK-801 produced a different drinking behaviour profile, with no effects 
on the hedonic measures of consumption and lick cluster size, but a trend towards an 
increase in the rate of licking. This result is somewhat surprising given that (+)MK- 
801 and PCP appear to have similar effects on operant responding (Gilmour et al., 
2009). This disparity may have arisen if the drug doses used here were not equivalent.
3.3 Experiment 4
In light of the results of Experiment 3, Experiment 4 investigated the effects of PCP 
and (+)MK-801 on the hedonic value of a sucrose reward by means of dose-response 
experiments.
PCP was selected for this experiment as it is the most popular 
pharmacological agent used for modelling schizophrenia (Morris, et al., 2005). It has 
also been claimed that an analogue of anhedonia is present in rats twenty hours after a 
large (15mg/kg) dose of PCP (Turgeon & Hoge, 2003; Turgeon & Hulick, 2007; 
Baird, et al., 2008). This was inferred from a decrease in the amount of sucrose 
consumed voluntarily by PCP-treated animals (see section 1.9). Since microstructural 
analysis of licking provides a detailed method of measuring reward value, sensitive to 
motor abnormality, Experiment 3 was able to show that a moderate dose of PCP
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Figure 3: Shows the amount consumed (Panel A), mean number of licks/cluster 
(Panel B) and mean inter-lick interval (ILI) (Panel C), with SEM, for lOmin exposure 
to 4% and 16% sucrose, following treatment with 1 mg/kg PCP or vehicle.
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Figure 4: Shows the amount consumed (Panel A), mean number of licks/cluster 
(Panel B) and mean inter-lick interval (ILI) (Panel C), with SEM, for lOmin exposure 
to 4% and 16% sucrose, following treatment with 5mg/kg ketamine or vehicle.
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Figure 5: Shows the amount consumed (Panel A), mean number of licks/cluster 
(Panel B) and mean inter-lick interval (ILI) (Panel C), with SEM for lOmin exposure 
to 4% and 16% sucrose, following treatment with 0.05mg/kg MK-801 or vehicle.
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produces motoric changes. By combining this method with a range of PCP doses, 
Experiment 4 sought to discover whether evidence of reduced reward value was 
present at doses low enough to avoid motor changes. This would provide a better 
informed judgement of whether PCP produces deficits in reward function.
Although (+)MK-801 produced no hint of a hedonic deficit in Experiment 3, 
this drug is most frequently used interchangeably with PCP in pre-clinical studies and 
so was also selected for examination in this experiment.
Subjects and Apparatus
Thirty-two male hooded Lister rats were used. Supplier, husbandry and experimental 
apparatus details were the same as those in Experiment 3. The rats’ initial free- 
feeding weights ranged 308-360 grams.
Drugs
PCP hydrochloride (Experiment 4a) and (+)MK-801 hydrogen maleate (Experiment 
4b), supplied by Sigma-Aldrich, UK, were used. These drugs were made into solution 
using 5% (weight / volume) glucose. PCP was formulated at 0.25 mg/ml; 0.5 mg/ml;
1 mg/ml and 2.5 mg/ml. (+)MK-801 was formulated at 0.0125 mg/ml; 0.025 mg/ml; 
0.5 mg/ml and 0.1 mg/ml. All drugs were injected at 1 mg/kg. The sterile glucose 
solution was also used for vehicle injections. The drug doses reported refer to the base 
weight of compounds.
Training
All animals received access to a 10% sucrose solution in the lickometer cages for 10 
minutes each day (Monday-Friday). A single intermediate sucrose concentration of
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10% was selected for this experiment because no drug x concentration interactions 
were observed in Experiment 3. Training and test sessions began approximately 2.5 
hours into the light part of the light / dark cycle. Animals received 13 days of pre­
training to ensure that a steady level of consumption was reached. Following pre­
training, animals received daily sessions for 5 days at a time.
Dosing
On the fifth day of each training block, animals received a drug dose. Injections were 
given sub-cutaneously with a pre-treatment time of 30 minutes. Between each set of 5 
days animals received a seven day rest period in which no training or testing was 
carried out, in order to minimise drug tolerance.
16 of the animals received drug tests with PCP (Experiment 4a) and 16 
received (+)MK-801 (Experiment 4b). The animals in each drug condition were 
divided so that half received drug doses in order of increasing size and half received 
the drug in decreasing doses. This manipulation controlled for order effects such as 
the effect of increasing body weight on response to a drug.
Data Analysis
The lick cluster criterion used was the same as in previous experiments and the same 
parameters were extracted from the data recorded. The data was analysed using 
repeated-measures analyses of variance (ANOVA) with ‘dose’ as a single factor. 
Planned contrasts compared each individual dose to vehicle for all parameters. The 
data for four animals were removed from the analysis, two because of blocked bottle 
spouts in the 2.5mg/kg PCP test, and the others because of blocked spouts in the 
0.05mg/kg or 0.25mg/kg (+)MK-801 tests. Another two animals were removed from
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the analysis of the PCP data, and one was removed from the (+)MK-801 analysis, due 
to failure to drink at the highest drug doses. No equipment malfunction was identified 
in these latter cases, suggesting that the rats’ failure to drink may have been due to 
drug effects. However, since no licks were made, it was not possible to obtain cluster 
size or ILI data for these animals. Neither replacing the missing data with the mean 
for that condition nor restricting the analysis to exclude the highest dose affected the 
pattern of results reported here.
Results of Experiment 4
Figure 6 shows the results of Experiment 4a including the mean amount of sucrose 
consumed (panel A), the mean number of licks per cluster (panel B) and the mean ILI 
(panel C) at each dose of PCP. PCP produced overall significant effects on 
consumption, F(4,44)= 19.15, /?<.001, cluster size, JF(4,44)=6.68, /K .001, and ILI 
F(4,44)=7.0, p < m  1. With respect to consumption, for the 0.25 mg/kg dose the 
volume consumed was above that for vehicle, F (l,l 1)=11.45,/?=.006, and the 
2.5mg/kg dose below, F(1,11)=37.04,/?<.001. Although cluster size was numerically 
higher than vehicle after 0.25mg/kg, this difference was not significant, F ( l,l  1)=2.8, 
p=. 123. The 2.5mg/kg dose significantly reduced cluster size, F (l,l l)=7.1,p =.022. 
ILI was significantly increased by 0.5mg/kg, lmg/kg, and 2.5mg/kg, with the smallest 
F(l,ll)=5.3,p=.042.
Figure 7 shows the results of Experiment 4b including the mean amount of 
sucrose consumed (panel A), the mean number of licks per cluster (panel B) and the 
mean ILI (panel C) at each dose of (+)MK-801. (+)MK-801 produced overall effects 
on consumption, F(4,48)=14.92,/?<.001, cluster size, F(4,48)=10.17,p<.001, and ILI, 
F(4,48)=5.29,/K.001. Consumption was increased relative to vehicle by 0.025mg/kg,
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F(l,12)=5.86,;?=.032, and 0.05mg/kg, F(l,12)=7.67,/?=.017. Consumption for the 
O.lmg/kg dose was below that for vehicle, F(l,12)=l 1.02,/?=.006. Cluster size was 
numerically higher than vehicle after 0.0125mg/kg, but this was not significant, 
F(l,12)=1.8/?= 205, and was significantly reduced after O.lmg/kg, F(l,12)=39.2 
/K.001. Interestingly the increase in consumption with the 0.05mg/kg dose was not 
mirrored by an increase in cluster size which was numerically but not significantly 
lower than vehicle at this dose, F(l,12)=4.3,p=.061. This suggests that something 
other than palatability changes was responsible for this increase in consumption. ILI 
was significantly increased by the O.lmg/kg dose, F(l,12)=l 1.7,p=.005.
Summary of Experiment 4
In Experiment 4, there was evidence of decreased cluster size following 
administration of both PCP and (+)MK-801, but only at the highest dose tested, when 
ILI was increased. As mentioned previously, raised ILI is indicative of confounding 
motor deficits. Therefore, this experiment provides no evidence of reduced reward 
value following acute treatment with either PCP or (+)MK-801.
3.4 Experiment 5
Although the results of Experiment 4 suggest that anhedonia is not present following 
acute PCP and (+)MK-801 treatment, it has been suggested that NMDA receptor 
antagonist-induced hedonic deficits may be detectable when a reward has a lower 
hedonic value. Vardigan, Huszar, McNaughton, Hutson and Uslaner (2010) found that 
when (+)MK-801-treated rats were given a choice between sucrose and water, 
consumption of a 7% sucrose solution was increased relative to controls, whereas 
consumption of a 0.8% sucrose solution was decreased. In addition, in the case of
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Figure 6: Shows the data obtained from an acute dose-response experiment using 
PCP. Panels A-C illustrate the mean amount of sucrose consumed, the mean number 
of licks per bout, and the mean ILI respectively, with SEM, as a function of PCP dose 
(mg/kg).
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Figure 7: Shows the data obtained from an acute dose-response experiment using 
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dose (mg/kg).
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PCP, a preliminary test suggested that when mildly water-restricted rats are presented 
with a choice between 1% sucrose and water, PCP-treated animals show a slight 
reduction in their sucrose/water consumption ratio relative to controls (see appendix 
1). Therefore, Experiment 5 used microstructural analysis of licking to investigate 
whether acute PCP and (+)MK-801 produce hedonic deficits that are evident at 
concentrations lower than those tested previously in this chapter.
Methods
Subjects and Apparatus
Forty eight male hooded Lister rats supplied by Charles River, Margate, Kent, UK, 
were used in this experiment. Half of these animals were used for Experiment 5a and 
half were used for Experiment 5b. Husbandry and experimental apparatus details 
were the same as those in the previous two experiments. Animals’ free-feeding 
weights ranged 338-388 grams.
The sucrose solutions used for test sessions were 1%, 3% and 10% sucrose, 
made weight/weight using deionised water. 8% maltodextrin (weight/weight) was 
used for pre-training.
Drugs
PCP hydrochloride (Experiment 5a) and (+)MK-801 hydrogen maleate (Experiment 
5b), supplied by Sigma-Aldrich, UK, were used. These drugs were made into solution 
using 5% (weight/volume) glucose. PCP was formulated at 1 mg/ml and (+)MK-801 
was formulated at 0.05 mg/ml. The sterile glucose solution was also used for vehicle 
injections. The drug doses reported refer to the base weight of compounds.
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Training
Training and test sessions were carried out Monday-Friday, 4 hours into the light 
period of the light/dark cycle. Training commenced with 5 pre-training sessions in 
which all rats received lOmin daily access to 8% maltodextrin in the lickometer cages 
to enable them to gain experience of drinking in the apparatus. Following this, rats 
were given daily lOmin sessions (Mon-Thurs) in which they received access to the 
solution with which they would receive drug testing at the end of the week.
Dosing
On the fifth day of exposure to each test solution (Friday), twelve of the animals 
received acute, sub-cutaneous PCP injections and twelve received vehicle injections 
(Experiment 5a) 30min prior to their daily session in the lickometer cages. 
Experiment 5b was run in parallel and involved the injection of twelve animals with 
(+)MK-801 and twelve with vehicle. After a 2-day washout, the animals received 
another test session in which rats previously treated with drug received vehicle, and 
those previously treated with vehicle received drug treatment. Following this, animals 
received a 6-day washout period prior to training with the next solution to be tested. 
The three sucrose concentrations to be tested were given to half of the animals in 
ascending order and half in descending order.
Data Analysis
The data were analysed using repeated measure analysis of variance (ANOVA), with 
drug treatment and sucrose concentration as within-subject factors. In Experiment 5a, 
one rat was re-tested in the 10% sucrose PCP condition and, in Experiment 5b, two
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rats were re-tested in the 10% sucrose (+)MK-801 condition as their data was lost due 
a lick recording problem. This replacement data was included in the analysis, 
although removing it had no effect on the outcome.
Results of Experiment 5
Experiment 5 a
Figure 8 shows the amount of sucrose consumed (panel A), the mean number of 
licks/cluster (panel B), and the mean ILI (panel C), for 1%, 3% and 10% sucrose, 
following PCP and vehicle treatment.
The amount of sucrose consumed increased with increasing concentration, 
F(2,46)=68.34,p<.001, and was unaffected by PCP treatment, F<\. There was no 
interaction between drug treatment and sucrose concentration, F< 1.
The number of licks/cluster increased with increasing concentration, 
F(2,46)=43,15,/K.001. PCP treatment significantly decreased licks/cluster, 
F(l,23)=47.53,/?<.001. However, there was no interaction between drug treatment 
and sucrose concentration, F(2,46)=2.92,p=.064.
The PCP-induced decrease in lick cluster size cannot be taken to indicate an 
anhedonic effect since PCP also increased ILI, F(l,23)=12.22,/?=.002. ILI was 
unaffected by sucrose concentration, F< 1, and no interaction occurred between 
sucrose concentration and drug treatment, F(2,46)=l .79, p=. 177.
Experiment 5b
Figure 9 shows the amount of sucrose consumed (panel A), the mean number of 
licks/cluster (panel B), and the mean ILI (panel C), for 1%, 3% and 10% sucrose, 
following MK-801 and vehicle treatment.
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The amount of sucrose consumed increased with increasing concentration, 
F(2,46)=34.36, p<.001, and was unaffected by (+)MK-801 treatment, F<\. There was 
no interaction between drug treatment and sucrose concentration, F<1. The number of 
licks/cluster increased with increasing concentration, F(2,46)=25.99,/?<.001. (+)MK- 
801 treatment had no effect on licks/cluster, F< 1, and there was no interaction 
between drug treatment and sucrose concentration, F< 1.
There was a significant effect of sucrose concentration on ILI, F(2,46)=10.48, 
/K.001. ILI was reduced following (+)MK-801 treatment, F(l,23)=16.21,p<.001. No 
interaction occurred between sucrose concentration and drug treatment, F<1. The 
significant effect of sucrose concentration on ILI arose because ILI was increased for 
3% sucrose. There is no obvious reason why this occurred. However, the fact that 
there was no interaction between sucrose concentration and drug treatment supports 
the conclusion that (+)MK-801 produced no effect on cluster size independent of 
motor effects.
Summary of Experiment 5
Experiment 5 demonstrated that, even at low sucrose concentrations, there is no 
evidence of a PCP-induced reduction in cluster size occurring independently of motor 
abnormality indicated by raised ILI. Similarly, the consumption and palatability of 
low sucrose conentrations were also unaffected by (+)MK-801 treatment. In 
Experiment 5 the effect of sucrose concentration on cluster size was stronger than in 
Experiment 3. This is probably because of the within-subject design of the 
experiment.
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Figure 8: Panels A-C show the mean amount of sucrose consumed, the mean number 
of licks per bout, and the mean ILI respectively, with SEM, for lOmin exposure to 
1%, 3% and 10% sucrose, following acute treatment with 1 mg/kg PCP and vehicle. 
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of licks per bout, and the mean ILI respectively, with SEM, for lOmin exposure to 
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3.5 Discussion
The main aim of the current set of experiments was to investigate whether evidence 
of anhedonia could be found in rodents following acute administration of selected 
NMDA receptor antagonists. Experiment 3 examined the effects of single doses of 
PCP, s-(+)-ketamine and (+)MK-801 on drinking behaviour and suggested a 
possibility that PCP and s-(+)-ketamine may reduce reward value, as indexed by 
reduced lick cluster size. However, this experiment was limited by the fact that the 
doses selected produced motor deficits. Since a single dose was selected for each 
drug, the discrepancy between (+)MK-801 and the other two drugs may have been 
due to a lack of equivalence between the doses selected, especially since PCP and 
(+)MK-801 have bi-directional effects on operant responding (Gilmour et al. 2009). 
Therefore, Experiment 4 compared the dose-response effects of PCP and (+)MK-801 
on drinking behaviour. It was reasoned that if changes in reward value underlie the 
effects on operant responding produced by PCP and (+)MK-801, then the patterns of 
palatability and general consumption generated by the acute drug treatment given in 
Experiment 4 would mimic the drug effects on lever pressing. This was generally 
found to be the case. At the highest doses tested, both drugs decreased sucrose 
consumption, where similar doses also decreased operant responding. There was also 
evidence of decreased lick cluster size at high doses of both drugs. However, this was 
only seen at doses which increased the ILI. ILI normally shows very little variability, 
except when motoric changes are induced: for example, by changes in posture 
(Weijnen, 1998), or disturbances in motor pattern generation in the hind brain (Aja, et 
al., 2001). The fact that cluster size decreased only when ILI was increased suggests 
that the reduced cluster size was an artefact of motor effects induced by the drugs.
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Therefore, we have no evidence here for reduced palatability, only motor 
abnormality.
Evidence from the literature suggests that PCP, in particular, may have 
potential for the pre-clinical modelling of anhedonia. PCP has been shown to induce a 
state in humans that closely reflects the positive, negative and cognitive symptoms of 
schizophrenia (e.g. Allen & Young, 1978; Adler, et al., 1999), and has therefore been 
favoured as a pharmacological agent for modelling schizophrenia in animals (Morris 
et al. 2005). Turgeon and Hoge (2003) found that voluntary sucrose consumption was 
decreased in rats who received a 15mg/kg injection of PCP 20 hours prior to testing. 
In Experiment 4a, this decrease in sucrose consumption was replicated following 
acute administration of 2.5mg/kg PCP (our highest dose). It should be noted however, 
that no significant decreases in consumption were observed at the lower doses used in 
Experiments 3 and 5. Several authors have suggested that decreased sucrose 
consumption in animal models of affective disorders indicates the presence of 
anhedonia (e.g. Papp, et al., 1991; Papp & Moryl, 1994; Rygula, et al., 2005; Willner, 
et al., 1994; Zurita, et al., 2000; Zurita & Molina, 1999). However, the use of 
microstructural analysis to examine palatability in Experiments 3-5 has provided a 
much more informed understanding of the processes underlying acute PCP-induced 
decreases in sucrose consumption, enabling us to determine whether or not they really 
are indicative of decreases in reward value. Using this method, I could find no 
evidence for reduction in reward value following acute treatment with either PCP or 
(+)MK-801 that was not confounded by the presence of motor abnormality. In fact, 
low to moderate doses of both drugs produced an increase in sucrose consumption 
and a trend towards an increase in palatability. Experiment 4 therefore provided no 
evidence that the acute effects of either PCP or (+)MK-801 include the production of
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anhedonia. Further, these results suggest that decreased sucrose consumption alone 
cannot be taken to indicate anhedonia, thereby highlighting a fundamental flaw with 
one way in which hedonic deficits are frequently assessed.
It is of course possible that the reduced sucrose consumption seen by Turgeon 
and Hoge (2003) (see also, Baird et al. 2008) on withdrawal from acute treatment 
with 15mg/kg PCP was due to the presence of anhedonia, since Baird et al. (2008) 
found no evidence of motor abnormality following this protocol. In addition, Turgeon 
and Hullick (2007) found that sub-chronic pre-treatment with the atypical 
antipsychotic clozapine prevented the PCP-induced reduction in sucrose 
consumption, further suggesting that the decreased consumption reflected a negative 
symptom. However, in addition to the problems that arise from using general 
consumption as a measure of anhedonia, the validity of this dosing regimen as a 
model of schizophrenia is also questionable, since high doses of PCP have been 
shown to cause degeneration of pyramidal neurones in the retrosplenial cortex. This is 
not consistent with human post-mortem studies, which show that it is the 
intemeurones that degenerate in schizophrenia (Olney, et al., 1989). The 
neurodegeneration caused by large doses of PCP raises the possibility that the ability 
of sub-chronic clozapine to reverse PCP-induced decreases in sucrose consumption 
may rely on the neuroprotective properties of clozapine. The effectiveness of 
clozapine as a neuroprotective agent has been demonstrated in several in vitro studies 
reporting decreased apoptosis and neurodegeneration among hippocampal and other 
cell populations, in response to challenges such as growth medium deprivation (e.g. 
Bai, et al., 2002; Qing, Xu, Wei, Gibson, & Li, 2003; Bastianetto, Danik, Mennicken, 
Williams, & Quirion, 2006).
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A potential limitation of Experiment 4 is that only one, relatively high 
concentration of sucrose was used in testing. It has been suggested that NMDA 
receptor antagonist-induced hedonic deficits may be detectable when a reward has a 
lower hedonic value. Vardigan, et al. (2010) found that when (+)MK-801 -treated rats 
were given a choice between sucrose and water, consumption of a 7% sucrose 
solution was increased relative to controls, whereas consumption of a 0.8% sucrose 
solution was decreased. Therefore, Experiment 5 used microstructural analysis of 
licking to investigate whether acute PCP and (+)MK-801 produce hedonic deficits 
that are evident at concentrations lower than those tested in Experiments 3 and 4. 
Again, no evidence of hedonic deficit was found with either drug in this experiment.
Vardigan et al. claimed that (+)MK-801 alters hedonic experience by shifting 
the inverted U-shaped concentration-consumption relationship to the right. Although 
such a shift may well indicate an attenuation of either a sensory or hedonic response 
to sucrose, the fact that only three concentrations of sucrose were tested in their 
experiment does not allow this claim to be validated. A further concern is that 
consumption of the 7% sucrose solution was raised in their experiment. However, the 
dose used was 0.3mg/kg, which is far higher than the highest used here in Experiment 
4, following which motor abnormality was evident via a significant decrease in 
consumption and significant increase in ILI.
In summary, the experiments presented here demonstrate that acute NMDA 
antagonist treatment produces no evidence of reduced reward value as indexed by 
palatability and consumption. This may reflect a disparity between the neurochemical 
changes induced by this drug and those thought to be responsible for the non- 
psychotic symptoms of schizophrenia. Acute administration of non-competitive 
NMDA receptor antagonists is associated with increased forebrain dopamine
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transmission (e.g. Schilstrom, Nomikos, Hertel, Nisell, & Svensson, 1996; Jentsch, 
Tran, Le, & Roth, 1997). This increase is thought to underlie the positive symptoms 
of schizophrenia since haloperidol, a typical antipsychotic effective in ameliorating 
positive symptoms, acts to reduce DA levels. On the other hand, atypical 
antipsychotics, such as clozapine, consistently elevate DA levels in the pre-frontal 
cortex (Moghaddam & Bunney, 1990). It is therefore more likely that the negative 
symptoms of schizophrenia may be reflected in animals following a reduction in 
frontal DA transmission, an effect that can be brought about by sub-chronic NMDA 
receptor antagonist administration (Jentsch, Taylor, et al., 1997; Jentsch, Tran, et al., 
1997).
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CHAPTER FOUR 
Antipsychotic treatment and licking microstructure/sucrose preference
4.1 Introduction
There is some evidence to suggest that atypical antipsychotics are superior to typical 
antipsychotics in the treatment of negative symptoms (see section 1.3). Another major 
advantage which has led to the increased usage of atypical drugs is that they produce 
less extrapyramidal side effects (Leucht, et al., 1999). Although all effective 
antipsychotics are dopamine D2 receptor antagonists, D2 antagonism is also 
responsible for the severe extrapyramidal side-effects associated with typical 
antipsychotics (Kerwin, 1994). It has been proposed that the benefits of atypical over 
typical drugs occur because of the relatively low D2 receptor occupancy produced by 
atypical drugs. Receptor occupancy is suggested to be mediated via the relative 
affinities of these drugs (i.e. the rate at which the drugs move on to and off of the D2 
receptors). Atypical drugs such as clozapine show low D2 receptor affinity, whereas 
typical drugs such as haloperidol have much higher affinity (e.g. Kapur & Seeman, 
2001; Seeman, 2002).
Despite the advantages of atypical antipsychotics, they are associated with 
greater weight gain than traditional drugs (e.g. Stanton, 1995; Allison, et al., 1999; 
Kraus, et al., 1999; Fell, Neill, Rao, & Marshall, 2005; Fell, Neill, Williams, 
Reynolds, & Marshall, 2003). The mechanisms underlying antipsychotic-induced 
weight gain are unclear, and may occur via a stimulation of food intake, or an 
endocrine disturbance that increases fat deposition (Baptista, 1999). There have been 
reports that clozapine increases food intake in rats (e.g. Antelman, Black, & Rowland, 
1977). It is possible that this effect may be due to a drug-induced increase in the
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perceived hedonic value of foods. Indeed, this may account for the restoration of 
voluntary sucrose consumption observed by Turgeon and Hulick (2007) when 
clozapine pre-treated animals received large doses of PCP.
The aim of the work contained in this thesis is to attempt to identify a pre- 
clinical analogue of anhedonia, which may be used for the screening of therapeutic 
compounds. However it is important for the study of antipsychotics that the 
independent effects these drugs on reward value are known, particularly in light of the 
suggestion that antipsychotics may increase food intake.
Using microstructural analysis of licking, Hartfield, Moore and Clifton (2003) 
investigated ingestive behaviour following acute clozapine, olanzapine and 
haloperidol administration in rats. They found that clozapine and olanzapine 
significantly increased intake of a high-calorie fat solution, whereas haloperidol 
decreased intake. Cluster size was unaffected by clozapine and olanzapine treatment, 
but was decreased by haloperidol treatment. Hartfield et al. suggested that these 
differences reflect the greater weight gain tendency with atypical antipsychotics and 
that delayed post-ingestive satiety and intact palatability are the mechanisms 
responsible for hyperphagia after treatment with these drugs. However, it is possible 
that these effects are limited to fat solutions, whereas throughout the experiments in 
this thesis sucrose has been used, in line with other published work investigating the 
presence of anhedonia. Therefore, the current experiment investigated the effects of 
clozapine and haloperidol on the hedonic value of sucrose.
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4.2 Experiment 6
Methods
Subjects and Apparatus
Twenty-four male hooded Lister rats were used. Supplier, husbandry and 
experimental apparatus details were the same as those used for Experiments 3-5. The 
rats’ initial free-feeding weights ranged 300-345 grams.
Drugs
Clozapine (Experiment 6a) and haloperidol (Experiment 6b), supplied by Sigma- 
Aldrich, UK, were used. Clozapine was dissolved in lactic acid before adding the 
appropriate amount of deionised water to make a solution of 0.3mg/ml. The solution 
was sonicated and neutralised with 1M NaOH. Haloperidol was made into a 
O.lmg/ml solution using 5% (weight / volume) glucose. Both drugs were injected at 
1 ml/kg. These drugs were selected because they were used by Hartfield et al. and 
were representative of typical and atypical drugs and their differing pharmacology. 
The doses were chosen because they were the middle of the three doses used by 
Hartfield et al., thereby allowing for comparison of the drugs’ effects on fat and 
carbohydrate solutions. The sterile glucose solution was also used for vehicle 
injections. The drug doses reported refer to the salt weight of compounds.
Training
All animals received access to a 4% sucrose solution in the lickometer cages for 20 
minutes each day (Monday-Friday). 4% sucrose was selected for this experiment as it 
was reasoned that anti-psychotic induced weight gain could be secondary to an
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increase in the palatability of sweet tastants. For this reason a lower sucrose 
concentration was chosen than used previously so that the test would be more 
sensitive to palatability increase. The sucrose solution was presented on the left and 
right side of the cage on alternate days. Training and test sessions began 
approximately 2 hours into the light part of the light / dark cycle. Animals received 9 
days of pre-training to ensure that a steady level of consumption was reached. 
Following pre-training, animals received daily sessions for 5 days at a time.
Dosing
On the fifth day of each training block, half of the animals received a drug dose 
(clozapine on week 1 and haloperidol on week 2), and half received vehicle. After a 
two day washout, the treatments were reversed so that each animal received drug 
treatment. Injections were given via the intra-peritoneal route with a pre-treatment 
time of 30 minutes. Between each set of five days animals received a seven day rest 
period in which no training or testing was carried out, in order to minimise drug 
tolerance.
Data Analysis
The lick cluster criterion used was the same as used previously and the same 
parameters were extracted from the data recorded. The data was analysed using 
ANOVA with drug treatment as a within-subject factor. The data for one animal was 
removed from the analysis of the clozapine drug test and the data for two animals 
were removed from the analysis of the haloperidol drug test because an abnormally 
low volume per lick calculation indicated that there was a blockage of the drinking
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bottles. This blockage occurred following vehicle treatment in Experiment 6a and 
haloperidol treatment in Experiment 6b.
Results of Experiment 6
Figures 10 and 11 show the results of Experiments 6a and 6b, including the mean 
amount of sucrose consumed (panel A), the mean number of licks/cluster (panel B) 
and the mean ILI (panel C), for 4% sucrose, after acute treatment with clozapine and 
haloperidol respectively.
Experiment 6a
Clozapine treatment had no effect on consumption, F(l,22)=1.21,/?=.284., or 
licks/cluster, F< 1. However, ILI was increased by clozapine, F(1,22)=18.15, /K.001.
Experiment 6b
Haloperidol decreased consumption, F(l,21)=53.61,/><.001, and also decreased 
licks/cluster, F(l,21)=31.15,/?<.001. Haloperidol had no effect on ILI, F<1.
Summary of Experiment 6
In Experiment 6, clozapine had no effect on the consumption and palatability of 
sucrose, but produced some motor abnormality, indicated by an increase in ILI. 
Haloperidol produced no evidence of motor effects but produced a decrease in the 
value of sucrose, indicated by decreased consumption and palatability.
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Figure 10: Shows the consumption (Panel A), licks/cluster (Panel B) and ILI (Panel 
C) for 20min access to 4% sucrose, following acute treatment with clozapine and 
vehicle, with SEM.
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Figure 11: Shows the consumption (Panel A), licks/cluster (Panel B) and ILI (Panel 
C) for 20min access to 4% sucrose, following acute treatment with haloperidol and 
vehicle, with SEM.
4.3 Experiment 7
Under certain circumstances, it has been suggested that assessing an animal’s 
preference for sucrose over water may provide a more sensitive test of reward value 
since it is less sensitive to confounds, such as large motor deficits, than consumption 
tests using a single solution. For this reason, preference tests have been used to study 
anhedonia in animal models of chronic mild stress (Willner, 2005). Experiment 7 
therefore examined the effects of clozapine and haloperidol on the preference of 
sucrose over water.
Subjects and Apparatus
This experiment followed Experiment 6 and used the same subjects and apparatus. 
Drugs
Clozapine (Experiment 7a) and haloperidol (Experiment 7b) were used in this 
experiment at the same doses used in Experiment 6a and 6b.
Training and testing
Animals received a 9 day rest period before re-training for this experiment 
commenced. They then received four pre-training sessions with 4% sucrose, the same 
as those in Experiments 6a and 6b. Following this, animals were given a choice 
between 1% sucrose and water following 4.5 hours of water deprivation. In 
Experiment 7a half of the animals received clozapine treatment and the other half 
received vehicle injections. After a 2-day washout, the treatment groups were 
reversed so that all animals received clozapine treatment. There was a 7-day washout
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period before pre-training for Experiment 7b began. Pre-training and testing for 
Experiment 7b followed the same format as Experiment 7a.
Data Analysis
For this experiment the parameter of interest was the amount of water and sucrose 
consumed. Lick analysis data is not reported as during preference testing animals tend 
to alternate between available solutions making lick cluster data unreliable.
The data is reported in figure 12. Two methods of analysis were used. The first 
method was ANOVA with drug treatment and reinforcer type (sucrose/water) as 
within-subject factors. The second method calculated the mean sucrose preference 
ratios following drug and vehicle treatment. In this case, the sucrose preference ratio 
is the amount of sucrose consumed as a proportion of the total amount consumed 
(both sucrose and water). This ranges between 1 (only sucrose consumed) and 0 (no 
sucrose consumed, only water). A paired samples t-test was then carried out on these 
ratios.
Results of Experiment 7
Experiment 7a
In the clozapine test there was an overall effect of reinforcer whereby animals drank 
more sucrose, F(l,23)=147.35.18,/K.001. There was no overall effect of clozapine 
treatment on consumption, and there was no drug treatment x reinforcer interaction, 
Fs<l. There was no significant difference between the sucrose preference ratios for 
vehicle-treatment and clozapine-treatment conditions; t<  1.
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Experiment 7b
In the haloperidol sucrose preference test, overall consumption of sucrose was higher 
than consumption of water, F(1,23)=26.65, /K .001. There was no overall effect of 
drug treatment, and no treatment x reinforcer interaction, Fs<\. However, in terms of 
the sucrose preference ratio, there was a significant reduction in the haloperidol 
condition compared to the vehicle condition, f(23)=2.95,/?=.007.
Summary of Experiment 7
In Experiment 7, clozapine produced no effect on the consumption of sucrose and 
water when presented simultaneously. Clozapine also produced no effect on the ratio 
of sucrose consumption relative to water consumption. Although haloperidol 
produced no overall effect on the consumption of sucrose and water, there was a 
reduction in the ratio of sucrose consumption relative to water consumption.
4.4 Discussion
On initial interpretation, the results of Experiment 6a and 7a suggest that clozapine 
does not increase sucrose intake, palatability, or preference, but causes some motor 
abnormality, indicated by raised ILI. However, in the experiments carried out 
previously in this chapter, raised ILI has always been accompanied by decreased lick 
cluster size. Since cluster size was not decreased following increased ILI for both fat 
(Hartfield, et al., 2003) and sucrose, it is possible that clozapine does enhance 
palatability of sucrose, but that this is masked by motor disturbance.
The absence of an increase in sucrose consumption stands in some contrast to 
the findings of Hartfield et al. (2003). However, if increased consumption is due to a 
reduction of a post-ingestive satiety signal then the session length used in the current
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Figure 12: Shows the mean consumption of water and 1% sucrose when presented 
simultaneously for 20min following acute treatment with 0.3mg/kg clozapine and 
vehicle (Panel A), or 0.1 mg/kg haloperidol and vehicle (Panel B), with SEM. 
Numbers beside each pair of bars represent the sucrose preference ratios, indicating 
the amount of sucrose consumed as a proportion of the total amount consumed (both 
sucrose and water).
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investigation may have been too short to reveal this (the session length used here was 
20min, but 30min sessions were used by Hartfield et al.). The deprivation state of the 
animals used in the study of Hartfield et al. may also play a part in the difference 
observed. In their study animals received ad libitum food, whereas in the current 
study animals were food restricted to 85% of their free-feeding weight. If clozapine 
increases food intake by reducing satiety, this rise in consumption would be more 
difficult to detect in animals that are hungry at the point of testing than it would be in 
sated animals. Additionally, the test solutions used may also play a part in the 
difference between the results of current experiment and those of Hartfield et al. 
Hartfield et al used a 10% fat solution whereas the current experiments used either 
4% or 1% sucrose. Fat has more than twice as many calories as sucrose, and the 
higher caloric density of the fat solution used by Hartfield et al. would be more 
satiating than the sucrose used here. Therefore, an effect mediated by reducing satiety 
may be more apparent in the previous study than it would be here.
Experiment 6b showed that haloperidol decreases both sucrose intake and lick 
cluster size, consistent with the reports of Hartfield et al. (2003). Although the normal 
preference for sucrose over water was not reversed by haloperidol, a sensitive 
analysis using sucrose preference ratios rather than overall consumption revealed that 
haloperidol decreased the ratio of sucrose intake over water compared to vehicle- 
treated animals. In this experiment, the decreases in consumption, palatability and 
sucrose preference could not be attributed to motor deficits as ILI was unaffected. 
Haloperidol is commonly associated with weight gain, although this is to a lesser 
extent than atypical drugs such as clozapine. In light of the current results it seems 
more likely that this weight gain is mediated via an altered endocrine response that 
increases fat deposition, because experimental consumption was reduced rather than
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increased. This is consistent with data from Fell et al. (2003) and Fell et al. (2005) 
who found that haloperidol increased weight gain in adult and juvenile rats without 
increasing food intake.
Hartfield et al. (2003) suggested that haloperidol decreases intake of fat 
solutions in rats by reducing their perceived palatability. The results of the current 
investigation support this conclusion. Sucrose solutions are normally highly palatable 
to rats. The decreased palatability brought about by haloperidol treatment may reflect 
the exacerbation of negative symptoms such as anhedonia, often reported with use of 
typical antipsychotics. The implications of these results for drug discovery will be 
considered in section 7.4 of the general discussion.
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CHAPTER FIVE 
Sub-chronic PCP treatment and reward value 
Section One: Sub-chronic PCP treatment and consummatory reward value
5.1 Introduction
Experiment 4 provided evidence that although acute treatment with NMD A 
antagonists can decrease cluster size, this only occurs when ILI is increased. As 
described in chapter 3, raised ILI is indicative of confounding motor deficits. 
However, several authors have suggested that sub-chronic PCP treatment is more 
relevant than acute treatment for modelling the non-psychotic symptoms of 
schizophrenia (Morris, et al., 2005). This is because, in contrast to acute PCP 
treatment, sub-chronic treatment produces a reduction in glucose utilisation and blood 
flow in the prefrontal cortex (hypofrontality). This hypofrontality is exhibited in 
schizophrenia and it correlates with deficits in cognitive function (e.g. Buchsbaum, et 
al., 1990). In addition to these pathological changes, rats given sub-chronic PCP 
treatment also exhibit cognitive deficits (Dunn & Killcross, 2006) and changes in 
social behaviour (e.g. Sams-Dodd, 1998, but see also Jenkins, et al., 2008). Rats 
treated sub-chronically with PCP are also sensitised to the effects of amphetamine on 
locomotor behaviour (Jentsch, Taylor, & Roth, 1998).
In light of this evidence, Experiment 8 sought to investigate the effects of sub­
chronic PCP treatment on the value of sucrose rewards.
104
5.2 Experiment 8
Method
Subjects
Experiment 8 was conducted in the behavioural neuroscience laboratory at the School 
of Psychology, Cardiff University. Forty eight male Hooded Lister rats were used. 
Their free-feeding weights ranged 296-338 grams. Supplier and husbandry details 
were as in chapters 2 and 3
Apparatus
The apparatus used for drinking tests were the same as in chapter 3 Animals were pre­
trained to drink in the lickometer cages using 8% maltodextrin prior to PCP 
treatment. Maltodextrin was used so that responses to sucrose following PCP 
treatment were not influenced by any memory of the hedonic value of the pre-training 
solution. Three concentrations of sucrose were used in the test stage: 4%, 8%, and 
16%. Either before or after these drinking tests, rats received locomotor activity 
assessments to test for augmented hyperlocomotion following amphetamine injection 
in the PCP treated animals, an effect seen consistently following this injection 
protocol. The apparatus used for this were white plastic boxes with grid floors and 
lids. The boxes measured 48cm x 31cm x 18cm. Two infra-red beams spanned the 
boxes. When these beams were interrupted by the movement of an animal, a signal 
was recorded by a linked computer.
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Drugs
PCP supplied by Sigma-Aldrich UK was used in this experiment. This was made into 
a 5mg/ml solution using 5% (w/w) glucose. D-Amphetamine sulphate from the same 
supplier was also dissolved in 5% glucose to obtain a 1 mg/ml solution. These doses 
refer to the salt weight of the compounds. Drugs were injected at lml/kg.
Dosing and Testing
All animals received access to an 8% maltodextrin solution in the lickometer cages,
10 minutes each day for 10 days, to ensure that a steady level of consumption was 
reached. Training and test sessions began at approximately 9.30am every morning 
(2.5 hours into the light phase of the light/dark cycle).
Following pre-training, twenty four of the rats received sub-cutaneous 
injections of 5mg/kg PCP twice daily (8.00hrs and 19.00hrs) for seven days, whilst 
twenty four rats received vehicle injections. Following a seven-day washout period, 
rats were given three concentrations of sucrose in the lickometer cages: 4%, 8% and 
16%. Each concentration was given for three consecutive days, and the order of 
sucrose presentations was balanced so that half of the animals received the sucrose 
concentrations in ascending order and half received them in descending order.
Locomotor activity testing
In addition to the drinking tests, rats received locomotor activity assessments to test 
for PCP-induced augmented hyperlocomotion following amphetamine injection. Half 
of the animals in both PCP and vehicle treated groups received this testing prior to the 
drinking tests, and the rest received locomotor activity testing following the drinking 
tests. The rats were placed in cages for a 30 min habituation period in which
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movements were recorded by the number of interruptions that occurred to infra red 
beams spanning the cages. They were then given 1 mg/kg amphetamine sub- 
cutaneously, and their activity was recorded for a further 60 min.
Data Analysis
The parameters measured via analysis of licking were the same as those described in 
chapters 2 and 3. Data from the drinking tests was analysed using mixed ANOVA 
with sucrose concentration as a within-subject factor, and drug treatment as a 
between-subject factor. The data used for analysis was averaged over the second and 
third session with each sucrose concentration. The data for the first session was not 
used in order to minimise contrast effects that may have occurred as a result of 
changing the sucrose concentration.
The apparatus used for locomotor activity testing counted the number of 
movements made and grouped them into ten-minute bins. The data was analysed 
using mixed ANOVA with ‘bin’ as a within-subject factor, and drug treatment as a 
between-subject factor. One animal was removed from the analysis of Experiment 8 
due to a failure in lick recording during one of the drinking test sessions.
Results of Experiment 8
Figure 13 shows the results of Experiment 8, including the mean amount of sucrose 
consumed (panel A), the mean number of licks per cluster (panel B) at each sucrose 
concentration. Increasing sucrose concentration produced an overall increase in the 
amount consumed, F(2,90)=8.08,/?<.001. Pairwise comparisons show that rats 
consumed significantly more 16% sucrose than 4%, F( 1,45)= 12.49, p<.001, and more
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Figure 13: Shows the lickometric data obtained from consumption of three sucrose 
concentrations follow sub-chronic PCP treatment. Panels A and B illustrate the mean 
amount of sucrose consumed and the mean number of licks per bout respectively, 
with SEM.
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8% sucrose than 4%, F(l,45)=9.21,p=.004. Consumption did not differ significantly 
between 8% and 16% sucrose, F(l,45)=1.414,/?=.241. Although consumption was 
numerically higher after PCP treatment this difference was not significant, 
F(l,45)=3.82,/?= 057. There was no interaction between sucrose concentration and 
drug treatment, F(2,90)=2.61,/t=.079. With respect to the number of licks per cluster, 
increasing sucrose concentration produced an overall significant increase in cluster 
size, F(2,90)=17.24,/?<.001. Pairwise comparisons show that cluster size was 
significantly greater for 16% sucrose than for 4%, F(1,45)=29.92, /?<.001, and 8% 
F(l,45)=13.90,/?<.001. Cluster size was also greater for 8% sucrose than for 4%, 
F(l,45)=5.81,p=.02. PCP treatment had no effect on cluster size, F(l,45)=3.22,/? 
=.079, and there was no interaction between these independent variables, F< 1.
Locomotor activity testing
Figure 14 shows the activity counts recorded, grouped into 10 minute bins across the 
session. Locomotor activity testing confirmed that the PCP treatment sensitised 
animals to the effects of amphetamine on locomotor activity. There was a significant 
effect of bin, F(8,360)=7.62, / k .001, and PCP treatment, F(l,45)=4.59,p=038.
There was a bin x PCP treatment interaction, F(8,360)=2.61,p=.009. Simple effects 
show that prior to amphetamine injection (bins 1-3) the pattern of activity in PCP and 
vehicle treated animals is similar (Fs <1). Following amphetamine injection, there 
was a significant difference between levels of activity in PCP and vehicle treated 
animals at bins 6, 7, and 8, smallest F(l,45)= 4.77,/?=.034. The difference between 
patterns of activity in bins 4, 5 and 9 did not reach significance, largest F(l,45)= 1.86, 
p=.\19.
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Figure 14: Graph shows the mean number of activity counts (with SEM) made over a 
90min session, before and after administration of 1 mg/kg amphetamine (given 
between bins 3 and 4). Counts are grouped into lOmin bins.
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5.3 Discussion
The main aim of this experiment was to investigate whether evidence of anhedonia 
could be found in rodents following sub-chronic administration of PCP. It is plausible 
that the existence of an identifiable analogue of consummatory anhedonia may be 
observed more readily following long-term PCP treatment than following acute 
treatment. Jentsch and Roth (1999) reviewed evidence that long-term PCP abuse in 
humans has been associated with reduced frontal blood flow (Hertzman, Reba, & 
Kotlyarov, 1990). A corresponding decrease in blood flow is seen in individuals with 
schizophrenia. Since schizophrenia sufferers frequently show deficits in cognitive 
tasks relying on frontal lobe function (e.g. spatial working memory deficits; Pantelis, 
et al., 1997), chronic PCP treatment may indeed be more relevant for modelling the 
non-psychotic symptoms of schizophrenia. The expectation that long-term PCP 
exposure may be important for the generation of a schizophrenia-like pattern of 
changes in the rat brain has been confirmed by Cochran et al. (2003), who found 
reduced glucose utilisation in the pre-frontal cortex, reticular nucleus of the thalamus 
and auditory system, in addition to decreased prefrontal parvalbumin expression -  
changes that resemble those in schizophrenia. However, despite this biological 
validity, we found no evidence of a reduction in reward value following our sub­
chronic dosing regimen. Indeed, sub-chronic PCP treatment produced an overall trend 
towards an increase in the consumption and palatability of sucrose solutions.
It is improbable that this outcome reflects problems with the dosing regimen 
used, since the sensitisation effect of PCP on amphetamine-induced hyperlocomotion 
(previously reported by Jentsch et al. 1998) was evident in this experiment. It is also 
unlikely that the regimen used here is inappropriate for modelling the non-psychotic 
symptoms of schizophrenia, since evidence of cognitive deficits have been found
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using this protocol. For example, using this protocol, Dunn & Killcross (2006) found 
impaired performance on tasks that required the use of conditional information to 
direct responding. This effect may reflect the inability to use task-setting cues to 
guide goal-directed behaviour in the human condition of schizophrenia. This deficit 
was reversed by the atypical drug clozapine, but not by the typical antipsychotic 
haloperidol, thereby mirroring clinical findings.
There is some evidence that withdrawal from chronic PCP treatment using 
higher doses can produce anhedonic effects using an intracranial self-stimulation 
paradigm (Olney, et al., 1989; Spielewoy & Markou, 2003). However, since such 
high doses are known to cause pathology that is not produced in schizophrenia 
(Olney, et al., 1989), any anhedonic effects may well be a manifestation of neural 
damage that is inconsistent with the disorder. It has also been reported that some 
effects of sub-chronic PCP withdrawal may be more apparent following a shorter (24 
hour) washout period (Jenkins, et al., 2008) although withdrawal effects remained 
consistent after the shortest test interval (and there are other reports that the length of 
withdrawal interval was without effects (Noda, Yamada, Furukawa, & Nabeshima, 
1995). In addition, the effects reported by Turgeon and Hoge (2003) were observed 
20 hours after acute treatment. However, a seven day washout period was selected for 
the current study in order to maximise the predictive validity of the model. The 
persistent nature of effects produced by sub-chronic PCP treatment is one of the 
reasons that long-term PCP exposure is favoured above acute treatment as a model of 
schizophrenia (Jentsch & Roth, 1999). A transient anhedonic-like effect would not 
accurately reflect the disease state.
In light of the fact that cognitive deficits occur following the treatment 
regimen used in this study, our findings suggest that consummatory anhedonia can be
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dissociated from cognitive deficits following sub-chronic PCP treatment. On one 
hand, it is possible that our inability to find evidence of reduced reward value could 
indicate that sub-chronic PCP treatment in rodents provides an incomplete model of 
negative schizophrenic symptomatology. On the other hand, the occurrence of 
cognitive deficits without the negative symptom of anhedonia may reflect an absence 
of anhedonia as a primary symptom of the disorder itself. This is an idea considered 
by several authors who suggest that individuals with schizophrenia experience 
amotivation (Foussias & Remington, 2010), or a deficit in the ability to experience 
and express all emotions (emotional blunting) (Romney & Candido, 2001), rather 
than anhedonia per se.
As the results presented here and in chapter 3 do not appear to reflect PCP- 
induced anhedonia, it is useful to examine whether other aspects of reward value are 
affected by acute and sub-chronic PCP treatment. Berridge (1996) proposed that an 
experience of a reward contains two distinguishable components -  ‘liking’ and 
‘wanting’. In light of the current measures, palatability may be associated with liking, 
whereas consumption, linked to appetite and motivation, may be associated with 
wanting. Berridge also cites evidence that these are controlled by independent 
neurotransmitter systems and thus can be separately measured and manipulated 
pharmacologically. This may mean that animals treated acutely with PCP ‘want’ a 
reinforcer less, and may explain why lever pressing is reduced following acute PCP 
treatment (Gilmour, et al., 2009). If an animal ‘wants’ a reinforcer less, they may be 
less willing to work for it. This does not necessarily mean that the animal ‘likes’ the 
reinforcer less when it is presented. This may account for our inability to find 
evidence for a decrease in reward value (consummatory anhedonia) via our analysis 
of palatability in Experiments 3-5. However, this suggestion cannot apply to sub-
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chronic PCP treatment as there was a marginal increase in the consumption of 
animals treated sub-chronically with PCP in the current experiment.
In summary, although sub-chronic PCP treatment is generally thought to be 
more relevant for modelling the non-psychotic symptoms of schizophrenia, 
microstructural analysis of licking yielded no evidence of reduced reward value. 
Therefore, the symptoms induced by both acute and sub-chronic PCP treatment do 
not seem to include the production of anhedonia. This may reflect either a weakness 
of PCP-induced animal models of schizophrenia, or it may suggest that 
consummatory anhedonia is not actually a primary symptom of the disorder.
Section two: Sub-chronic PCP treatment and the anticipation of reward
5.4 Introduction
Research from both social psychology and neuroscience has suggested that the 
experience of pleasure has two distinct components; consummatory and anticipatory. 
Consummatory pleasure refers to the in-the-moment pleasure experienced when a 
person is engaging in an enjoyable activity, whilst anticipatory pleasure is the 
pleasure experienced in anticipation of things to come. Gard et al. (2006) developed 
two different scales to measure individual trait dispositions in anticipatory and 
consummatory pleasure experiences. They found that the scales measured distinct 
constructs, with individual differences in anticipatory pleasure being more closely 
related to motivational processes than consummatory pleasure. They also found that 
there was less than 10% overlap between individuals showing diminished anticipatory 
pleasure and those showing a consummatory pleasure deficit. This distinction has also 
been supported by functional neuroimaging studies where it has been found that the
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pre-frontal cortex is activated during consumption of a reward, whereas the nucleus 
accumbens (but not the pre-frontal cortex) is activated in anticipation of the reward.
A debate has ensued concerning the relevance of these two distinct pleasure 
types in the psychopathology of schizophrenia. This has arisen because of discrepant 
findings regarding the manifestation of anhedonia. For example, people with 
schizophrenia often report that they experience lower levels of pleasure than controls 
(Miller, 1987), and engage in fewer enjoyable activities (Devries & Delespaul, 1989). 
However, some laboratory studies have not found that people with schizophrenia 
experience less pleasant emotion than controls. For example, Berenbaum and 
Oltmanns (1992) found that individuals with schizophrenia did not differ from 
controls in their self reports of consummatory pleasure whilst watching comic film 
clips, even though they were less facially expressive. Furthermore, Kring (1999) took 
electromyographical recordings from facial muscles and found that people with 
schizophrenia do not differ from controls in their unobservable muscle responses to 
pleasant stimuli, even though these movements were less likely to reach the threshold 
at which they could be detected visually.
To reconcile these findings, it has been suggested that people with 
schizophrenia can and do experience comparably normal levels of consummatory 
pleasure, but experience less pleasure than normal in anticipation of future events. 
Evidence from Gard, Kring, Gard, Horan, and Green (2007) supports this hypothesis. 
In this study, participants made consummatory pleasure ratings whilst conducting 
everyday tasks. At the same time, they were required to indicate what they looked 
forward to doing and how much they thought they would enjoy the activity. 
Participants with schizophrenia did not differ from controls in their reports of 
consummatory pleasure, but exhibited deficits in anticipatory pleasure, particularly
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concerning goal-directed activities. Furthermore, anticipatory (but not consummatory) 
pleasure deficits were related to clinical ratings of anhedonia, including scores on the 
Behavioural Activation Scale (BAS) measuring reward sensitivity (developed by 
Carver & White, 1994), and anhedonia scores on the Schedule for the Assessment of 
Negative Symptoms (SANS) scale (developed by Andreasen, 1982). Additional 
evidence in favour of the idea that people with schizophrenia have deficits in their 
ability to anticipate the value of future rewards comes from a study of delayed 
discounting by Heerey, Robinson, McMahon and Gold (2007). In a delayed 
discounting test, participants are asked to judge the subjective value of a reward 
according to how long they have to wait for it. Heerey et al. found that people with 
schizophrenia discounted the value of delayed rewards at a greater rate than controls. 
In light of these findings, it is possible that the inability to find evidence of 
consummatory anhedonia in rats following sub-chronic PCP treatment may reflect an 
absence of this symptom in the disorder itself. Therefore, the experiments detailed in 
this section investigated the occurrence of anticipatory anhedonia in this model using 
an anticipatory contrast paradigm.
Negative anticipatory contrast occurs when rats receive brief, sequential 
access to two solutions, once each day. Repeated pairing of the two solutions allows 
animals to anticipate what the second solution will be, and this affects their intake of 
the first solution. If the second solution is preferred over the first, intake of the first 
solution is suppressed (see Flaherty, 1996 for a full review). In the first demonstration 
of this effect rats were given 3-min access to 0.15% saccharin, followed by 5-min 
access to 32% sucrose after a 15-second inter-solution interval. Control animals had 
access to saccharin only and increased their consumption of this solution across days.
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However, in animals receiving 32% sucrose, this rise in saccharin consumption across 
days was reduced (Flaherty, 1996).
It is now known that the magnitude of the negative anticipatory contrast effect 
can be influenced by several factors. For example, the greater the hedonic value of the 
second solution, the greater the contrast effect (e.g. Flaherty & Checke, 1982). Also, 
when the inter-solution interval exceeds 1-min, the contrast effect is decreased with 
increasing interval (Flaherty & Checke, 1982). In addition, contrast is enhanced when 
the duration of access to the second solution is longer than the first solution,
(Flaherty, 1996). With these findings in mind, the following experiment was designed 
to optimise the negative anticipatory contrast effect.
Using this paradigm, it is possible to detect whether PCP produces a deficit in 
an animal’s ability to anticipate the value associated with future rewards. A failure to 
expect the second solution, or to accurately predict its value, will bring about a 
reduction in the anticipatory contrast effect, manifested by an increase in 
consumption of the first solution when presented repeatedly across days.
5.5 Experiment 9
Methods
Subjects
This experiment was carried out as a follow-up to Experiment 8. Twenty four animals 
were used from the initial cohort. The husbandry details, prior drug treatment of these 
animals, previous sucrose exposure, and locomotor activity testing were described in 
section 4.2.
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Apparatus
Testing was carried out in a room containing six automated drinking chambers 
measuring 30x24x2lcm. The chamber floor consisted of 19 steel rods measuring 
4.8mm in diameter. Two of the chamber walls were clear perspex and two were 
aluminium. Two holes were positioned 5cm above the grid floor on the left and right 
hand side of one of the aluminium walls to allow rats to access solutions during 
experimental sessions. Solutions were given in 50ml bottles attached to stainless steel 
drinking spouts. These were fastened to motorised holders that positioned the metal 
spout level with the wall of the chamber, and retracted them when required. A 
contact-sensitive lickometer registered the time of each lick to the nearest 0.01s. This 
was recorded by a computer using MED-PC software (Med Associates Inc., St 
Albans, VT, USA). The solutions used for this experiment were 4% and 32% sucrose, 
formulated (weight/weight) using deionised water.
Dosing and testing
The anticipatory contrast test sessions discussed here began 20 days after the final
sub-chronic PCP injections described in section 4.2. Rats were given daily
anticipatory contrast sessions in which they received 3min access to a 4% sucrose
solution presented on the left side of the automated chamber. This was followed by
the presentation of either a 4% or 32% sucrose solution for 6min, after a 4 second
pause. The concentration of this second solution remained consistent throughout the
$
experiment. For half of the animals in the PCP and vehicle treated groups the second 
solution concentration was 4%, and for the other half of the animal so it was 32%.
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Test sessions began at approximately 9.30am every morning and were conducted for 
18 consecutive days.
Data Analysis
The parameters recorded and the lick cluster criterion used for this experiment were 
the same as those used in previous chapters. The anticipatory contrast data obtained 
from both the first and second solutions presented was analysed via mixed analysis of 
variance (ANOVA) with ‘block’ as the within-subject factor, and second solution 
concentration and drug treatment as between-subject factors. The data from all 
eighteen days of testing was used to analyse the effects of sub-chronic PCP treatment 
on acquisition of the anticipatory contrast effect. This was averaged into two-day 
blocks prior to analysis.
Results
Figures 15 shows the amount of sucrose consumed (panel A) and the mean number of 
lick/cluster (panel B) for both the first solution presented. Figure 16 shows the same 
data for the second solution presented. The first solution presented was always 4% 
sucrose and the second was either 4% or 32% sucrose. In terms of the amount 
consumed of the first solution, there was an overall increase in consumption across 
days, F(8,160)=48.15, p<.001, and consumption was higher when the second solution 
was 4% sucrose than when it was 32% sucrose, F(1,20)=19.98,/k.001. There was a 
significant interaction between ‘block’ and second solution concentration consistent 
with the observation that consumption rose more steeply across days when the second 
solution was 4% sucrose than when it was 32% sucrose, F(8,160)=8.94, p<.001. Sub­
chronic PCP treatment had no effect on consumption, F< 1, there was no interaction
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between day and sub-chronic treatment, F< 1, no interaction between treatment and 
second solution concentration, F(l,20)=3.60,/?=.072, and no three-way interaction 
with second solution concentration, F  < 1.
With respect to licks/cluster, there was an overall increase across days,
F(8,160)=12.47, /K.001. Licks/cluster was also higher when the second solution was 
4% sucrose than when it was 32% sucrose, F(l,20)=8.46,/?=.009. There was no 
interaction between day and second solution concentration, F(8,160)=l.ll,p=.358. 
There was no effect of sub-chronic PCP treatment on the number of licks/cluster,
F<1. There was also no interaction between day and sub-chronic treatment, no 
interaction between drug treatment and second solution concentration, F< 1, and no 
three-way interaction with second solution concentration, Fs<l.
The amount consumed of the second solution presented increased across days, 
F(8,160)=43.20, p<.001. Consumption of the 32% solution was significantly higher 
than the 4% solution, F(l,20)=9.61,/?=.006. An interaction occurred between day and 
solution concentration whereby consumption of the 32% sucrose rose more steeply 
over time than consumption of the 4% solution, F(8,160)=2.31,p=023. Sub-chronic 
PCP treatment had no effect on consumption, F<1. No interaction occurred between 
day and sub-chronic treatment, F(8,160)=1.30, p=.245, or between drug treatment and 
second solution concentration, F< 1, and there was no three-way interaction with 
second solution concentration, F< 1.
The number of licks/cluster for the second solution increased across days, 
F(8,160)=4.51,p<.001. Unexpectedly, there was no significant difference in 
licks/cluster between the 4% and 32% second solution concentrations, F(l,20)=3.41, 
/?=.080. However, there was an interaction between day and second solution 
concentration whereby licks/cluster showed a larger increase across days when the
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Figure 15: Graphs show the consumption (Panel A) and number of licks/cluster 
(Panel B), with SEM, for a 4% sucrose solution consistently presented prior to either 
4% sucrose or 32% sucrose, for animals treated sub-chronically with PCP or vehicle.
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Figure 16: Graphs show the consumption (Panel A) and number of licks/cluster 
(Panel B), with SEM, for 4% and 32% sucrose solutions presented after 4% sucrose, 
for animals treated sub-chronically with PCP or vehicle.
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solution was 32% sucrose than when it was 4% sucrose, F(8,160)=2.32, />=.022. Sub­
chronic PCP treatment had no effect on the number of licks/cluster, F(l,20)=1.81, 
p=.194. There was no interaction between day and sub-chronic treatment, F< 1, no 
interaction between drug treatment an second solution concentration, F< 1, and no 
three-way interaction with the second solution concentration, F(8,160)=1.10,/?=.367.
Summary of Experment 9
The results of Experiment 9 showed that anticipatory contrast effects could be seen 
both in terms of overall consumption and palatability. This was evident from the 
lower consumption and cluster size measurements associated with the first solution 
presented when it was consistently followed by a more palatable solution. This 
contrast effect was not affected by prior sub-chronic PCP treatment.
5.6 Experiment 10
Experiment 9 was conducted to follow an earlier experiment and the test sessions 
began 20 days after sub-chronic PCP treatment, by which time, any effects of PCP 
withdrawal may have attenuated. The rats used in Experiment 9 had also received 
prior exposure to sucrose solutions. Since the conditions of Experiment 9 were not 
optimal, Experiment 10 was necessary to confirm that sub-chronic PCP treatment 
does not affect anticipatory contrast. The conditions used for Experiment 10 were the 
same as Experiment 9 except that the animals used were experimentally naive. For 
this reason, fewer sessions were required to obtain a stable anticipatory contrast 
effect.
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Methods
Subjects and Apparatus
Forty eight male hooded Lister rats supplied by OLAC, Bicester, UK were used in 
this experiment. Husbandry details and apparatus used were the same as those in 
Experiment 9.
Dosing and testing
Prior to testing, 24 rats received sub-cutaneous injections of 5mg/kg PCP twice daily 
(0800 and 1900hours) for 7 days, whilst 24 rats received 5% glucose vehicle 
injections. Following a 7-day washout period, all rats were exposed to daily 
experimental sessions, the same as those in Experiment 9. Test sessions began at 
approximately 9.30am every morning and were conducted for 8 consecutive days.
After the acquisition phase of the experiment, test sessions were continued for 
a further 3 days. On the first and third of these days all animals received a sub­
cutaneous vehicle injection. On the second day all animals were given a 1 mg/kg 
injection of PCP.
Locomotor activity testing
All rats received locomotor activity assessments to test for PCP-induced augmented 
hyper-locomotion following amphetamine treatment. For half of the animals, this 
testing took place before they experienced the anticipatory contrast schedule. The rest 
of the animals were tested at the end of the experiment. The equipment and procedure 
for this testing was the same as that recorded for Experiment 8.
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Data Analysis
The data from the acquisition phase of the experiment was analysed using the same 
methods as those reported in Experiment 9. The data from the last three days of 
testing (the acute PCP test) was analysed using a mixed ANOVA with acute treatment 
as the within-subject factor and sub-chronic treatment as the between-subject factor. 
The vehicle data used was averaged across the first and third day (i.e. before and after 
acute PCP treatment).
During each session, the apparatus used for locomotor activity testing counted 
the number of movements made by an animal and grouped them into lOmin bins.
This data was analysed using a mixed ANOVA with ‘bin’ as a within-subject factor 
and drug treatment as a between-subject factor.
Results
Figures 17 shows the amount of sucrose consumed (panel A) and the mean number of 
lick/cluster (panel B) for the first solution presented. Figure 18 shows the same data 
for the second solution presented. The first solution presented was always 4% sucrose 
and the second was either 4% or 32% sucrose. In terms of the amount consumed of 
the first solution, there was an overall increase in consumption across days, 
F(3,132)=12.22,/?<.001, and consumption was higher when the second solution was 
4% sucrose than when it was 32% sucrose, F(l,44)=103.01,p<.001. A significant 
interaction between ‘day’ and second solution concentration indicated that 
consumption rose more steeply across days when the second solution was 4% sucrose 
than when it was 32% sucrose, F(3,132)=13.55,/?<.001. Sub-chronic PCP treatment 
had no effect on consumption, F(1,44)=2.04, p=. 161, there was no interaction 
between day and sub-chronic
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F ig u re  17: Graphs show the consumption (Panel A) and number of licks/cluster 
(Panel B), with SEM, for a 4% sucrose solution consistently presented prior to either 
4% sucrose or 32% sucrose, for animals treated sub-chronically with PCP or vehicle.
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Figure 18: Graphs show the consumption (Panel A) and number of licks/cluster 
(Panel B), with SEM, for 4% and 32% sucrose solutions presented after 4% sucrose, 
for animals treated sub-chronically with PCP or vehicle.
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treatment, no interaction between drug treatment and second solution concentration, 
and no three-way interaction with second solution concentration, Fs<l.
With respect to licks/cluster, there was an overall increase across days, 
F(3,132)=17.09,/?<.001. Licks/cluster was also higher when the second solution was 
4% sucrose than when it was 32% sucrose, F(l,44)=26.89,/?<.001. An interaction 
occurred between day and second solution concentration whereby the number of 
licks/cluster rose across days only when the second solution was 4% sucrose (i.e. the 
same concentration as the first solution), F(3,132)=13.71,/?<.001. There was no 
effect of sub-chronic PCP treatment on the number of licks/cluster, F(l,44)=2.45, 
p=. 125. There was also no interaction between day and sub-chronic treatment,
F(3,132)=1.24,/?=. 193, no interaction between drug treatment and second solution 
concentration, F< 1, and no three-way interaction with second solution concentration, 
F< 1.
The amount consumed of the second solution presented increased across days, 
F(3,132)=26.14, p<.001. Consumption of the 32% solution was significantly higher 
than the 4% solution, F(l,44)=39.39,/?<.001. An interaction occurred between day 
and solution concentration whereby consumption of the 32% sucrose rose more 
steeply over time than consumption of the 4% solution, F(3,32)=4.53,/?=.005. Sub­
chronic PCP treatment had no effect on consumption, F< 1. No interaction occurred 
between day and sub-chronic treatment, or between drug treatment and second 
solution concentration, and there was no three-way interaction with second solution 
concentration, Fs<l.
The number of licks/cluster increased across days, F(3,132)=24.21, p<.001. 
Unexpectedly, there were no significant differences in licks/cluster between the 4% 
and 32% second solution concentrations, F(l,44)=3.40,/?=.072. However, there was
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an interaction between day and second solution concentration whereby licks/cluster 
showed a larger increase across days when the solution was 32% sucrose than when it 
was 4% sucrose, F(3,132)=7.15,/?<.001. Sub-chronic PCP treatment had no effect on 
the number of licks/cluster, F(1,44)=1.02,/f=.319. There was no interaction between 
day and sub-chronic treatment, F(3,132)=1.59,/?=.197, or between drug treatment and 
second solution concentration, F< 1, and there was no three-way interaction with the 
second solution concentration, F(3,132)=1.48,/?=.222.
Post-acquisition acute PCP test
Figure 19 shows the consumption (panel A) and number of licks/cluster (panel B), 
with SEM, following administration of acute PCP and vehicle treatment, for the first 
solution presented. Figure 20 shows this data for the second solution presented. Data 
was collapsed over sub-chronic PCP treatment conditions as there were no significant 
effects or interactions involving the sub-chronic PCP factor (see below). Acute PCP 
treatment had no effect on the amount consumed of the first solution presented,
F(1,44)=1.08, p=.305. Consumption of the first solution was lower when it preceded 
32% sucrose than when it preceded 4% sucrose, F< 1. There was no acute treatment x 
second solution concentration interaction, demonstrating that, in terms of 
consumption, acute PCP treatment did not alter the anticipatory contrast effect 
acquired, F<1. Additionally, there was no effect of prior sub-chronic treatment on 
consumption of the first solution, and no interaction between sub-chronic treatment 
and second solution concentration. There was no interaction between acute PCP 
treatment and sub-chronic treatment and no 3-way interaction with second solution 
concentration (all Fs < 1). This demonstrates that, in terms of consumption, the
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absence of an effect of acute PCP treatment on anticipatory contrast was true for both 
animals treated sub-chronically with PCP and those treated with vehicle.
Acute PCP treatment produced no overall effect on the number of licks/cluster 
during consumption of the first solution, F< 1. The number of licks/cluster during 
consumption of the first solution was lower when it preceded 32% sucrose than when 
it preceded 4% sucrose, F(1,44)=34.13, /?<.001. There was no acute treatment x 
second solution concentration interaction, demonstrating that, in terms of 
consumption, acute PCP treatment did not alter the anticipatory contrast effect 
acquired, F(l,44)=1.01,/?=.321. Again, there was no effect of sub-chronic treatment 
on licks/cluster during consumption of the first solution, F(1,44)=1.96,/?= 169 There 
was no interaction between sub-chronic treatment and second solution concentration, 
no interaction between acute PCP treatment and sub-chronic treatment, and no 3-way 
interaction with second solution concentration, Fs<l. This demonstrates that, as with 
consumption, the absence of an effect of acute PCP treatment on anticipatory contrast 
in terms of licks/cluster was true for animals treated sub-chronically with PCP and 
with vehicle.
With respect to the second solution presented, consumption of 32% sucrose 
was higher than 4% sucrose, F(l,44)=31.74, p<.001. Consumption was not affected 
by acute PCP treatment, F< 1. There was no acute treatment x solution concentration 
interaction, F<1, and no acute treatment x sub-chronic treatment interaction,
F(1,44)=1.75, p=. 193.
The number of licks/cluster was numerically higher for 32% sucrose than 4% 
sucrose, but this did not reach significance, F(1,44)=2.72, p=. 106. Acute PCP 
treatment did not affect licks/cluster, F(l,44)=2.71,/?=.107. There was no acute
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Figure 19: Graphs show the consumption (Panel A) and number of licks/cluster 
(Panel B), with SEM, following administration of acute PCP and vehicle treatment, 
for a 4% sucrose solution consistently presented prior to either 4% sucrose or 32% 
sucrose. Data is shown for sub-chronic PCP pre-treatment and vehicle pre-treatment 
conditions.
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Figure 20: Graphs show the consumption (Panel A) and number of licks/cluster 
(Panel B), with SEM, following administration of acute PCP and vehicle treatment 
for 4% and 32% sucrose solutions presented after 4% sucrose. Data is shown for sub­
chronic PCP pre-treatment and vehicle pre-treatment conditions.
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treatment x solution concentration interaction, no acute treatment x sub-chronic 
treatment interaction, and no 3-way interaction, all Fs<l.
Locomotor activity testing
Figure 21 shows the activity counts recorded during locomotor activity testing. These 
have been grouped into 10-min bins across the session. There was a significant effect 
of bin, F(8,368)=67.39,/K.001. Although there was no overall effect of PCP 
treatment, F(l,46)=2.04,/?=.160, there was a significant bin x PCP treatment 
interaction, F(8,368)=2.94,/?=004, suggesting that withdrawal from sub-chronic PCP 
treatment sensitised animals to the effects of amphetamine on locomotor activity. 
Analysis of simple effects showed that the levels of activity in PCP and vehicle 
treated animals were similar prior to amphetamine injection (bins 1-3), with PCP- 
treated animals showing a non-significant decrease in activity relative to controls, 
largest F(l,46)=2.22,/?=. 143. Following amphetamine administration, PCP-treated 
animals showed numerically higher levels of activity than control animals in all bins, 
although these differences did not reach significance, largest F(l,46)=3.83,/?=.056.
Summary of Experiment 10
The results of Experiment 10 provide further evidence that anticipatory contrast 
effects can be seen both in terms of consumption and palatability. Again, this was 
indicated by the lower consumption and cluster size measurements associated with 
the first solution presented, when it was consistently followed by a more palatable 
solution. As in Experiment 9, this contrast effect was not affected by prior sub­
chronic PCP treatment. Experiment 10 also showed that, once anticipatory contrast is 
established, acute PCP treatment has no impact on this effect.
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Figure 21: Graph shows the mean number of activity counts (with SEM) made over a 
90min session, before and after administration of 1 mg/kg amphetamine (given 
between bins 3 and 4). Counts are grouped into lOmin bins. The scale for the No. of 
activity counts/min extends to 200counts/min because higher activity levels were 
reached than in the previous locomotor activity test using the same apparatus 
(Experiment 8).
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5.7 Discussion
The primary purpose of the current experiments was to examine the acquisition of a 
negative anticipatory contrast effect in control and sub-chronic PCP-treated animals. 
Both Experiment 9 and Experiment 10 showed that the amount consumed of the first 
solution presented rose less steeply across days when the second solution was 32% 
than when it was 4%, demonstrating that the perceived hedonic value of the first 
solution was moderated by the greater value of the second. To my knowledge, there 
have been no prior reports of detailed lick analysis being used in conjunction with this 
paradigm. In the current experiments this has revealed a novel finding that the 
anticipatory contrast effect is also reflected in terms of cluster size, so that the 
perceived palatability of the first solution is also reduced when it is followed by a 
solution of greater hedonic value. This suggests that anticipatory contrast produces an 
effect on perception, such that the hedonic reaction to the first solution is reduced by 
the expectation of a more palatable alternative.
Interestingly, no overall significant differences were observed between the 
cluster size of 4% and 32% solutions presented as the second solution in both 
experiments. Although the experiment had a between-subject design, the difference in 
concentration between 4% and 32% sucrose is large enough to expect a significant 
difference in cluster size. The lack of a difference suggests that the differences 
observed in the consumption and palatability of the first solution may affect how the 
animals interact with or perceive the second solution. The implications of the 
anticipatory contrast procedure for responding to the second solution has never been 
previously considered. However, the current results indicate that this issue warrants 
further exploration.
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Anticipatory contrast effects, both in terms of consumption and palatability, 
was unaffected by sub-chronic PCP treatment in both Experiments 9 and 10. 
Following the acquisition phase of Experiment 10, animals were given acute 
treatment with 1 mg/kg PCP. This also produced no changes in the acquired contrast 
effects. This acute test does not suffer from the motor confound present in my acute 
tests for consummatory anhedonia (Experiments 3 and 4), in that for anticipatory 
anhedonia to be evident in this paradigm an animal would need to drink a greater 
amount of the first solution when treated acutely with PCP. Tests of consummatory 
anhedonia rely on decreased consumption as a marker of the symptom, but it is 
difficult to draw conclusions from such an effect as ILI is often increased following 
acute PCP treatment, raising the possibility that decreased consumption is due to a 
motor deficit.
The inability to find evidence of anticipatory anhedonia following sub-chronic 
and acute PCP treatment may highlight a short-coming of PCP treatment as a model 
of negative symptomology. However, it is also possible that anhedonia may not exist 
as a primary feature of schizophrenia. (This idea will be addressed in detail in section
7.4 of the general discussion).
Since anticipatory anhedonia does not appear to be a feature of acute and sub­
chronic PCP models of schizophrenia, chapter 6 will investigate the presence of 
motivational deficits.
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CHAPTER SIX 
Motivation in the sub-chronic PCP and MAM model of schizophrenia
6.1 Introduction
In chapter 4 the suggestion was raised that anhedonia may not be a feature of the sub­
chronic and acute PCP models of schizophrenia. If this is the case, this may reflect a 
failure of PCP models, or it may suggest that anhedonia, when strictly defined as a 
diminished capacity to experience reward, is not a primary symptom of the disorder. 
Although diagnostic tools state that anhedonia is a primary symptom of 
schizophrenia, it is difficult to verify this because it is conceivable that anhedonia 
may be secondary to other core symptoms such as hallucinations and delusions that 
are detrimental to the quality of life experienced by sufferers. Avolition (lack of 
motivation) is a symptom of schizophrenia that appears to be the most closely linked 
with anhedonia. Indeed, Foussias and Remington (2010) reviewed evidence that 
measures of anhedonia and avolition are moderately related when assessed using the 
MATRICS analysis (correlation coefficients between 0.47 and 0.57). The problem of 
deciphering whether anhedonia is a primary symptom of the disorder is further 
impacted by the fact that current, frequently used scales of assessment such as SANS, 
use questions relating to the frequency of engagement in enjoyable activities in order 
to detect anhedonia (Horan, et al., 2006). Clearly, engagement in recreational 
activities reflects motivational as well as hedonic factors, and since much of the 
evidence suggesting that anhedonia is a primary symptom of schizophrenia has 
utilised such scales, it is possible that motivational deficits are actually the core 
problem. Evidence from Gard et al. (2007), introduced in section 4.4, is consistent
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with this suggestion. In this study the deficits in anticipatory pleasure reported were 
observed mainly in relation to goal-directed activities (e.g. preparing dinner) rather 
than non-goal-directed activities (e.g. eating). Schizophrenia sufferers also reported 
less frequent engagement in such activities. Experiments 9 and 10 showed that PCP 
does not produce an anticipatory pleasure deficit. However, since Gard et al. found 
pleasure deficits most commonly occur when rating pleasure associated with goal- 
directed activities, it is possible that that the apparent pleasure deficits observed by 
Gard et al. actually reflect a reduction in motivation.
In light of the evidence that anhedonia and avolition may represent different 
facets of a familiar underlying issue, it is important to assess whether motivational 
deficits are present in the PCP model, since an abnormal experience of reward may 
manifest itself in this way.
The current experiments employed a progressive ratio procedure to examine 
motivation in the sub-chronic PCP model and in an alternative, neurodevelopmental, 
methylazoxymethanol acetate (MAM) model. In a progressive ratio paradigm the 
number of lever presses required to obtain reinforcement increases across a session 
with successive reinforcers. The ratio at which the rat ceases to respond, or the 
highest ratio obtained within a defined period (the breakpoint) is often used as an 
index of motivation or reinforcer efficacy. This technique was first used by Hodos 
(1961) who found that animals achieved a higher breakpoint when the concentration 
of a palatable liquid reward was increased. Further support for the use of breakpoint 
measures as an index of motivation has come from findings that breakpoint is 
influenced by changes in reinforcer magnitude (Skjoldager, Pierre, & Mittleman, 
1993), and deprivation state (Ferguson & Paule, 1997). Progressive ratio performance 
has also been used as a means of assessing the effects of drug treatments on
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motivational processes (Zhang, et al., 2005, with typical and atypical antipsychotics). 
Additionally, it has been used as a tool to discover the brain areas required in 
motivational processes and the evaluation of reinforcer efficacy (Bezzina, Body, et 
al., 2008; Bezzina, den Boon, et al., 2008).
Schizophrenia is a disorder in which similar pathology can arise from multiple 
different etiologies (e.g. environmental and genetic). This is consistent with the fact 
that a number of methods (e.g. pharmacological and neurodevelopmental 
manipulation) can be used to produce animal models of schizophrenia. The MAM 
model relies upon disruption of neurodevelopment by administration of a DNA 
methylating agent to pregnant rats on gestational day 17 (GDI7). At this stage in 
development MAM exposure affects development of the frontal and temporal 
cortices, resulting in neuroanatomical and behavioural features resembling those in 
schizophrenia (see section 1.9). Neuroanatomically, GDI7 MAM exposure produces 
reductions in cortical thickness in the medial pre-frontal cortex and the hippocampus 
(Flagstad, et al., 2004; Le Pen, et al., 2006). In the human condition, similar 
reductions in cortical thickness have been found in the pre-frontal cortex and the 
temporal lobe (Wright, et al., 2000).
The decision to use MAM-exposed animals in addition to the sub-chronic PCP 
model was based on behavioural evidence reporting that this treatment produces 
effects analogous to the positive, negative and cognitive symptoms of schizophrenia, 
which develop during adolescence. For example, it has been suggested that people 
with schizophrenia experience abnormalities in attending to and filtering relevant 
sensory information, and that this results in an inability to distinguish self-generated 
cognitive stimuli from external information, which may underlie aspects of positive 
symptomatology (see Braff, 1993, for a review). Assessment of latent inhibition is a
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technique used to examine attentional processes in animals. Latent inhibition refers to 
a reduction in the capacity to leam conditioned associations with a stimulus that has 
been presented previously without any consequence. Flagstad, Glenthoj and 
Didriksen (2005) found that control rats that received pre-exposure to a conditioning 
stimulus showed strong latent inhibition, but this was absent in MAM-exposed 
animals. Gray, Hemsley, & Gray (1992) also showed that latent inhibition is absent in 
newly-medicated schizophrenia patients, but is restored following chronic 
antipsychotic treatment. However, Williams et al. (1998) suggest that abolishment of 
latent inhibition may be an effect of antipsychotic medication that wears off with 
chronic use.
In addition to the positive symptom profile of MAM-exposed rats, Flagstad et 
al. (2004) showed that MAM-exposed rats display significantly less social 
interactions than controls in terms of the amount of time spent in close proximity (less 
than 20cm) to an unfamiliar rat. They suggested that this effect is analogous to the 
negative symptom, asociality, although this observation is confounded by the 
hyperactivity exhibited in MAM-exposed animals. MAM-exposed rats also display 
deficits in multiple cognitive domains (Featherstone, Rizos, Nobrega, Kapur, & 
Fletcher, 2007). For example, MAM-exposed animals show deficits in attentional set- 
shifting, a task in which animals leam an initial rule in order to solve a series of 
discriminations, but must then shift to using an alternative rule. This shift is 
analogous to what is required for humans to perform the Wisconsin card-sort test, a 
task in which people with schizophrenia show impairment (Goldberg, Weinberger, 
Berman, Pliskin, & Podd, 1987).
It has been suggested that motivational and cognitive deficits in schizophrenia 
are inextricably linked. Gorissen, Sanz and Schmand (2005) measured mental effort
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in schizophrenia sufferers using a word memory test. Participants were also given a 
selection of cognitive tests. It was found that lower than average scores on the effort 
test accounted for around one-third of the variance in cognitive test performance. 
Gorissen et al. proposed that mental effort is a motivational factor, and that their 
finding highlights the detrimental effect motivational problems can have on cognitive 
functioning. Since cognitive abnormalities are evident in both the MAM model 
(Flagstad, et al., 2004) and the sub-chronic PCP model (Dunn & Killcross, 2006) this 
may further suggest that motivational deficits are likely to be evident in these models.
6.2 Experiment 11
Methods
Subjects
This experiment was carried out at Lilly Research Centre, Surrey. Thirty-two male 
Wistar rats supplied by Harlan, Bicester, UK, were used. They were housed in groups 
of four, in individually ventilated cages, on a 12hr/12hr light/dark cycle. Animals 
were food restricted to no less than 85% of their free-feeding weight, and weighed 
between 291 and 352 grams at the time of testing. All other husbandry procedures 
were the same as those reported for experiments carried out at Cardiff School of 
Psychology. Experimental procedures were carried out Monday-Friday in the light 
part of the cycle.
Apparatus
Testing was carried out in standard operant chambers (dimensions as reported in 
section 4.5). These chambers were housed in sound and light attenuation boxes (Med
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Associates, US). Two retractable levers were located either side of a recessed 
magazine where sucrose pellets (Noyes, 45mg, formula P) were delivered from an 
automatic pellet dispenser. Experimental sessions were controlled and recorded using 
MedPC IV software.
Drugs
PCP supplied by Sigma-Aldrich UK was used in this experiment. This was made into 
a 5mg/ml solution using 5% (w/w) glucose. D-Amphetamine sulphate from the same 
supplier was also dissolved in 5% glucose to obtain a 1 mg/ml solution. These 
concentrations refer to the salt weight of the compounds.
Dosing and testing
Half of the animals were treated sub-chronically with PCP using the same seven-day 
procedure used in the other sub-chronic experiments reported in this thesis. The other 
half of the animals received an equal number of 5% glucose vehicle injections. 
Training began 9 days after the last PCP dose. Rats initially received two 30-min 
sessions of nose-poke training in which they received pellets on a variable interval 
(VI 60s) schedule. Following this, rats were assigned a left or right lever and received 
a fixed ratio 1 (FR1) schedule for two days. Rats then underwent daily training 
sessions under the progressive ratio schedule using the following exponential 
progression: 1, 2, 4, 6, 9, 12, 15, 20, 25 32, 40, 50, .This was developed by Roberts 
and Richardson (1992), based on the formula (5><e0 2")-5, where n is the position in 
the ratio sequence. After animals made the required number of presses to be rewarded 
at a particular ratio, there was a delay of 15 seconds before the lever became 
operational again. In the first 3 days of training, sessions allowed animals to achieve
142
the first 10 components of the progression. Following this, animals received sessions 
in which 20 ratios could be achieved for 6 days.
Locomotor Activity Testing
In addition to the progressive ratio tests, rats received locomotor activity assessments 
to test for PCP-induced hyperlocomotion in response to amphetamine injection. Half 
of the animals in both PCP and vehicle treated groups received this testing prior to the 
progressive ratio tests and half were tested after the completion of these sessions. This 
testing took place in a completely dark test room. Animals were placed in clear 
Perspex boxes (40><40x30cm) and their activity was recorded based on infrared fields 
that spanned 100x100cm. Four boxes were placed on each field and one animal was 
placed in each box. Overhead infra red cameras (Sanyo VCV-3412P, TrackSys Ltd, 
UK) tracked the movement of each animal. This was recorded by a Quad compressor 
unit (Sanyo VDM-801P, TrackSys Ltd, UK) linked to a PC running Ethovision v2.2 
Software (Noldus, NL). Animals were initially placed in the boxes for a 30-min 
habituation period. They were then given 1 mg/kg amphetamine sub-cutaneously and 
their activity was recorded for a further 60-min.
Data Analysis
The data reported is based on the breakpoints achieved. The breakpoint is defined as 
the last ratio to have been completed by the end of a 45-min session. The analysis of 
the progressive ratio data was based on an averaged snapshot of two consecutive 
days. These days were selected as they represented performance towards the end of 
training on days that fell at the end of a week rather than after a weekend. One rat was 
removed from the analysis due to failure to acquire the lever-press response.
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The measurement of interest for the locomotor activity testing was distance 
moved (cm). This distance was grouped into 10-min bins and analysed using repeated 
measures ANOVA with ‘bin’ as the within-subject factor and ‘treatment group’ as the 
between-subject factor.
Results of Experiment 11
Figure 22 shows the progressive ratio breakpoints for sub-chronic PCP-treated and 
control animals. There was no effect of sub-chronic PCP treatment on the breakpoint 
achieved, F<1. The apparent trend towards increased breakpoint in the PCP-treated 
animals is not significant and is in the opposite direction to what would be expected if 
a motivational deficit was present.
Locomotor Activity Testing
Figure 23 shows the distance moved in 10-min bins across the session. There was a 
significant effect of bin, F(5,145)=l 14.82, /K.001. There was no overall effect of 
PCP treatment, F<1. However, there was a significant bin x treatment interaction,
F(5,145)=4.14, />=.002, consistent with a greater increase in locomotor activity in 
PCP-treated animals relative to controls following amphetamine administration.
Summary of Experiment 11
The analysis of progressive ratio breakpoints in Experiment 11 provided no evidence 
that sub-chronic PCP treatment produces a motivational deficit, despite the fact that 
the treatment regimen did produce the expected amphetamine-induced augmented 
hyperlocomotion that normally occurs following this treatment.
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Figure 22: Shows the highest mean response ratios (breakpoints) achieved, with 
SEM, for animals treated sub-chronically with PCP or vehicle during a progressive 
ratio schedule.
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Figure 23: Shows the distance moved by PCP and vehicle-treated rats over a 90min 
session, before and after administration of 1 mg/kg amphetamine (given between bins 
3 and 4). Counts are grouped into lOmin bins.
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6.3 Experiment 12
Thirty-two male Wistar rats were used in this experiment. 16 of these had been 
exposed pre-natally to methylazoxymethanol acetate (MAM), and 16 were control 
rats. All rats were bred by in-house at Lilly Research Centre. MAM-exposed rats 
were generated by injecting pregnant dams intraperitoneally with 28mg/kg MAM on 
gestational day 17. MAM was supplied by Midwest Research Institute, Kansas City, 
Missouri. It was formulated using 0.9% saline. Control rats were generated by 
injecting pregnant dams with saline on gestational day 17.
The offspring were 5 months old and weighed between 327 and 560 grams 
when testing commenced. They had received no prior operant training. General 
husbandry procedures were the same as those for Experiment 11.
Apparatus and procedure
This experiment was run in parallel with Experiment 11. The apparatus and 
procedural details were the same except that 0.1 mg/kg (+)MK-801 was used for 
locomotor activity testing instead of amphetamine. The decision to use this drug was 
based on the experience of researchers at Lilly Research Centre who had found that 
(+)MK-801-induced augmented hyperlocomotion provided a reliable positive control 
for MAM treatment effects. The data were analysed in the same way as Experiment 
11 .
Results of Experiment 12
Figure 24 shows the mean breakpoints for the progressive ratio experiment. The 
MAM-exposed rats showed a decrease in breakpoint, consistent with a reduced 
motivation to work for the reinforcer, F(l,29)=44.63,/?<.043.
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Locomotor Activity Testing
Figure 25 shows the distance animals moved grouped into 10-min bins across the 
session. There was a significant effect of bin, F(5,145)=22.31, p<.001. MAM-treated 
rats showed higher levels of activity overall, F (1,29)=13.79,/?= 001, and there was a 
bin x treatment group interaction indicating that activity levels were augmented in the 
MAM-exposed rats following (+)MK-801 treatment, F(5,145)=2.30,/?=.048.
Summary of Experiment 12
Experiment 12 showed that breakpoints are lowered in MAM-exposed animals, an 
effect that may be consistent with decreased motivation. Locomotor activity testing 
confirmed that the MAM treatment was able to produce augmented hyperlocomotion 
in response to (+)MK-801, an effect that would be expected after this treatment.
6.4 Discussion
The current set of experiments used analysis of progressive ratio breakpoints as an 
index of motivational deficits in the sub-chronic PCP and neurodevelopmental MAM 
model of schizophrenia. Experiment 11 showed that sub-chronic PCP treatment 
produced no significant effect on progressive ratio breakpoints. In fact, there was a 
numerical, but not significant, trend towards an increase in breakpoint in the PCP- 
treated animals. This trend is in the opposite direction to what would be expected if a 
motivational deficit was present. Therefore, Experiment 11 provided no evidence that 
a motivational deficit exists in the sub-chronic PCP model of schizophrenia. This 
cannot be attributed to problems with the dosing regimen since PCP-treated animals
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Figure 24: Shows the highest mean response ratios (breakpoints) achieved, with 
SEM, for animals exposed pre-natally to MAM or vehicle, during a progressive ratio 
schedule.
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Figure 25: Shows the distance moved by MAM and control rats over a 90min 
session, before and after administration of 1 mg/kg amphetamine (given between bins 
3 and 4). Counts are grouped into lOmin bins.
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showed augmented hyperlocomotion in response to acute amphetamine challenge, an 
effect that would be expected in these animals.
When considered in conjunction with the data presented in the previous 
chapters of this thesis, it can be concluded that there is no evidence for hedonic 
deficits in the sub-chronic PCP model of schizophrenia in terms of consummatory or 
anticipatory pleasure, or in terms of motivation. The implications of these findings 
will be discussed in detail in section 7.3 of the general discussion.
Interestingly, Experiment 12 demonstrated that motivation, as indexed by 
breakpoint, is reduced in MAM-exposed animals. Reduced motor activity cannot 
account for this effect since locomotor activity testing showed that these animals are 
hyperactive relative to controls. In addition, there appeared to be no problems with 
the treatment regimen since MAM-exposed animals showed augmented 
hyperlocomotion in response to (+)MK-801 treatment, a well documented effect 
following this treatment. The reduction in breakpoints could, however, represent a 
satiety confound whereby MAM-treated animals were sated more readily than 
controls. This cannot be equated to a genuine deficit in the experience of reward since 
the MAM-exposed animals would effectively experience an effect which would be 
likened to a milder state of food deprivation relative to controls. The idea that a 
satiety confound may exist in MAM-exposed rats is consistent with the finding that 
MAM exposure has been found to cause a 13% decrease in the body weight of rats 
when they reach adulthood (Greiner, et al., 1992).
A confound of effort may also be present. In chapter 2 it was reported that the 
palatability of a reinforcer increases with effort expended. That is, an interaction may 
be observed between the effort expended and reward value, whereby lever pressing 
makes a reinforcer more palatable. Animals will then be more inclined to press the
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lever to gain access to this enhanced reinforcer. This positive feedback may be 
interfered with by factors that influence initial lever pressing, such as motor problems 
or a reduction in the initial palatability of the reward. Therefore, if the MAM-treated 
animals were initially less inclined to press the lever, perhaps because they 
experienced the reward as less palatable, or because the rats were not as hungry as 
controls, these animals would not experience the same increase in perceived 
palatability experienced by controls due to lever pressing. This may enhance the 
difference in breakpoint between MAM-treated animals and controls, without there 
being a genuine deficit in motivational processing in the MAM model.
It is indeed possible that the reduced breakpoint observed in MAM-treated 
animals reflects the negative symptom of avolition seen in human schizophrenia. Lick 
analysis experiments such as those reported in previous chapters would enable further 
characterisation of the deficit observed in this experiment and would determine 
whether MAM-exposed animals experience a reduction in their hedonic capacity. 
However, since avolition is suggested to be closely linked to schizophrenic 
anhedonia, the discovery of reduced breakpoints in these animals may indicate that 
this model has potential to provide an analogue of anhedonia.
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CHAPTER SEVEN
7.1 Summary of experimental results
Experiments 1 and 2 combined analysis of licking with schedules of operant 
responding. It was initially thought that since operant responding is already used as an 
indicator of motivation in animal assays, its combination with lick analysis would 
provide a more accurate measure of hedonic value. It was established that rats will 
produce a lever press response to gain access to a liquid reinforcer. These 
experiments also demonstrated that when the response required to obtain 
reinforcement is high, the palatability of the reinforcer is greater than when the 
response requirement is low. This was discovered by comparing the palatability of a 
reinforcer when 10 lever presses were required with the palatability of the same 
reinforcer when 50 lever presses were required. Furthermore, Experiment 2 used a 
yoking paradigm whereby some rats pressed a lever to obtain the reinforcer, whilst 
corresponding animals simply waited the same length of time. This showed that 
although it took longer for a rat to press a lever 50 times than 10 times, this difference 
in waiting time did not increase the palatability of a reinforcer as much as the 
requirement to work for the reinforcer.
Experiments 3, 4 and 5 assessed the effects of acute NMD A receptor 
antagonist treatment on the voluntary consumption and palatability of sucrose 
solutions. Experiment 3 showed that single intermediate doses of the NMDA receptor 
antagonists PCP and s-(+)-ketamine produced a decrease in cluster size, but this only 
occurred in the presence of motor abnormality indicated by raised ILI. (+)MK-801 
produced no effect on cluster size or consumption. In order to assess whether a
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reduction in consumption or cluster size is present at doses low enough to avoid 
motor abnormality, PCP was selected for a dose response experiment (Experiment 
4a). Since (+)MK-801 is often used interchangeably with PCP in pre-clinical 
modelling, a dose response experiment was also carried out with this drug 
(Experiment 4b). There was evidence of reduced consumption and cluster size with 
both drugs, but again, this only occurred when ILI was increased.
Experiment 5 investigated whether evidence of reduced consumption and 
cluster size could be found at lower sucrose concentrations than those examined in 
Experiments 3 and 4. It was found that even at low sucrose concentrations, there was 
no evidence of a PCP-induced reduction in cluster size occurring independently of 
motor abnormality. The consumption and palatability of low sucrose concentrations 
were unaffected by (+)MK-801 treatment. Since no reduction in palatability was 
observed, Experiments 3, 4 and 5 provided no evidence of anhedonia following acute 
NMDA receptor antagonist treatment.
Experiments 7 and 8 compared the effects o f the typical and atypical 
antipsychotics clozapine and haloperidol using lick analysis and sucrose preference 
testing. Clozapine did not affect sucrose intake, palatability, or preference for sucrose 
over water. Haloperidol, on the other hand, decreased both sucrose intake and lick 
cluster size. The ratio of sucrose over water intake was also decreased in haloperidol- 
treated animals relative to controls. Thus current drug treatments for schizophrenia 
have direct effects on consumption independent of their antipsychotic action.
Experiment 8 examined the effects of sub-chronic PCP treatment on the 
consumption and palatability of sucrose. As with acute PCP treatment, sub-chronic 
treatment produced no effect on consumption or cluster size, thus providing no 
evidence of consummatory anhedonia. Experiments 9 and 10 assessed negative
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anticipatory contrast following sub-chronic PCP treatment. Negative anticipatory 
contrast occurs when rats receive brief, sequential access to two solutions, once each 
day. Repeated pairing of the two solutions allows animals to anticipate what the 
second solution will be and this affects their intake of the first solution. If the second 
solution is preferred over the first, intake of the first solution is suppressed. In both 
experiments anticipatory contrast effects could be seen, both in terms of overall 
consumption, and in terms of palatability. This contrast effect was unaffected by prior 
sub-chronic PCP treatment. Furthermore, Experiment 10 showed that after the 
anticipatory contrast effect was acquired, it was not affected by acute PCP challenge. 
Therefore, Experiments 9 and 10 provided no evidence of anticipatory anhedonia. 
These experiments also provided additional evidence for the absence of 
consummatory anhedonia since there was no overall effect of sub-chronic PCP 
treatment.
Experiment 11 used analysis of progressive ratio performance to assess 
whether motivational deficits are present following sub-chronic PCP treatment. PCP 
treatment was found to have no affect on the breakpoint (highest response ratio 
achieved) in this context. However, Experiment 12 investigated the same paradigm in 
the developmental MAM model of schizophrenia, and found that breakpoint was 
reduced. This suggests that MAM exposure may provide an analogue of avolition, but 
this is not the case with PCP treatment.
7.2 Novel effects arising from the use of microstructural analysis of licking
The reliability of the lick analysis method in the measurement of hedonic value has 
been affirmed by the experiments contained in this thesis. As detailed in the 
introduction, many authors have reported that during ingestion the number of licks
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per cluster (cluster size) has a positive, monotonic relationship with the concentration 
of a palatable solution such as sucrose (e.g. Davis & Smith, 1992; Davis & Perez, 
1993; Hsiao & Fan, 1993; Spector et al. 1998). Similarly, in Experiments 3, 5, 9 and 
10, where rats were exposed to more than one concentration of sucrose, cluster size 
was consistently largest for the highest concentration tested.
The use of lick analysis in the experiments reported has given rise to some 
very interesting effects demonstrating novel ways in which the palatability of a 
solution can be changed without altering the concentration itself. For example, 
Experiments 1 and 2 showed that when rats are required to expend effort, the 
palatability of a reinforcer is increased. The effort involved in the lever-press 
response requirement employed in Experiments 1 and 2 has two obvious components: 
physical work and waiting time, because it takes more work and more time to press a 
lever 50 times than 10 times. However, Experiment 2 showed that physical work had 
effects on palatability that were greater than simply imposing a delay prior to 
reinforcement. This effect could not be accounted for by a physiological 
compensatory mechanism to alleviate thirst or energy expenditure since the amount 
consumed during each presentation of the reinforcer was not increased by raising the 
effort requirement. This discovery has provided the first direct analogue of the human 
effort justification phenomenon in animals. The fact that the explanation of this effect 
need not require the use of complex cognitive theories is a useful reminder that 
scientists should avoid resorting to such theories without direct evidence if simpler 
alternatives may suffice.
In addition to its implications for the analysis of ‘effort’ effects per se, the use 
of lick analysis in combination with operant schedules has also demonstrated an 
important consideration to be borne in mind when interpreting data from operant
154
schedules in terms of hedonic and motivational effects. The results of these 
experiments suggest that an interaction may be observed between the effort expended 
and reward value, whereby lever pressing makes a reinforcer more palatable. Animals 
will then be more inclined to press the lever to gain access to the reinforcer. This 
positive feedback may be interfered with by factors that influence initial lever 
pressing, such as motor problems or a reduction in the initial palatability of the 
reward. This means that effects such as reduced breakpoint, which are normally 
considered to be indicative of reduced motivation, may actually reflect other factors 
unrelated to motivation. It is possible that this problem can be circumvented by using 
a reinforcer that is not very palatable in the first instance. However, this confound 
should not be ignored.
The use of lick analysis in Experiments 9 and 10 has also given new insight 
into the mechanisms underlying the effect known as anticipatory contrast. Several 
authors and, in particular, Flaherty (1996) have noted that the consumption of a 
solution is attenuated when it precedes access to a solution that has greater hedonic 
value. Experiments 9 and 10 have revealed, for the first time, that the effects of 
reward anticipation on consumption are also reflected in terms of palatability, such 
that the palatability of the same solution is lower when that solution precedes a more 
palatable solution than when it precedes a solution of the same hedonic value. This 
suggests that, as with simultaneous contrast (Dwyer, Lydall & Hayward, in press), 
anticipatory contrast appears to reflect a change in the sensory experience of the 
reward.
The novel findings produced via the employment of lick analysis has 
demonstrated the potential of this method to provide valuable new insight into the 
mechanisms underlying long-established behavioural effects. The two novel effects
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discussed above emphasise that fact that the palatability of a reinforcer can be 
changed without changing the concentration of the reinforcer itself. This confirms 
that measurements of palatability made using lick analysis are not solely determined 
by the properties of a solution, but by an interaction between the solution, the state of 
an individual animal, and the context of consumption. This reaffirms the expectation 
that measurements made using lick analysis should be sensitive to any changes in the 
hedonic capacity of an animal, such as those that might have been brought about by 
NMDA receptor antagonist treatment.
7.3 Implications of thesis experiments for the modelling of anhedonia
As previously noted, anhedonia may take two forms. The first of these is 
consummatory anhedonia, characterised by a deficit in in-the-moment pleasure. The 
presence of consummatory anhedonia in rodents was assessed following acute 
treatment with PCP, s-(+)-ketamine and (+)MK-801 (Experiments 3, 4 and 5), and 
following sub-chronic PCP treatment (Experiments 8, 9 and 10). Although acute 
NMDA receptor antagonist treatment decreased consumption and lick cluster size at 
some doses, this should not be interpreted as a hedonic deficit because such decreases 
were always accompanied by motor abnormality. This highlights a critical flaw in the 
assumption made by many authors, that reduced consumption alone indicates the 
presence of anhedonia (e.g. Papp & Moryl, 1994; Papp, et al., 1991; Papp & Moryl, 
1994; Rygula, et al., 2005; Willner, et al., 1994; Zurita, et al., 2000; Zurita & Molina, 
1999). It also suggests that the interpretation of reduced consumption following large 
doses of PCP treatment as an analogue of anhedonia (Turgeon & Hoge, 2003) is 
unsupported.
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Although sub-chronic PCP treatment is associated with pathological changes 
that more closely resemble those that occur in schizophrenia than is acute PCP 
treatment (e.g. Jentsch & Roth, 1999), sub-chronic administration produced no effect 
on the hedonic value of sucrose rewards in terms of either consumption or palatability 
(Experiments 8, 9 and 10). Therefore, no evidence of consummatory anhedonia was 
found following either acute NMDA receptor antagonist treatment or sub-chronic 
PCP treatment.
As discussed in chapter 5, there have been suggestions that anhedonia is 
actually anticipatory in nature. That is, people with schizophrenia experience a 
reduced capacity to anticipate the pleasure associated with future rewards. However, 
acquisition of an anticipatory contrast effect was unaffected by sub-chronic PCP 
treatment. Once the effect was acquired, it was also unaffected by acute PCP 
challenge. This indicates that anticipatory anhedonia is also not a feature of PCP 
models of schizophrenia.
It has also been argued that anhedonia is closely linked to motivational 
deficits in schizophrenia (Foussias & Remington, 2010). However, no evidence of a 
reduction in motivation was found using progressive ratio analysis in animals treated 
sub-chronically with PCP. There is therefore no evidence that acute NMDA receptor 
antagonist or sub-chronic PCP treatment is able to produce any effect that could be 
considered as an analogue of a hedonic deficit, since there was no consummatory, 
anticipatory or motivational deficit present in these models.
The decision to use NMDA receptor antagonists in an attempt to identify an 
analogue of anhedonia was based upon the apparent plausibility of the glutamate 
hypothesis of schizophrenia, suggesting that N-methyl-D-aspartate (NMDA) 
(glutamate) receptor hypofunction may underlie the positive, negative and cognitive
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symptoms of the disorder (see section 1.4). In humans, NMDA receptor antagonists 
such as phencyclidine (PCP) and s-(+)-ketamine produce a psychotic state that is 
more reminiscent of schizophrenia than dopaminergic psychostimulants, such as 
amphetamine, since negative and cognitive symptoms are also induced (e.g. Javitt & 
Zukin, 1991; Lahti et al. 2001). The suggestion that the glutamate hypothesis may 
account for negative symptoms as well as positive symptoms is supported by animal 
studies showing that acute NMDA receptor antagonist treatment produces other non- 
psychotic symptoms of schizophrenia, such as increased stereotyped behaviours 
(Verma and Moghaddam, 1996) and cognitive deficits (Dunn and Killcross, 2006)
(see section 1.9). Likewise, sub-chronic PCP treatment is known to produce cognitive 
deficits (e.g. Cosgrove et al, 1991; Dunn and Killcross, 2006) and also produces 
pathological changes likened to those in schizophrenia, such as hypofrontality relating 
to the pre-frontal cortex (see section 1.9). In addition, NMDA antagonists such as 
PCP are able to produce contrasting effects on dopamine in mesolimbic and 
mesocortical brain systems. This is thought to be necessary for the production of the 
whole range o f schizophrenic symptoms (Weinberger, 1987). It was therefore 
expected that NMDA receptor antagonist treatment, and in particular, sub-chronic 
PCP treatment would provide an ‘all-round’ model of schizophrenia, as suggested by 
Morris et al. (2005).
The absence of hedonic deficits following both acute NMDA receptor 
antagonist treatment and sub-chronic PCP treatment is therefore somewhat suprising, 
and it seems to suggest one of two possibilities concerning the validity of the 
glutamate hypothesis. Firstly, it is possible that the glutamate hypothesis provides an 
accurate account of the mechanisms underlying schizophrenia, but that NMDA 
antagonists such as PCP are unable to fully reproduce all aspects of brain function
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relevant to the hypothesis. Alternatively, it is possible that the glutamate hypothesis is 
incomplete and is only able to account for the pathology underlying positive and 
cognitive deficits.
To assert both that the glutamate hypothesis is accurate and that PCP 
treatment provides a complete model of schizophrenia in animals would raise the 
controversial idea that anhedonia may not exist as a primary symptom of 
schizophrenia. This controversial line of thought has received support from Tremeau, 
Antonius, Ziwich, Butler, Cacioppo and Javitt (2008). Controls and individuals with 
schizophrenia were presented with series of emotionally evocative pictures and 
sounds and asked to rate how positive and negative they felt following each stimulus. 
Prior to each series of stimuli, participants evaluated the degree of pleasure they 
anticipated from each sub-task. Following the task, in order to rate motivation, 
participants were asked how willing they would be to repeat the task. Participants 
with schizophrenia did not differ from controls in terms of anticipatory and in-the- 
moment pleasure. They also showed greater remembered pleasure than controls. 
However, they displayed lower correlation between affective and motivational 
measures. Tremeau et al. have therefore suggested that the reward system deficit seen 
in schizophrenia lies not in the ability to experience pleasure, but in the ability to 
translate pleasure into motivational processes.
Foussias and Remington (2010) have reviewed evidence that they believe 
argues against anhedonia as a core symptom of schizophrenia. They suggest that the 
apparent anticipatory pleasure deficit in schizophrenia observed by Gard et al. (2006) 
is closely related to motivation and goal-directed behaviour. They argue that since 
worse functional outcomes are reported in individuals with prominent negative 
symptoms, amotivation is likely to be the main contributor in this relationship.
159
Although they acknowledge that cognitive dysfunction contributes to functional 
outcome in schizophrenia, there is a strong influence of motivation over cognitive 
functioning (Gorissen, Sanz & Scmand, 2005). They therefore proposed a model in 
which all negative symptoms are conceptualised as avolition (lack of motivation). 
They suggest that other symptoms, such as attentional impairment, inappropriate 
affect, and poverty of speech content, traditionally believed to be negative symptoms, 
are more closely related to the cognitive or disorganised symptoms of schizophrenia. 
They argue that since research has failed to find evidence of diminished emotional 
experience, despite finding deficits in emotional expression, anhedonia is not a core 
symptom of schizophrenia, but is related to the engagement of motivational processes 
which control goal-directed behaviour. They consequently suggest that amotivation is 
a core negative symptom and that loss of motivation is phenotypically expressed in 
terms of asociality and alogia, observed clinically as increased social withdrawal. 
Blunted affect parallels a loss of motivation, but they argue that this is distinguishable 
from hedonic capacity, which remains intact in schizophrenia, even though this is not 
complimented by an individual’s premorbid capacity for goal-seeking. In this way, 
avolition is proposed to directly lead to functional decline in schizophrenia. It also 
plays an indirect role via its influence on cognitive dysfunction.
The progressive ratio paradigm used in Experiment 11 showed no evidence of 
a motivational deficit following sub-chronic PCP treatment and therefore does not 
add any support to the suggestion of Foussias and Remington (2010). However, it is 
possible that all negative symptoms, including motivational and social deficits, may 
occur secondary to the cognitive deficits observed in schizophrenia. The data 
presented in this thesis cannot help to clarify this possibility since hedonic 
measurements were not made in conjunction with cognitively demanding tasks.
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However, the suggestion that negative symptoms may occur secondary to cognitive 
deficits is supported by the striking lack of evidence for negative symptoms in 
animals following PCP treatment. Indeed, it has been reported that animals treated 
sub-chronically with PCP show reduced social interaction with unfamiliar rats 
(Bruins Slot, Kleven, & Newman-Tancredi, 2005; Sams-Dodd, 1998). However, 
these deficits were observed less than one hour after the last PCP dose. Although 
Snigdha and Neill (2008) found social interaction deficits in terms of following, 
sniffing and climbing over unfamiliar rats, 6 weeks after sub-chronic PCP 
administration in female rats, other studies have not identified social deficits after an 
extended period of PCP withdrawal (Egerton, et al., 2008; Sams-Dodd, 2004). Indeed, 
Jenkins et al. (2008) found that sub-chronic PCP treatment actually increased the 
amount of time rats engaged in social interaction, thus demonstrating that findings in 
this regard do not provide conclusive evidence for a reduction in social interaction 
following sub-chronic PCP treatment.
Findings from Heerey, Bell-Warren and Gold (2008) also suggest that reward 
experience may be intact in schizophrenia and that cognitive problems may be 
implicated in what appears to be anhedonia. In this study, reward sensitivity was 
found to be normal when measured using a signal detection task in which participants 
develop a bias when choosing between two stimuli, one of which is rewarded more 
often than the other. However, participants were also given a decision-making task in 
which they received a choice between two gambles, along with information on the 
reward magnitude, probability of winning, and potential gains and losses. In this task, 
participants with schizophrenia were less able to weigh up potential outcomes when 
making their choice. Heerey et al. concluded that people with schizophrenia have 
reduced ability to utilise working memory in order to draw on their experience of
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reward when making decisions. If this is the case, motivational deficits may exist in 
schizophrenia because the potential rewarding outcomes of activities are not 
immediately obvious to the individual, rather than because they have reduced 
capacity to experience pleasure. If this line of thought is accurate, it may explain the 
absence of hedonic deficits following PCP treatment, even though cognitive deficits 
are present. However, the lack of a direct correlation between the presence of 
negative symptoms and positive symptoms following PCP treatment might question 
the idea that negative symptoms are secondary to other symptoms in schizophrenia.
Using animal models it may not possible to draw a firm conclusion as to 
whether anhedonia exists as a core feature of schizophrenia. However, further 
investigation of the MAM model, which showed some evidence of motivational 
deficits, may go some way towards clarifying this issue. Tests of hedonic capacity 
such as those carried out with NMDA receptor antagonists in this thesis would 
identify whether a deficit in the ability to experience pleasure is present. If further 
testing confirmed that the motivational deficit reported in Experiment 12 is genuine 
and not a product of altered satiety mechanisms or confounding effects of effort, the 
presence of a hedonic deficit would support the conclusion that anhedonia is indeed a 
core symptom of schizophrenia. However, if  hedonic deficits were absent but 
motivational deficits present, this would support the possibility that anhedonia may 
not exist as a primary symptom in schizophrenia, but that diagnostic scales of 
assessment actually detect a motivational deficit rather than a hedonic one.
7.4 Implications of thesis findings for drug discovery
The data presented in this thesis have shown that antipsychotic drugs can 
independently alter hedonic capacity in animals. For this reason, if further
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investigations show that anhedonia can be modelled in animals, potential 
antipsychotic drugs will need to be screened for their effects on hedonic capacity in 
normal animals prior to testing for their ability to ameliorate anhedonia.
The experiments described in this thesis sought to find an animal analogue of 
anhedonia. This was deemed important because anhedonia is purported to be a core 
negative symptom of schizophrenia, and negative symptom severity is associated with 
poor functional outcome in schizophrenia patients (Ho et al, 2004) (see section 1.1).
In addition, current antipsychotic treatments are ineffective in improving negative 
symptoms, which may account for the great lack of adherence to medication in this 
disorder (see section 1.8).
The finding that acute NMDA receptor antagonist and sub-chronic PCP 
treatment does not produce anhedonia in rodents has raised a question as to whether 
anhedonia does actually exist as a primary symptom of schizophrenia. Further efforts 
to establish a model of anhedonia should seek to resolve this question. For this 
reason, tests of hedonic value, such as those described in this thesis with lick analysis, 
should be carried out with other models of schizophrenia (e.g. the MAM model). If no 
evidence of hedonic deficits can be found in other models, this may suggest that 
anhedonia is not a primary symptom as initially suspected, but may be secondary to 
other symptoms, such as cognitive deficits. If anhedonia is secondary to cognitive 
deficits, this may be difficult to detect as it would require examination of hedonic 
capacity during a cognitive task that animal models of schizophrenia experience 
problems with. The additional confound of effort increasing reward value will present 
a further obstacle in this endeavour.
As discussed, investigation of hedonic capacity in other models of 
schizophrenia may elucidate whether anhedonia is in fact a core symptom. The
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suggestion that motivational deficits occur in the MAM model raises the possibility 
that models replicating the developmental aspects of the disorder offer greater 
potential for the modelling of negative symptoms.
It can, however, be concluded that NMDA receptor antagonist treatment 
cannot be used to model anhedonia in rodents. It is also now clear that reduced 
voluntary sucrose consumption, used previously by numerous authors as an indicator 
of anhedonia, is not an appropriate method by which to assess the presence of the 
symptom and that analysis of licking provides a superior method.
In short, the examination of hedonic reactions via analysis of licking 
microstructure has revealed novel behavioural effects whereby the affective value of 
sucrose is influenced by the context of ingestion. However, despite their plausibility, 
NMDA receptor antagonist-based models of schizophrenia show no evidence of 
producing an analogue of anhedonia when assessed using the same methods. Thus 
attempts to model such symptoms should focus on other models of schizophrenia, 
such as the neurodevelopmental MAM model.
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APPENDIX 1 
Sucrose preference test and acute PCP
This experiment used the same subjects, apparatus and procedures as Experiment 6.
In brief, following mild water-restriction, animals were given 20min access to both 
1% sucrose and water. 30 minutes prior to this experimental session an acute sub­
cutaneous dose of PCP (1 mg/kg) was administered to half of the animals, whilst the 
other half received vehicle. After a 2-day washout period, the drug-treatment 
conditions were reversed.
For this experiment, the parameter of interest was the amount of water and 
sucrose consumed. The data was analysed in the same way as for Experiment 6. This 
involved analysing the consumption of both solutions using ANOVA, in addition to 
calculating sucrose/water preference ratios and comparing the ratios for each 
treatment group using a paired samples t test.
Results
Table 2 shows the consumption of sucrose and water in the PCP and vehicle 
treatment conditions. Overall consumption of sucrose was higher than consumption of 
water following PCP treatment, F(l,23)=51.28,/?<.001. PCP treatment did not affect 
overall consumption, and there was no drug treatment x reinforcer interaction, Fs<l. 
There was a significant difference between the sucrose preference ratios for vehicle 
treatment (M=.8804, SD=. 14439) and PCP treatment (M=.7345, SD=. 14439) 
conditions; f=3.12,/?=.001.
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Table 2:
Water Consumption (g) 1% Sucrose Consumption (g)
1 mg/kg PCP Mean= 0.5 SEM=.116 Mean= 3.5 SEM= .590
Vehicle Mean= 0.3 SEM= .034 Mean= 4.2 SEM= .548
Conclusion
The results of this experiment suggest that although there was no effect of PCP 
treatment on the overall consumption of water and sucrose. However, when the ratio 
of sucrose consumption relative to water was examined, it was found that controls 
drink slightly more sucrose relative to water than controls. This raises the possibility 
that PCP treatment may reduce an animal’s preference for sucrose when presented 
alongside water following water restriction.
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